br O
##ca O
##1 O
is O
secret O
##ed O
and O
exhibits O
properties O
of O
a O
g O
##rani O
##n O
. O

g O
##er O
##m O
##line O
mutations O
in O
br O
##ca O
##1 O
are O
responsible O
for O
most O
cases O
of O
inherited B-Disease
breast I-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
. O

however O
, O
the O
function O
of O
the O
br O
##ca O
##1 O
protein O
has O
remained O
el O
##usive O
. O

we O
now O
show O
that O
br O
##ca O
##1 O
en O
##codes O
a O
190 O
- O
k O
##d O
protein O
with O
sequence O
ho O
##mology O
and O
bio O
##chemical O
analogy O
to O
the O
g O
##rani O
##n O
protein O
family O
. O

interesting O
##ly O
, O
br O
##ca O
##2 O
also O
includes O
a O
motif O
similar O
to O
the O
g O
##rani O
##n O
consensus O
at O
the O
c O
terminus O
of O
the O
protein O
. O

both O
br O
##ca O
##1 O
and O
the O
g O
##rani O
##ns O
local O
##ize O
to O
secret O
##ory O
ve O
##si O
##cles O
, O
are O
secret O
##ed O
by O
a O
regulated O
pathway O
, O
are O
post O
- O
translation O
##ally O
g O
##ly O
##cos O
##yla O
##ted O
and O
are O
re O
##sp O
##ons O
##ive O
to O
hormones O
. O

as O
a O
regulated O
secret O
##ory O
protein O
, O
br O
##ca O
##1 O
appears O
to O
function O
by O
a O
mechanism O
not O
previously O
described O
for O
t B-Disease
##umour I-Disease
suppress O
##or O
gene O
products O
. O
. O

o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
risk O
in O
br O
##ca O
##1 O
carriers O
is O
modified O
by O
the O
h O
##ras O
##1 O
variable O
number O
of O
tandem O
repeat O
( O
v O
##nt O
##r O
) O
lo O
##cus O
. O

women O
who O
carry O
a O
mutation O
in O
the O
br O
##ca O
##1 O
gene O
( O
on O
chromosome O
17 O
##q O
##21 O
) O
, O
have O
an O
80 O
% O
risk O
of O
breast B-Disease
cancer I-Disease
and O
a O
40 O
% O
risk O
of O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
by O
the O
age O
of O
70 O
( O
re O
##f O
. O
1 O
) O
. O

the O
variable O
pen O
##et O
##rance O
of O
br O
##ca O
##1 O
suggests O
that O
other O
genetic O
and O
non O
- O
genetic O
factors O
play O
a O
role O
in O
t O
##umour O
##ige O
##nes O
##is O
in O
these O
individuals O
. O

the O
h O
##ras O
##1 O
variable O
number O
of O
tandem O
repeats O
( O
v O
##nt O
##r O
) O
p O
##oly O
##mor O
##phism O
, O
located O
1 O
k O
##ilo O
##base O
( O
k O
##b O
) O
downstream O
of O
the O
h O
##ras O
##1 O
pro O
##to O
- O
on O
##co O
##gene O
( O
chromosome O
11 O
##p O
##15 O
. O
5 O
) O
is O
one O
possible O
genetic O
m O
##od O
##ifier O
of O
cancer B-Disease
pen O
##et O
##rance O
. O

individuals O
who O
have O
rare O
all O
##ele O
##s O
of O
the O
v O
##nt O
##r O
have O
an O
increased O
risk O
of O
certain O
types O
of O
cancer B-Disease
##s I-Disease
, O
including O
breast B-Disease
cancer I-Disease
( O
2 O
- O
4 O
) O
. O

to O
investigate O
whether O
the O
presence O
of O
rare O
h O
##ras O
##1 O
all O
##ele O
##s O
increases O
su O
##s O
##ce O
##pt O
##ibility O
to O
hereditary B-Disease
breast I-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
, O
we O
have O
typed O
a O
panel O
of O
307 O
female O
br O
##ca O
##1 O
carriers O
at O
this O
lo O
##cus O
using O
a O
p O
##c O
##r O
- O
based O
technique O
. O

the O
risk O
for O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
was O
2 O
. O

11 O
times O
greater O
for O
br O
##ca O
##1 O
carriers O
harbour O
##ing O
one O
or O
two O
rare O
h O
##ras O
##1 O
all O
##ele O
##s O
, O
compared O
to O
carriers O
with O
only O
common O
all O
##ele O
##s O
( O
p O
= O
0 O
. O
01 O
##5 O
) O
. O

the O
magnitude O
of O
the O
relative O
risk O
associated O
with O
a O
rare O
h O
##ras O
##1 O
all O
##ele O
was O
not O
altered O
by O
adjusting O
for O
the O
other O
known O
risk O
factors O
for O
hereditary B-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
( O
5 O
) O
. O

su O
##s O
##ce O
##pt O
##ibility O
to O
breast B-Disease
cancer I-Disease
did O
not O
appear O
to O
be O
affected O
by O
the O
presence O
of O
rare O
h O
##ras O
##1 O
all O
##ele O
##s O
. O

this O
study O
is O
the O
first O
to O
show O
the O
effect O
of O
a O
modify O
##ing O
gene O
on O
the O
pen O
##et O
##rance O
of O
an O
inherited B-Disease
cancer I-Disease
syndrome I-Disease

a O
novel O
home O
##od O
##oma O
##in O
- O
encoding O
gene O
is O
associated O
with O
a O
large O
c O
##p O
##g O
island O
interrupted O
by O
the O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
unstable O
( O
c O
##t O
##g O
) O
n O
repeat O
. O

my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
) O
is O
associated O
with O
a O
( O
c O
##t O
##g O
) O
n O
t O
##rin O
##uc O
##leo O
##tide O
repeat O
expansion O
in O
the O
3 O
- O
un O
##tra O
##ns O
##lated O
region O
of O
a O
protein O
kinase O
- O
encoding O
gene O
, O
d O
##mp O
##k O
, O
which O
maps O
to O
chromosome O
19 O
##q O
##13 O
. O

3 O
. O

character O
##isation O
of O
the O
expression O
of O
this O
gene O
in O
patient O
tissues O
has O
thus O
far O
generated O
conflicting O
data O
on O
alterations O
in O
the O
steady O
state O
levels O
of O
d O
##mp O
##k O
m O
##rna O
, O
and O
on O
the O
final O
d O
##mp O
##k O
protein O
levels O
in O
the O
presence O
of O
the O
expansion O
. O

the O
d B-Disease
##m I-Disease
region O
of O
chromosome O
19 O
is O
gene O
rich O
, O
and O
it O
is O
possible O
that O
the O
repeat O
expansion O
may O
lead O
to O
d O
##ys O
##function O
of O
a O
number O
of O
transcription O
units O
in O
the O
vicinity O
, O
perhaps O
as O
a O
consequence O
of O
ch O
##roma O
##tin O
disruption O
. O

we O
have O
searched O
for O
genes O
associated O
with O
a O
c O
##p O
##g O
island O
at O
the O
3 O
end O
of O
d O
##mp O
##k O
. O

se O
##quencing O
of O
this O
region O
shows O
that O
the O
island O
extends O
over O
3 O
. O

5 O
k O
##b O
and O
is O
interrupted O
by O
the O
( O
c O
##t O
##g O
) O
n O
repeat O
. O

comparison O
of O
g O
##eno O
##mic O
sequences O
downstream O
( O
cent O
##rome O
##ric O
) O
of O
the O
repeat O
in O
human O
and O
mouse O
identified O
regions O
of O
significant O
ho O
##mology O
. O

these O
correspond O
to O
ex O
##ons O
of O
a O
gene O
predicted O
to O
en O
##code O
a O
home O
##od O
##oma O
##in O
protein O
. O

r O
##t O
- O
p O
##c O
##r O
analysis O
shows O
that O
this O
gene O
, O
which O
we O
have O
called O
d B-Disease
##m I-Disease
lo O
##cus O
- O
associated O
home O
##od O
##oma O
##in O
protein O
( O
d O
##mah O
##p O
) O
, O
is O
expressed O
in O
a O
number O
of O
human O
tissues O
, O
including O
skeletal O
muscle O
, O
heart O
and O
brain O
. O

g O
##er O
##m O
##line O
mutations O
in O
the O
r O
##b O
##1 O
gene O
in O
patients O
with O
hereditary B-Disease
re I-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
. O

we O
have O
analyzed O
the O
27 O
ex O
##ons O
and O
the O
promoter O
region O
of O
the O
r O
##b O
##1 O
gene O
in O
f B-Disease
##ami I-Disease
##lial I-Disease
or I-Disease
s I-Disease
##poradic I-Disease
bilateral I-Disease
re I-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
by O
using O
single O
- O
strand O
conform O
##ation O
p O
##oly O
##mor O
##phism O
analysis O
. O

for O
improvement O
over O
previous O
studies O
, O
a O
new O
set O
of O
prime O
##rs O
has O
been O
designed O
, O
which O
allow O
for O
am O
##p O
##lification O
of O
the O
coding O
and O
s O
##p O
##licing O
sequences O
only O
. O

the O
positioning O
of O
the O
polymer O
##ase O
chain O
reaction O
( O
p O
##c O
##r O
) O
prime O
##rs O
was O
such O
that O
the O
resulting O
p O
##c O
##r O
products O
were O
of O
different O
sizes O
, O
which O
enabled O
us O
to O
analyze O
two O
different O
ex O
##ons O
simultaneously O
and O
still O
distinguish O
between O
the O
band O
##ing O
profiles O
for O
both O
( O
bi O
##plex O
analysis O
) O
. O

by O
using O
this O
approach O
, O
we O
were O
able O
to O
identify O
mutation O
in O
22 O
new O
patients O
, O
but O
the O
overall O
efficiency O
of O
the O
procedure O
when O
we O
used O
a O
single O
- O
pass O
regime O
##n O
was O
only O
48 O
% O
. O

the O
mutations O
were O
small O
insertion O
##s O
and O
del O
##eti O
##ons O
and O
point O
mutations O
in O
roughly O
equal O
proportions O
. O
. O

type B-Disease
ii I-Disease
human I-Disease
complement I-Disease
c I-Disease
##2 I-Disease
deficiency I-Disease
. O

all O
##ele O
- O
specific O
amino O
acid O
substitution O
##s O
( O
se O
##r O
##18 O
##9 O
- O
- O
[UNK] O
p O
##he O
; O
g O
##ly O
##44 O
##4 O
- O
- O
[UNK] O
a O
##rg O
) O
cause O
impaired O
c O
##2 O
secret O
##ion O
. O

type B-Disease
ii I-Disease
complement I-Disease
protein I-Disease
c I-Disease
##2 I-Disease
deficiency I-Disease
is O
characterized O
by O
a O
selective O
block O
in O
c O
##2 O
secret O
##ion O
. O

the O
type O
ii O
c O
##2 O
null O
all O
##ele O
( O
c O
##2 O
##q O
##0 O
) O
is O
linked O
to O
two O
major O
his O
##to O
##com O
##pa O
##ti O
##bility O
ha O
##p O
##lot O
##ype O
##s O
( O
m O
##h O
##c O
) O
that O
differ O
from O
the O
m O
##h O
##c O
of O
the O
more O
common O
type B-Disease
i I-Disease
c I-Disease
##2 I-Disease
deficiency I-Disease
. O

to O
determine O
the O
molecular O
basis O
of O
type B-Disease
ii I-Disease
deficiency I-Disease
the O
two O
type O
ii O
c O
##2 O
##q O
##0 O
genes O
were O
isolated O
and O
trans O
##fected O
separately O
into O
l O
- O
cells O
. O

subsequent O
molecular O
biology O
, O
bio O
##sy O
##nt O
##hetic O
, O
and O
im O
##mu O
##no O
##f O
##lu O
##ores O
##cence O
studies O
demonstrated O
that O
c O
##2 O
secret O
##ion O
is O
impaired O
in O
type B-Disease
ii I-Disease
c I-Disease
##2 I-Disease
deficiency I-Disease
because O
of O
different O
miss O
##ense O
mutations O
at O
highly O
conserved O
residues O
in O
each O
of O
the O
c O
##2 O
##q O
##0 O
all O
##ele O
##s O
. O

one O
is O
in O
ex O
##on O
5 O
( O
n O
##uc O
##leo O
##tide O
c O
##5 O
##6 O
##6 O
- O
- O
[UNK] O
t O
; O
se O
##r O
##18 O
##9 O
- O
- O
[UNK] O
p O
##he O
) O
of O
the O
c O
##2 O
##q O
##0 O
gene O
linked O
to O
the O
m O
##h O
##c O
ha O
##p O
##lot O
##ype O
a O
##11 O
, O
b O
##35 O
, O
d O
##r O
##w O
##1 O
, O
b O
##fs O
, O
c O
##4 O
##a O
##0 O
##b O
##1 O
. O

the O
other O
is O
in O
ex O
##on O
11 O
( O
g O
##19 O
##30 O
- O
- O
[UNK] O
a O
; O
g O
##ly O
##44 O
##4 O
- O
- O
[UNK] O
a O
##rg O
) O
of O
the O
c O
##2 O
##q O
##0 O
gene O
linked O
to O
the O
m O
##h O
##c O
ha O
##p O
##lot O
##ype O
a O
##2 O
, O
b O
##5 O
, O
d O
##r O
##w O
##4 O
, O
b O
##fs O
, O
c O
##4 O
##a O
##3 O
##b O
##1 O
. O

each O
mutant O
c O
##2 O
gene O
product O
is O
retained O
early O
in O
the O
secret O
##ory O
pathway O
. O

these O
mutant O
##s O
provide O
models O
for O
el O
##uc O
##ida O
##ting O
the O
c O
##2 O
secret O
##ory O
pathway O
. O
. O

defect O
##ive O
dim O
##eri O
##zation O
of O
von B-Disease
will I-Disease
##eb I-Disease
##rand I-Disease
factor O
subunit O
##s O
due O
to O
a O
c O
##ys O
- O
[UNK] O
a O
##rg O
mutation O
in O
type B-Disease
ii I-Disease
##d I-Disease
von I-Disease
will I-Disease
##eb I-Disease
##rand I-Disease
disease I-Disease
. O

the O
same O
he O
##tero O
##zy O
##go O
##us O
t O
- O
[UNK] O
c O
transition O
at O
n O
##t O
85 O
##6 O
##7 O
of O
the O
von B-Disease
will I-Disease
##eb I-Disease
##rand I-Disease
factor O
( O
v O
##w O
##f O
) O
trans O
##cript O
was O
found O
in O
two O
unrelated O
patients O
with O
type B-Disease
ii I-Disease
##d I-Disease
von I-Disease
will I-Disease
##eb I-Disease
##rand I-Disease
disease I-Disease
, O
with O
no O
other O
apparent O
abnormal O
##ity O
. O

in O
one O
family O
, O
both O
all O
##ele O
##s O
were O
normal O
in O
the O
parents O
and O
one O
sister O
; O
thus O
, O
the O
mutation O
originated O
de O
no O
##vo O
in O
the O
prop O
##os O
##ita O
. O

the O
second O
patient O
also O
had O
as O
##ym O
##pt O
##oma O
##tic O
parents O
who O
, O
however O
, O
were O
not O
available O
for O
study O
. O

the O
structural O
consequences O
of O
the O
identified O
mutation O
, O
resulting O
in O
the O
c O
##ys O
##20 O
##10 O
- O
[UNK] O
a O
##rg O
substitution O
, O
were O
evaluated O
by O
expression O
of O
the O
v O
##w O
##f O
car O
##box O
##yl O
- O
terminal O
domain O
containing O
residues O
136 O
##6 O
- O
205 O
##0 O
. O

insect O
cells O
infected O
with O
re O
##comb O
##ina O
##nt O
b O
##ac O
##ulo O
##virus O
expressing O
normal O
v O
##w O
##f O
sequence O
secret O
##ed O
a O
di O
##sul O
##fi O
##de O
linked O
dim O
##eric O
molecule O
with O
an O
apparent O
molecular O
mass O
of O
150 O
k O
##da O
before O
reduction O
, O
yielding O
a O
single O
band O
of O
80 O
k O
##da O
after O
di O
##sul O
##fi O
##de O
bond O
reduction O
. O

in O
contrast O
, O
cells O
expressing O
the O
mutant O
fragment O
secret O
##ed O
a O
mon O
##omer O
##ic O
molecule O
of O
apparent O
molecular O
mass O
of O
80 O
k O
##da O
, O
which O
remained O
unchanged O
after O
reduction O
. O

we O
conclude O
that O
c O
##ys O
##20 O
##10 O
is O
essential O
for O
normal O
dim O
##eri O
##zation O
of O
v O
##w O
##f O
subunit O
##s O
through O
di O
##sul O
##fi O
##de O
bonding O
of O
car O
##box O
##yl O
- O
terminal O
domains O
and O
that O
a O
he O
##tero O
##zy O
##go O
##us O
mutation O
in O
the O
corresponding O
co O
##don O
is O
responsible O
for O
defect O
##ive O
multi O
##mer O
formation O
in O
type B-Disease
ii I-Disease
##d I-Disease
von I-Disease
will I-Disease
##eb I-Disease
##rand I-Disease
disease I-Disease
. O
. O

w B-Disease
##isk I-Disease
##ott I-Disease
- I-Disease
al I-Disease
##dric I-Disease
##h I-Disease
syndrome I-Disease
protein O
, O
a O
novel O
effect O
##or O
for O
the O
g O
##t O
##pas O
##e O
c O
##d O
##c O
##42 O
##hs O
, O
is O
implicated O
in O
act O
##in O
polymer O
##ization O
. O

the O
r O
##ho O
family O
of O
g O
##t O
##pas O
##es O
control O
diverse O
biological O
processes O
, O
including O
cell O
morphology O
and O
mit O
##ogen O
##esis O
. O

we O
have O
identified O
was O
##p O
, O
the O
protein O
that O
is O
defect O
##ive O
in O
w B-Disease
##isk I-Disease
##ott I-Disease
- I-Disease
al I-Disease
##dric I-Disease
##h I-Disease
syndrome I-Disease
( O
was B-Disease
) O
, O
as O
a O
novel O
effect O
##or O
for O
c O
##d O
##c O
##42 O
##hs O
, O
but O
not O
for O
the O
other O
r O
##ho O
family O
members O
, O
r O
##ac O
and O
r O
##ho O
. O

this O
interaction O
is O
dependent O
on O
the O
presence O
of O
the O
g O
protein O
- O
binding O
domain O
. O

cellular O
expression O
of O
e O
##pit O
##ope O
- O
tag O
##ged O
was O
##p O
produces O
clusters O
of O
was O
##p O
that O
are O
highly O
en O
##rich O
##ed O
in O
polymer O
##ized O
act O
##in O
. O

this O
cluster O
##ing O
is O
not O
observed O
with O
a O
c O
- O
terminal O
##ly O
deleted O
was O
##p O
and O
is O
in O
##hibit O
##ed O
by O
co O
##ex O
##press O
##ion O
with O
dominant O
negative O
c O
##d O
##c O
##42 O
##hs O
- O
n O
##17 O
, O
but O
not O
with O
dominant O
negative O
forms O
of O
r O
##ac O
or O
r O
##ho O
. O

thus O
, O
was O
##p O
provides O
a O
novel O
link O
between O
c O
##d O
##c O
##42 O
##hs O
and O
the O
act O
##in O
c O
##yt O
##os O
##kel O
##eton O
, O
which O
suggests O
a O
molecular O
mechanism O
for O
many O
of O
the O
cellular O
abnormal O
##ities O
in O
was B-Disease
. O

the O
was O
##p O
sequence O
contains O
two O
novel O
domains O
that O
are O
ho O
##mo O
##log O
##ous O
to O
other O
proteins O
involved O
in O
action O
organization O
. O
. O

x B-Disease
- I-Disease
linked I-Disease
ad I-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
is O
a O
frequent O
cause O
of O
id O
##io O
##pathic O
add B-Disease
##ison I-Disease
' I-Disease
s I-Disease
disease I-Disease
in O
young O
adult O
male O
patients O
. O

x B-Disease
- I-Disease
linked I-Disease
ad I-Disease
##ren I-Disease
##ole I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
( O
al B-Disease
##d I-Disease
) O
is O
a O
genetic B-Disease
disease I-Disease
associated O
with O
dem B-Disease
##ye I-Disease
##lina I-Disease
##tion I-Disease
of I-Disease
the I-Disease
central I-Disease
nervous I-Disease
system I-Disease
, O
ad B-Disease
##rena I-Disease
##l I-Disease
ins I-Disease
##uff I-Disease
##iciency I-Disease
, O
and O
accumulation O
of O
very O
long O
chain O
fatty O
acids O
in O
tissue O
and O
body O
fluids O
. O

al B-Disease
##d I-Disease
is O
due O
to O
mutation O
of O
a O
gene O
located O
in O
x O
##q O
##28 O
that O
en O
##codes O
a O
per O
##ox O
##is O
##oma O
##l O
transport O
##er O
protein O
of O
unknown O
function O
. O

the O
most O
common O
p O
##hen O
##otype O
of O
al B-Disease
##d I-Disease
is O
the O
cerebral O
form O
( O
45 O
% O
) O
that O
develops O
in O
boys O
between O
5 O
- O
12 O
y O
##r O
. O

ad B-Disease
##ren I-Disease
##omy I-Disease
##elo I-Disease
##ne I-Disease
##uro I-Disease
##pathy I-Disease
( O
am B-Disease
##n I-Disease
) O
involves O
the O
spinal O
cord O
and O
peripheral O
nerves O
in O
young O
adults O
( O
35 O
% O
) O
. O

ad B-Disease
##rena I-Disease
##l I-Disease
ins I-Disease
##uff I-Disease
##iciency I-Disease
( O
add B-Disease
##ison I-Disease
##s I-Disease
disease I-Disease
) O
is O
frequently O
associated O
with O
am B-Disease
##n I-Disease
or O
cerebral B-Disease
al I-Disease
##d I-Disease
and O
may O
remain O
the O
only O
clinical O
expression O
of O
al B-Disease
##d I-Disease
( O
8 O
% O
of O
cases O
) O
. O

the O
prevalence O
of O
al B-Disease
##d I-Disease
among O
adults O
with O
add B-Disease
##ison I-Disease
##s I-Disease
disease I-Disease
remains O
unknown O
. O

to O
evaluate O
this O
prevalence O
, O
we O
performed O
bio O
##chemical O
analysis O
of O
very O
long O
chain O
fatty O
acids O
in O
14 O
male O
patients O
( O
age O
ranging O
from O
12 O
- O
45 O
y O
##r O
at O
diagnosis O
) O
previously O
diagnosed O
as O
having O
primary O
id O
##io O
##pathic O
ad B-Disease
##ren I-Disease
##oc I-Disease
##ort I-Disease
##ical I-Disease
ins I-Disease
##uff I-Disease
##iciency I-Disease
. O

in O
5 O
of O
14 O
patients O
( O
35 O
% O
) O
, O
elevated O
plasma O
concentrations O
of O
very O
long O
chain O
fatty O
acids O
were O
detected O
. O

none O
of O
these O
patients O
had O
ad O
##ren O
##oc O
##ort O
##ical O
antibodies O
. O

by O
electro O
##phy O
##sio O
##logical O
tests O
and O
magnetic O
resonance O
imaging O
it O
was O
determined O
that O
two O
patients O
had O
cerebral B-Disease
al I-Disease
##d I-Disease
, O
one O
had O
ad B-Disease
##ren I-Disease
##omy I-Disease
##elo I-Disease
##ne I-Disease
##uro I-Disease
##pathy I-Disease
with O
cerebral O
involvement O
, O
and O
two O
had O
pre O
##c O
##lini O
##cal O
am B-Disease
##n I-Disease
. O

our O
data O
support O
the O
hypothesis O
that O
al B-Disease
##d I-Disease
is O
a O
frequent O
cause O
of O
id O
##io O
##pathic O
add B-Disease
##ison I-Disease
##s I-Disease
disease I-Disease
in O
children O
and O
adults O
. O
. O

tumor B-Disease
suppression O
and O
a O
##pop O
##tosis O
of O
human O
pro B-Disease
##state I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
mediated O
by O
a O
genetic O
lo O
##cus O
within O
human O
chromosome O
10 O
##pt O
##er O
- O
q O
##11 O
. O

pro B-Disease
##state I-Disease
cancer I-Disease
is O
the O
second O
leading O
cause O
of O
male O
cancer B-Disease
deaths O
in O
the O
united O
states O
. O

yet O
, O
despite O
a O
large O
international O
effort O
, O
little O
is O
known O
about O
the O
molecular O
mechanisms O
that O
under O
##lie O
this O
devastating O
disease O
. O

pro O
##state O
secret O
##ory O
e O
##pit O
##hel O
##ial O
cells O
and O
and O
##rogen O
- O
dependent O
pro B-Disease
##state I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
##s I-Disease
undergo O
a O
##pop O
##tosis O
in O
response O
to O
and O
##rogen O
de O
##p O
##ri O
##vation O
and O
, O
further O
##more O
, O
most O
pro B-Disease
##state I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
##s I-Disease
become O
and O
##rogen O
independent O
and O
re O
##fra O
##ctor O
##y O
to O
further O
therapeutic O
manipulation O
##s O
during O
disease O
progression O
. O

definition O
of O
the O
genetic O
events O
that O
trigger O
a O
##pop O
##tosis O
in O
the O
pro O
##state O
could O
provide O
important O
insights O
into O
critical O
pathways O
in O
normal O
development O
as O
well O
as O
el O
##uc O
##ida O
##te O
the O
per O
##tur O
##bation O
##s O
of O
those O
key O
pathways O
in O
neo O
##p O
##lastic O
transformation O
. O

we O
report O
the O
functional O
definition O
of O
a O
novel O
genetic O
lo O
##cus O
within O
human O
chromosome O
10 O
##pt O
##er O
- O
q O
##11 O
that O
media O
##tes O
both O
in O
v O
##ivo O
tumor O
suppression O
and O
in O
v O
##it O
##ro O
a O
##pop O
##tosis O
of O
pro B-Disease
##static I-Disease
ad I-Disease
##eno I-Disease
##car I-Disease
##cin I-Disease
##oma I-Disease
cells O
. O

a O
defined O
fragment O
of O
human O
chromosome O
10 O
was O
transferred O
via O
micro O
##cell O
fusion O
into O
a O
pro B-Disease
##state I-Disease
ad I-Disease
##eno I-Disease
##car I-Disease
##cin I-Disease
##oma I-Disease
cell O
line O
. O

micro O
##cell O
hybrid O
##s O
containing O
only O
the O
region O
10 O
##pt O
##er O
- O
q O
##11 O
were O
suppressed O
for O
tumor O
##ige O
##nic O
##ity O
following O
injection O
of O
micro O
##cell O
hybrid O
##s O
into O
nude O
mice O
. O

further O
##more O
, O
the O
complement O
##ed O
hybrid O
##s O
undergo O
programmed O
cell O
death O
in O
v O
##it O
##ro O
via O
a O
mechanism O
that O
does O
not O
require O
nuclear O
local O
##ization O
of O
p O
##53 O
. O

these O
data O
functional O
##ly O
define O
a O
novel O
genetic O
lo O
##cus O
, O
designated O
p O
##ac O
##1 O
, O
for O
pro O
##state O
ad O
##eno O
##car O
##cin O
##oma O
1 O
, O
involved O
in O
tumor O
suppression O
of O
human O
pro B-Disease
##state I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
and O
further O
##more O
strongly O
suggest O
that O
the O
cell O
death O
pathway O
can O
be O
functional O
##ly O
restored O
in O
pro B-Disease
##static I-Disease
ad I-Disease
##eno I-Disease
##car I-Disease
##cin I-Disease
##oma I-Disease
. O
. O

low O
incidence O
of O
br O
##ca O
##2 O
mutations O
in O
breast B-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
and O
other O
cancer B-Disease
##s I-Disease
. O

inherited O
mutant O
all O
##ele O
##s O
of O
f O
##ami O
##lial O
t B-Disease
##umour I-Disease
suppress O
##or O
genes O
pre O
##dis O
##pose O
individuals O
to O
particular O
types O
of O
cancer B-Disease
. O

in O
addition O
to O
an O
involvement O
in O
inherited O
su O
##s O
##ce O
##pt O
##ibility O
to O
cancer B-Disease
, O
these O
t B-Disease
##umour I-Disease
suppress O
##or O
genes O
are O
targets O
for O
so O
##matic O
mutations O
in O
s B-Disease
##poradic I-Disease
cancer I-Disease
##s I-Disease
of O
the O
same O
type O
found O
in O
the O
f O
##ami O
##lial O
forms O
. O

an O
exception O
is O
br O
##ca O
##1 O
, O
which O
contributes O
to O
a O
significant O
fraction O
of O
f B-Disease
##ami I-Disease
##lial I-Disease
breast I-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
, O
but O
undergo O
##es O
mutation O
at O
very O
low O
rates O
in O
s B-Disease
##poradic I-Disease
breast I-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
##s I-Disease
. O

this O
finding O
suggests O
that O
other O
genes O
may O
be O
the O
principal O
targets O
for O
so O
##matic O
mutation O
in O
breast B-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
. O

a O
second O
, O
recently O
identified O
f B-Disease
##ami I-Disease
##lial I-Disease
breast I-Disease
cancer I-Disease
gene O
, O
br O
##ca O
##2 O
( O
re O
##fs O
5 O
- O
8 O
) O
, O
accounts O
for O
a O
proportion O
of O
breast B-Disease
cancer I-Disease
roughly O
equal O
to O
br O
##ca O
##1 O
. O

like O
br O
##ca O
##1 O
, O
br O
##ca O
##2 O
behave O
##s O
as O
a O
dominant O
##ly O
inherited O
t B-Disease
##umour I-Disease
suppress O
##or O
gene O
. O

individuals O
who O
inherit O
one O
mutant O
all O
##ele O
are O
at O
increased O
risk O
for O
breast B-Disease
cancer I-Disease
, O
and O
the O
t B-Disease
##umour I-Disease
##s I-Disease
they O
develop O
lose O
the O
wild O
- O
type O
all O
##ele O
by O
he O
##tero O
##zy O
##go O
##us O
del O
##eti O
##on O
. O

the O
br O
##ca O
##2 O
coding O
sequence O
is O
huge O
, O
composed O
of O
26 O
ex O
##ons O
that O
span O
10 O
, O
44 O
##3 O
b O
##p O
. O

here O
we O
investigate O
the O
rate O
of O
br O
##ca O
##2 O
mutation O
in O
s B-Disease
##poradic I-Disease
breast I-Disease
cancer I-Disease
##s I-Disease
and O
in O
a O
set O
of O
cell O
lines O
that O
represent O
twelve O
other O
t B-Disease
##umour I-Disease
types O
. O

surprisingly O
, O
mutations O
in O
br O
##ca O
##2 O
are O
in O
##f O
##re O
##quent O
in O
cancer B-Disease
##s I-Disease
including O
breast B-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
. O

however O
, O
a O
probable O
g O
##er O
##m O
##line O
mutation O
in O
a O
pan B-Disease
##cre I-Disease
##atic I-Disease
t I-Disease
##umour I-Disease
cell O
line O
suggests O
a O
role O
for O
br O
##ca O
##2 O
in O
su O
##s O
##ce O
##pt O
##ibility O
to O
pan B-Disease
##cre I-Disease
##atic I-Disease
cancer I-Disease
. O
. O

founding O
br O
##ca O
##1 O
mutations O
in O
hereditary B-Disease
breast I-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
in O
southern O
s O
##wed O
##en O
. O

nine O
different O
g O
##er O
##m O
- O
line O
mutations O
in O
the O
br O
##ca O
##1 O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
su O
##s O
##ce O
##pt O
##ibility O
gene O
were O
identified O
in O
15 O
of O
47 O
kind O
##red O
##s O
from O
southern O
s O
##wed O
##en O
, O
by O
use O
of O
s O
##s O
##c O
##p O
and O
he O
##tero O
##du O
##plex O
analysis O
of O
all O
ex O
##ons O
and O
flank O
##ing O
intro O
##n O
region O
and O
by O
a O
protein O
- O
t O
##run O
##cation O
test O
for O
ex O
##on O
11 O
, O
followed O
by O
direct O
se O
##quencing O
. O

all O
but O
one O
of O
the O
mutations O
are O
predicted O
to O
give O
rise O
to O
premature O
translation O
termination O
and O
include O
seven O
frames O
##hi O
##ft O
insertion O
##s O
or O
del O
##eti O
##ons O
, O
a O
nonsense O
mutation O
, O
and O
a O
s O
##p O
##lice O
accept O
##or O
site O
mutation O
. O

the O
remaining O
mutation O
is O
a O
miss O
##ense O
mutation O
( O
c O
##ys O
##6 O
##1 O
##gly O
) O
in O
the O
zinc O
- O
binding O
motif O
. O

four O
novel O
s O
##wed O
##ish O
founding O
mutations O
were O
identified O
the O
n O
##uc O
##leo O
##tide O
25 O
##9 O
##5 O
del O
##eti O
##on O
a O
was O
found O
in O
five O
families O
, O
the O
c O
1806 O
t O
nonsense O
mutation O
in O
three O
families O
, O
the O
316 O
##6 O
insertion O
t O
##ga O
##ga O
in O
three O
families O
, O
and O
the O
n O
##uc O
##leo O
##tide O
120 O
##1 O
del O
##eti O
##on O
11 O
in O
two O
families O
. O

analysis O
of O
the O
in O
##tra O
##genic O
p O
##oly O
##mor O
##phism O
d O
##17 O
##s O
##8 O
##55 O
supports O
common O
origins O
of O
the O
mutations O
. O

eleven O
of O
the O
15 O
kind O
##red O
##s O
manifest O
##ing O
br O
##ca O
##1 O
mutations O
were O
breast B-Disease
- I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
families O
, O
several O
of O
them O
with O
a O
predominant O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
p O
##hen O
##otype O
. O

the O
set O
of O
32 O
families O
in O
which O
no O
br O
##ca O
##1 O
alterations O
were O
detected O
included O
1 O
breast B-Disease
- I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
kind O
##red O
manifest O
##ing O
clear O
link O
##age O
to O
the O
br O
##ca O
##1 O
region O
and O
loss O
of O
the O
wild O
- O
type O
chromosome O
in O
associated O
tumors B-Disease
. O

other O
tumor B-Disease
types O
found O
in O
br O
##ca O
##1 O
mutation O
/ O
ha O
##p O
##lot O
##ype O
carriers O
included O
pro B-Disease
##static I-Disease
, I-Disease
pan I-Disease
##cre I-Disease
##as I-Disease
, I-Disease
skin I-Disease
, I-Disease
and I-Disease
lung I-Disease
cancer I-Disease
, O
a O
ma B-Disease
##li I-Disease
##gnant I-Disease
me I-Disease
##lan I-Disease
##oma I-Disease
, O
an O
o B-Disease
##li I-Disease
##go I-Disease
##den I-Disease
##dr I-Disease
##og I-Disease
##lio I-Disease
##ma I-Disease
, O
and O
a O
car B-Disease
##cin I-Disease
##osa I-Disease
##rc I-Disease
##oma I-Disease
. O

in O
all O
, O
12 O
of O
16 O
kind O
##red O
##s O
manifest O
##ing O
br O
##ca O
##1 O
mutation O
or O
link O
##age O
contained O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
, O
as O
compared O
with O
only O
6 O
of O
the O
remaining O
31 O
families O
( O
p O
[UNK] O
. O
00 O
##1 O
) O
. O

the O
present O
study O
confirms O
the O
involvement O
of O
br O
##ca O
##1 O
in O
disease O
pre O
##dis O
##position O
for O
a O
subset O
of O
hereditary B-Disease
breast I-Disease
cancer I-Disease
families O
often O
characterized O
by O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
##s I-Disease
. O

rapid O
detection O
of O
regional O
##ly O
cluster O
##ed O
g O
##er O
##m O
- O
line O
br O
##ca O
##1 O
mutations O
by O
multiple O
##x O
he O
##tero O
##du O
##plex O
analysis O
. O

uk O
##cc O
##c O
##r O
f O
##ami O
##lial O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
study O
group O
. O

g O
##er O
##m O
- O
line O
mutations O
of O
the O
br O
##ca O
##1 O
gene O
are O
responsible O
for O
a O
substantial O
proportion O
of O
families O
with O
multiple O
cases O
of O
early O
- O
onset O
breast B-Disease
and I-Disease
/ I-Disease
or I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
. O

since O
the O
isolation O
of O
br O
##ca O
##1 O
last O
year O
, O
[UNK] O
65 O
distinct O
mutations O
scattered O
throughout O
the O
coding O
region O
have O
been O
detected O
, O
making O
analysis O
of O
the O
gene O
time O
consuming O
and O
technically O
challenging O
. O

we O
have O
developed O
a O
multiple O
##x O
he O
##tero O
##du O
##plex O
analysis O
that O
is O
designed O
to O
analyze O
one O
- O
quarter O
of O
the O
coding O
sequence O
in O
a O
single O
- O
step O
screening O
procedure O
and O
that O
will O
detect O
approximately O
50 O
% O
of O
all O
br O
##ca O
##1 O
mutations O
so O
far O
reported O
in O
breast B-Disease
/ I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
families O
. O

we O
have O
used O
this O
technique O
to O
analyze O
br O
##ca O
##1 O
in O
162 O
families O
with O
a O
history O
of O
breast B-Disease
and I-Disease
/ I-Disease
or I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
and O
identified O
12 O
distinct O
mutations O
in O
35 O
families O
. O
. O

a O
previously O
und O
##es O
##cribed O
mutation O
within O
the O
te O
##tra O
##mer O
##isation O
domain O
of O
t O
##p O
##53 O
in O
a O
family O
with O
l B-Disease
##i I-Disease
- I-Disease
f I-Disease
##ra I-Disease
##ume I-Disease
##ni I-Disease
syndrome I-Disease
. O

we O
report O
details O
of O
a O
family O
with O
classic O
l B-Disease
##i I-Disease
- I-Disease
f I-Disease
##ra I-Disease
##ume I-Disease
##ni I-Disease
syndrome I-Disease
in O
which O
there O
is O
a O
mutation O
in O
co O
##don O
34 O
##4 O
of O
the O
t B-Disease
##umour I-Disease
suppress O
##or O
gene O
t O
##p O
##53 O
. O

co O
##don O
34 O
##4 O
is O
a O
key O
residue O
within O
the O
te O
##tra O
##mer O
##isation O
domain O
, O
and O
the O
amino O
acid O
substitution O
of O
a O
pro O
##line O
for O
a O
le O
##uc O
##ine O
is O
predicted O
to O
have O
profound O
implications O
for O
te O
##tra O
##mer O
##isation O
and O
potentially O
d O
##na O
binding O
. O

this O
is O
the O
first O
report O
of O
a O
mutation O
at O
this O
residue O
in O
either O
s B-Disease
##poradic I-Disease
t I-Disease
##umour I-Disease
##s I-Disease
or O
in O
the O
g O
##er O
##m O
##line O
and O
the O
first O
report O
of O
a O
g O
##er O
##m O
##line O
mutation O
within O
the O
te O
##tra O
##mer O
##isation O
domain O
. O

the O
family O
does O
not O
appear O
to O
be O
remarkable O
in O
the O
spectrum O
of O
t B-Disease
##umour I-Disease
##s I-Disease
, O
and O
there O
is O
loss O
of O
the O
wild O
- O
type O
all O
##ele O
in O
a O
le B-Disease
##io I-Disease
##my I-Disease
##osa I-Disease
##rc I-Disease
##oma I-Disease
from O
the O
pro O
##band O
. O

a O
cell O
line O
has O
been O
established O
from O
the O
t B-Disease
##umour I-Disease
of O
the O
pro O
##band O
and O
c O
##yt O
##ogen O
##etic O
and O
molecular O
studies O
carried O
out O
, O
providing O
an O
extensive O
analysis O
in O
this O
family O
. O
. O

the O
spectrum O
of O
r O
##b O
##1 O
g O
##er O
##m O
- O
line O
mutations O
in O
hereditary B-Disease
re I-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
. O

we O
have O
searched O
for O
g O
##er O
##m O
- O
line O
r O
##b O
##1 O
mutations O
in O
119 O
patients O
with O
hereditary B-Disease
re I-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
. O

previous O
investigations O
by O
southern O
b O
##lot O
hybrid O
##ization O
and O
p O
##c O
##r O
fragment O
- O
length O
analysis O
had O
revealed O
mutations O
in O
48 O
patients O
. O

here O
we O
report O
on O
the O
analysis O
of O
the O
remaining O
71 O
patients O
. O

by O
applying O
he O
##tero O
##du O
##plex O
analysis O
, O
non O
##is O
##oto O
##pic O
s O
##s O
##c O
##p O
, O
and O
direct O
se O
##quencing O
, O
we O
detected O
g O
##er O
##m O
- O
line O
mutations O
resulting O
in O
premature O
termination O
co O
##don O
##s O
or O
disruption O
of O
s O
##p O
##lice O
signals O
in O
51 O
( O
72 O
% O
) O
of O
the O
71 O
patients O
. O

four O
patients O
also O
showed O
rare O
sequence O
variants O
. O

no O
region O
of O
the O
r O
##b O
##1 O
gene O
was O
prefer O
##ential O
##ly O
involved O
in O
single O
base O
substitution O
##s O
. O

re O
##current O
transitions O
were O
observed O
at O
most O
of O
the O
14 O
co O
##don O
##s O
within O
the O
r O
##b O
##1 O
. O

no O
mutation O
was O
observed O
in O
ex O
##ons O
25 O
- O
27 O
, O
although O
this O
region O
contains O
two O
c O
##ga O
co O
##don O
##s O
. O

this O
suggests O
that O
mutations O
within O
the O
3 O
- O
terminal O
region O
of O
the O
r O
##b O
##1 O
gene O
may O
not O
be O
on O
##co O
##genic O
. O

when O
these O
data O
were O
combined O
with O
the O
results O
of O
our O
previous O
investigations O
, O
mutations O
were O
identified O
in O
a O
total O
of O
99 O
( O
83 O
% O
) O
of O
119 O
patients O
. O

the O
spectrum O
comprises O
15 O
% O
large O
del O
##eti O
##ons O
, O
26 O
% O
small O
length O
alterations O
, O
and O
42 O
% O
base O
substitution O
##s O
. O

no O
correlation O
between O
the O
location O
of O
frames O
##hi O
##ft O
or O
nonsense O
mutations O
and O
p O
##hen O
##otypic O
features O
, O
including O
age O
at O
diagnosis O
, O
the O
number O
of O
tumor B-Disease
f O
##oc O
##i O
, O
and O
manifest O
##ation O
of O
non B-Disease
##oc I-Disease
##ular I-Disease
tumors I-Disease
was O
observed O
. O
. O

p O
##hen O
##otypic O
characterization O
of O
individuals O
with O
30 O
- O
40 O
ca O
##g O
repeats O
in O
the O
hunting B-Disease
##ton I-Disease
disease I-Disease
( O
h B-Disease
##d I-Disease
) O
gene O
reveals O
h B-Disease
##d I-Disease
cases O
with O
36 O
repeats O
and O
apparently O
normal O
elderly O
individuals O
with O
36 O
- O
39 O
repeats O
. O

abnormal O
ca O
##g O
expansion O
##s O
in O
the O
it O
- O
15 O
gene O
are O
associated O
with O
hunting B-Disease
##ton I-Disease
disease I-Disease
( O
h B-Disease
##d I-Disease
) O
. O

in O
the O
diagnostic O
setting O
it O
is O
necessary O
to O
define O
the O
limits O
of O
the O
ca O
##g O
size O
ranges O
on O
normal O
and O
h B-Disease
##d I-Disease
- O
associated O
chromosome O
##s O
. O

most O
large O
analyses O
that O
defined O
the O
limits O
of O
the O
normal O
and O
path O
##ological O
size O
ranges O
employed O
p O
##c O
##r O
ass O
##ays O
, O
which O
included O
the O
ca O
##g O
repeats O
and O
a O
cc O
##g O
repeat O
tract O
that O
was O
thought O
to O
be O
invariant O
. O

many O
of O
these O
experiments O
found O
an O
overlap O
between O
the O
normal O
and O
disease O
size O
ranges O
. O

subsequent O
findings O
that O
the O
cc O
##g O
repeats O
vary O
by O
8 O
t O
##rin O
##uc O
##leo O
##tide O
lengths O
suggested O
that O
the O
limits O
of O
the O
normal O
and O
disease O
size O
ranges O
should O
be O
re O
##eval O
##uated O
with O
ass O
##ays O
that O
exclude O
the O
cc O
##g O
p O
##oly O
##mor O
##phism O
. O

since O
patients O
with O
between O
30 O
and O
40 O
repeats O
are O
rare O
, O
a O
consortium O
was O
assembled O
to O
collect O
such O
individuals O
. O

all O
178 O
samples O
were O
re O
##ana O
##ly O
##zed O
in O
ca O
##mb O
##ridge O
by O
using O
ass O
##ays O
specific O
for O
the O
ca O
##g O
repeats O
. O

we O
have O
op O
##ti O
##mized O
methods O
for O
reliable O
si O
##zing O
of O
ca O
##g O
repeats O
and O
show O
cases O
that O
demonstrate O
the O
dangers O
of O
using O
p O
##c O
##r O
ass O
##ays O
that O
include O
both O
the O
ca O
##g O
and O
cc O
##g O
p O
##oly O
##mor O
##phism O
##s O
. O

seven O
h B-Disease
##d I-Disease
patients O
had O
36 O
repeats O
, O
which O
confirms O
that O
this O
all O
##ele O
is O
associated O
with O
disease O
. O

individuals O
without O
apparent O
symptoms O
or O
signs O
of O
h B-Disease
##d I-Disease
were O
found O
at O
36 O
repeats O
( O
aged O
74 O
, O
78 O
, O
79 O
, O
and O
87 O
years O
) O
, O
37 O
repeats O
( O
aged O
69 O
years O
) O
, O
38 O
repeats O
( O
aged O
69 O
and O
90 O
years O
) O
, O
and O
39 O
repeats O
( O
aged O
67 O
, O
90 O
, O
and O
95 O
years O
) O
. O

the O
detailed O
case O
histories O
of O
an O
exceptional O
case O
from O
this O
series O
will O
be O
presented O
a O
95 O
- O
year O
- O
old O
man O
with O
39 O
repeats O
who O
did O
not O
have O
classical O
features O
of O
h B-Disease
##d I-Disease
. O

the O
apparently O
healthy O
survival O
into O
old O
age O
of O
some O
individuals O
with O
36 O
- O
39 O
repeats O
suggests O
that O
the O
h B-Disease
##d I-Disease
mutation O
may O
not O
always O
be O
fully O
pen O
##et O
##rant O
. O
. O

identification O
and O
expression O
of O
eight O
novel O
mutations O
among O
non O
- O
j O
##ew O
##ish O
patients O
with O
can B-Disease
##avan I-Disease
disease I-Disease
. O

can B-Disease
##avan I-Disease
disease I-Disease
is O
inherited O
as O
an O
auto O
##so O
##mal O
re O
##cess O
##ive O
trait O
that O
is O
caused O
by O
the O
deficiency B-Disease
of I-Disease
as I-Disease
##par I-Disease
##to I-Disease
##acy I-Disease
##lase I-Disease
( O
as O
##pa O
) O
. O

the O
majority O
of O
patients O
with O
can B-Disease
##avan I-Disease
disease I-Disease
are O
from O
an O
ash O
##ken O
##azi O
j O
##ew O
##ish O
background O
. O

mutations O
in O
as O
##pa O
that O
lead O
to O
loss O
of O
en O
##zy O
##matic O
activity O
have O
been O
identified O
, O
and O
e O
##28 O
##5 O
##a O
and O
y O
##23 O
##1 O
##x O
are O
the O
two O
predominant O
mutations O
that O
account O
for O
97 O
% O
of O
the O
mutant O
chromosome O
##s O
in O
ash O
##ken O
##azi O
j O
##ew O
##ish O
patients O
. O

the O
current O
study O
was O
aimed O
at O
finding O
the O
molecular O
basis O
of O
can B-Disease
##avan I-Disease
disease I-Disease
in O
25 O
independent O
patients O
of O
non O
- O
j O
##ew O
##ish O
background O
. O

eight O
novel O
and O
three O
previously O
characterized O
mutations O
accounted O
for O
80 O
% O
( O
40 O
/ O
50 O
) O
of O
mutant O
chromosome O
##s O
. O

the O
a O
##30 O
##5 O
##e O
miss O
##ense O
mutation O
accounted O
for O
48 O
% O
( O
24 O
/ O
50 O
) O
of O
mutant O
chromosome O
##s O
in O
patients O
of O
western O
euro O
##pe O
##an O
descent O
, O
while O
the O
two O
predominant O
j O
##ew O
##ish O
mutations O
each O
accounted O
for O
a O
single O
mutant O
chromosome O
. O

the O
eight O
novel O
mutations O
identified O
included O
1 O
- O
and O
4 O
- O
b O
##p O
del O
##eti O
##ons O
( O
32 O
delta O
##t O
and O
87 O
##6 O
delta O
##aga O
##a O
, O
respectively O
) O
and O
i O
##16 O
##t O
, O
g O
##27 O
##r O
, O
d O
##11 O
##4 O
##e O
, O
g O
##12 O
##3 O
##e O
, O
c O
##15 O
##2 O
##y O
, O
and O
r O
##16 O
##8 O
##c O
miss O
##ense O
mutations O
. O

the O
ho O
##mo O
##zy O
##go O
##us O
32 O
delta O
##t O
del O
##eti O
##on O
was O
identified O
in O
the O
only O
known O
patient O
of O
a O
##f O
##rica O
##n O
- O
am O
##eric O
##an O
origin O
with O
can B-Disease
##avan I-Disease
disease I-Disease
. O

the O
he O
##tero O
##zy O
##gos O
##ity O
for O
87 O
##6 O
delta O
##aga O
##a O
mutation O
was O
identified O
in O
three O
independent O
patients O
from O
en O
##g O
##land O
. O

six O
single O
- O
base O
changes O
leading O
to O
miss O
##ense O
mutations O
were O
identified O
in O
patients O
from O
turkey O
( O
d O
##11 O
##4 O
##e O
, O
r O
##16 O
##8 O
##c O
) O
, O
the O
net O
##her O
##lands O
( O
i O
##16 O
##t O
) O
, O
g O
##erman O
##y O
( O
g O
##27 O
##r O
) O
, O
i O
##rel O
##and O
( O
c O
##15 O
##2 O
##y O
) O
, O
and O
can O
##ada O
( O
g O
##12 O
##3 O
##e O
) O
. O

a O
p O
##c O
##r O
- O
based O
protocol O
is O
described O
that O
was O
used O
to O
introduce O
mutations O
in O
wild O
- O
type O
c O
##dn O
##a O
. O

in O
v O
##it O
##ro O
expression O
of O
mutant O
c O
##dn O
##a O
clone O
##s O
demonstrated O
that O
all O
of O
these O
mutations O
led O
to O
a O
deficiency B-Disease
of I-Disease
as I-Disease
##pa I-Disease
and O
should O
therefore O
result O
in O
can B-Disease
##avan I-Disease
disease I-Disease
. O
. O

identification O
and O
ch O
##rom O
##oso O
##mal O
local O
##ization O
of O
at O
##m O
, O
the O
mouse O
ho O
##mo O
##log O
of O
the O
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
gene O
. O

at O
##m O
, O
the O
mouse O
ho O
##mo O
##log O
of O
the O
human O
at O
##m O
gene O
defect O
##ive O
in O
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
( O
a B-Disease
- I-Disease
t I-Disease
) O
, O
has O
been O
identified O
. O

the O
entire O
coding O
sequence O
of O
the O
at O
##m O
trans O
##cript O
was O
clone O
##d O
and O
found O
to O
contain O
an O
open O
reading O
frame O
encoding O
a O
protein O
of O
306 O
##6 O
amino O
acids O
with O
84 O
% O
overall O
identity O
and O
91 O
% O
similarity O
to O
the O
human O
at O
##m O
protein O
. O

variable O
levels O
of O
expression O
of O
at O
##m O
were O
observed O
in O
different O
tissues O
. O

flu O
##ores O
##cence O
in O
sit O
##u O
hybrid O
##ization O
and O
link O
##age O
analysis O
located O
the O
at O
##m O
gene O
on O
mouse O
chromosome O
9 O
, O
band O
9 O
##c O
, O
in O
a O
region O
ho O
##mo O
##log O
##ous O
to O
the O
at O
##m O
region O
on O
human O
chromosome O
11 O
##q O
##22 O
- O
q O
##23 O
. O
. O

the O
mouse O
ho O
##mo O
##log O
of O
the O
w B-Disease
##isk I-Disease
##ott I-Disease
- I-Disease
al I-Disease
##dric I-Disease
##h I-Disease
syndrome I-Disease
protein O
( O
was O
##p O
) O
gene O
is O
highly O
conserved O
and O
maps O
near O
the O
s O
##cu O
##rf O
##y O
( O
s O
##f O
) O
mutation O
on O
the O
x O
chromosome O
. O

the O
mouse O
was O
##p O
gene O
, O
the O
ho O
##mo O
##log O
of O
the O
gene O
m O
##uta O
##ted O
in O
w B-Disease
##isk I-Disease
##ott I-Disease
- I-Disease
al I-Disease
##dric I-Disease
##h I-Disease
syndrome I-Disease
, O
has O
been O
isolated O
and O
sequence O
##d O
. O
the O
predicted O
amino O
acid O
sequence O
is O
86 O
% O
identical O
to O
the O
human O
was O
##p O
sequence O
. O

a O
distinct O
feature O
of O
the O
mouse O
gene O
is O
an O
expanded O
p O
##oly O
##morphic O
g O
##ga O
t O
##rin O
##uc O
##leo O
##tide O
repeat O
that O
codes O
for O
p O
##oly O
##gly O
##cine O
and O
varies O
from O
15 O
to O
17 O
triple O
##ts O
in O
different O
m O
##us O
m O
##us O
##culus O
strains O
. O

the O
g O
##eno O
##mic O
structure O
of O
the O
mouse O
was O
##p O
gene O
is O
expressed O
as O
an O
approximately O
2 O
. O

4 O
- O
k O
##b O
m O
##rna O
in O
thy O
##mus O
and O
s O
##ple O
##en O
. O

ch O
##rom O
##oso O
##mal O
mapping O
in O
an O
inter O
##sp O
##ec O
##ific O
m O
. O

m O
##us O
##culus O
/ O
m O
. O
s O
##p O
##ret O
##us O
back O
##cross O
placed O
the O
was O
##p O
lo O
##cus O
near O
the O
cent O
##rome O
##re O
of O
the O
mouse O
x O
chromosome O
, O
ins O
##ep O
##ara O
##ble O
from O
g O
##ata O
##1 O
, O
t O
##c O
##fe O
##3 O
, O
and O
s O
##cu O
##rf O
##y O
( O
s O
##f O
) O
. O

this O
local O
##ization O
makes O
was O
##p O
a O
candidate O
for O
involvement O
in O
s O
##cu O
##rf O
##y O
, O
a O
t O
cell O
- O
mediated O
fatal B-Disease
l I-Disease
##ymph I-Disease
##ore I-Disease
##tic I-Disease
##ular I-Disease
disease I-Disease
of O
mice O
that O
has O
previously O
been O
proposed O
as O
a O
mouse O
ho O
##mo O
##log O
of O
w B-Disease
##isk I-Disease
##ott I-Disease
- I-Disease
al I-Disease
##dric I-Disease
##h I-Disease
syndrome I-Disease
. O

northern O
analysis O
of O
s O
##f O
tissue O
samples O
indicated O
the O
presence O
of O
was O
##p O
m O
##rna O
in O
liver O
and O
skin O
, O
presumably O
as O
a O
consequence O
of O
l O
##ymph O
##oc O
##ytic O
in O
##fi O
##ltration O
, O
but O
non O
abnormal O
##ities O
in O
the O
amount O
or O
size O
of O
m O
##rna O
present O
. O

co O
##l O
##chi O
##cine O
in O
breast O
milk O
of O
patients O
with O
f B-Disease
##ami I-Disease
##lial I-Disease
me I-Disease
##dit I-Disease
##er I-Disease
##rane I-Disease
##an I-Disease
fever I-Disease
. O

objective O
. O

to O
c O
##lar O
##ify O
whether O
co O
##l O
##chi O
##cine O
is O
ex O
##cre O
##ted O
in O
breast O
milk O
, O
and O
to O
compare O
its O
concentrations O
in O
the O
serum O
and O
breast O
milk O
of O
la O
##ct O
##ating O
women O
who O
have O
f B-Disease
##ami I-Disease
##lial I-Disease
me I-Disease
##dit I-Disease
##er I-Disease
##rane I-Disease
##an I-Disease
fever I-Disease
( O
f B-Disease
##m I-Disease
##f I-Disease
) O
. O

methods O
. O

using O
a O
specific O
radio O
##im O
##mu O
##no O
##ass O
##ay O
, O
we O
determined O
co O
##l O
##chi O
##cine O
concentrations O
in O
the O
serum O
and O
breast O
milk O
of O
4 O
patients O
at O
various O
time O
points O
, O
following O
oral O
administration O
of O
the O
drug O
. O

the O
study O
evaluated O
4 O
patients O
with O
f B-Disease
##m I-Disease
##f I-Disease
who O
had O
been O
taking O
co O
##l O
##chi O
##cine O
on O
a O
long O
- O
term O
basis O
. O

results O
. O

co O
##l O
##chi O
##cine O
was O
found O
to O
be O
ex O
##cre O
##ted O
in O
breast O
milk O
. O

its O
levels O
ranged O
between O
1 O
. O

9 O
and O
8 O
. O

6 O
ng O
/ O
m O
##l O
, O
which O
were O
similar O
to O
those O
found O
in O
the O
serum O
( O
parallel O
concentration O
time O
curves O
) O
. O

however O
, O
there O
appeared O
to O
be O
a O
considerable O
variation O
in O
co O
##l O
##chi O
##cine O
milk O
concentration O
among O
the O
different O
patients O
, O
which O
might O
be O
related O
to O
individual O
breast O
milk O
composition O
and O
, O
possibly O
, O
to O
other O
nutrition O
##al O
or O
metabolic O
factors O
. O

conclusion O
. O

the O
extensive O
peripheral O
tissue O
binding O
and O
relatively O
low O
concentration O
of O
co O
##l O
##chi O
##cine O
in O
breast O
milk O
suggests O
that O
the O
amount O
ing O
##ested O
by O
the O
infant O
is O
small O
. O

further O
##more O
, O
based O
on O
our O
clinical O
experience O
, O
nursing O
appears O
to O
be O
safe O
for O
la O
##ct O
##ating O
women O
with O
f B-Disease
##m I-Disease
##f I-Disease
who O
continue O
to O
take O
co O
##l O
##chi O
##cine O
. O

abnormal O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
protein O
kinase O
levels O
produce O
only O
mild O
my B-Disease
##op I-Disease
##athy I-Disease
in O
mice O
. O

my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
) O
is O
commonly O
associated O
with O
c O
##t O
##g O
repeat O
expansion O
##s O
within O
the O
gene O
for O
d O
##m O
- O
protein O
kinase O
( O
d O
##mp O
##k O
) O
. O

the O
effect O
of O
altered O
expression O
levels O
of O
d O
##mp O
##k O
, O
which O
is O
u O
##bi O
##quito O
##us O
##ly O
expressed O
in O
all O
muscle O
cell O
lineage O
##s O
during O
development O
, O
was O
examined O
by O
disrupt O
##ing O
the O
end O
##ogen O
##ous O
d O
##mp O
##k O
gene O
and O
over O
##ex O
##pressing O
a O
normal O
human O
d O
##mp O
##k O
trans O
##gene O
in O
mice O
. O

null O
##iz O
##y O
##go O
##us O
( O
- O
/ O
- O
) O
mice O
showed O
only O
inconsistent O
and O
minor O
size O
changes O
in O
head O
and O
neck O
muscle O
fibre O
##s O
at O
older O
age O
, O
animals O
with O
the O
highest O
d O
##mp O
##k O
trans O
##gene O
expression O
showed O
h B-Disease
##yper I-Disease
##tro I-Disease
##phic I-Disease
card I-Disease
##io I-Disease
##my I-Disease
##op I-Disease
##athy I-Disease
and O
enhanced O
neon O
##ata O
##l O
mortality O
. O

however O
, O
both O
models O
lack O
other O
frequent O
d B-Disease
##m I-Disease
symptoms O
including O
the O
fibre O
- O
type O
dependent O
at B-Disease
##rop I-Disease
##hy I-Disease
, O
my B-Disease
##oto I-Disease
##nia I-Disease
, O
cat B-Disease
##ara I-Disease
##ct I-Disease
and O
male B-Disease
- I-Disease
in I-Disease
##fer I-Disease
##tility I-Disease
. O

these O
results O
strengthen O
the O
contention O
that O
simple O
loss O
- O
or O
gain O
- O
of O
- O
expression O
of O
d O
##mp O
##k O
is O
not O
the O
only O
crucial O
requirement O
for O
development O
of O
the O
disease O
. O
. O

mice O
lacking O
the O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
protein O
kinase O
develop O
a O
late O
onset O
progressive O
my B-Disease
##op I-Disease
##athy I-Disease
. O

my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
) O
is O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
dominant I-Disease
disorder I-Disease
resulting O
from O
the O
expansion O
of O
a O
c O
##t O
##g O
repeat O
in O
the O
3 O
un O
##tra O
##ns O
##lated O
region O
of O
a O
put O
##ative O
protein O
kinase O
( O
d O
##mp O
##k O
) O
. O

to O
el O
##uc O
##ida O
##te O
the O
role O
of O
d O
##mp O
##k O
in O
d B-Disease
##m I-Disease
path O
##ogen O
##esis O
we O
have O
developed O
d B-Disease
##mp I-Disease
##k I-Disease
def I-Disease
##icient I-Disease
( O
d O
##mp O
##k O
- O
/ O
- O
) O
mice O
. O

d O
##mp O
##k O
- O
/ O
- O
mice O
develop O
a O
late O
- O
onset O
, O
progressive B-Disease
skeletal I-Disease
my I-Disease
##op I-Disease
##athy I-Disease
that O
shares O
some O
path O
##ological O
features O
with O
d B-Disease
##m I-Disease
. O

muscles O
from O
mature O
mice O
show O
variation O
in O
fibre O
size O
, O
increased O
fibre B-Disease
de I-Disease
##gene I-Disease
##ration I-Disease
and O
fi B-Disease
##bro I-Disease
##sis I-Disease
. O

adult O
d O
##mp O
##k O
- O
/ O
- O
mice O
show O
ultra O
##st O
##ructural O
changes O
in O
muscle O
and O
a O
50 O
% O
decrease O
in O
force O
generation O
compared O
to O
young O
mice O
. O

our O
results O
indicate O
that O
d O
##mp O
##k O
may O
be O
necessary O
for O
the O
maintenance O
of O
skeletal O
muscle O
structure O
and O
function O
and O
suggest O
that O
a O
decrease O
in O
d O
##mp O
##k O
levels O
may O
contribute O
to O
d B-Disease
##m I-Disease
path O
##ology O
. O
. O

the O
tumor B-Disease
suppress O
##or O
gene O
br O
##ca O
##1 O
is O
required O
for O
em O
##b O
##ryo O
##nic O
cellular O
proliferation O
in O
the O
mouse O
. O

mutations O
of O
the O
br O
##ca O
##1 O
gone O
in O
humans O
are O
associated O
with O
pre O
##dis O
##position O
to O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
##s I-Disease
. O

we O
show O
here O
that O
br O
##ca O
##1 O
+ O
/ O
- O
mice O
are O
normal O
and O
fertile O
and O
lack O
tumors B-Disease
by O
age O
eleven O
months O
. O

ho O
##mo O
##zy O
##go O
##us O
br O
##ca O
##1 O
( O
5 O
- O
6 O
) O
mutant O
mice O
die O
before O
day O
7 O
. O

5 O
of O
em O
##b O
##ryo O
##genesis O
. O

mutant O
em O
##b O
##ryo O
##s O
are O
poorly O
developed O
, O
with O
no O
evidence O
of O
me O
##so O
##der O
##m O
formation O
. O

the O
extra O
##em O
##b O
##ryo O
##nic O
region O
is O
abnormal O
, O
but O
a O
##gg O
##regation O
with O
wild O
- O
type O
te O
##tra O
##p O
##lo O
##id O
em O
##b O
##ryo O
##s O
does O
not O
rescue O
the O
lethal O
##ity O
. O

in O
v O
##ivo O
, O
mutant O
em O
##b O
##ryo O
##s O
do O
not O
exhibit O
increased O
a O
##pop O
##tosis O
but O
show O
reduced O
cell O
proliferation O
accompanied O
by O
decreased O
expression O
of O
c O
##y O
##c O
##lin O
e O
and O
m O
##d O
##m O
- O
2 O
, O
a O
regulator O
of O
p O
##53 O
activity O
. O

the O
expression O
of O
c O
##y O
##c O
##lin O
- O
dependent O
kinase O
inhibitor O
p O
##21 O
is O
dramatically O
increased O
in O
the O
mutant O
em O
##b O
##ryo O
##s O
. O

butt O
##ress O
##ing O
these O
in O
v O
##ivo O
observations O
is O
the O
fact O
that O
mutant O
blast O
##oc O
##ys O
##t O
growth O
is O
gross O
##ly O
impaired O
in O
v O
##it O
##ro O
. O

thus O
, O
the O
death O
of O
br O
##ca O
##1 O
( O
5 O
- O
6 O
) O
mutant O
em O
##b O
##ryo O
##s O
prior O
to O
gas O
##tr O
##ulation O
may O
be O
due O
to O
a O
failure O
of O
the O
pro O
##life O
##rative O
burst O
required O
for O
the O
development O
of O
the O
different O
g O
##er O
##m O
layers O
. O

increased O
co B-Disease
##rona I-Disease
##ry I-Disease
heart I-Disease
disease I-Disease
in O
j O
##apa O
##nese O
- O
am O
##eric O
##an O
men O
with O
mutation O
in O
the O
ch O
##ole O
##ster O
##yl O
est O
##er O
transfer O
protein O
gene O
despite O
increased O
h O
##dl O
levels O
. O

plasma O
high O
density O
lip O
##op O
##rote O
##in O
( O
h O
##dl O
) O
levels O
are O
strongly O
genetically O
determined O
and O
show O
a O
general O
inverse O
relationship O
with O
co B-Disease
##rona I-Disease
##ry I-Disease
heart I-Disease
disease I-Disease
( O
ch B-Disease
##d I-Disease
) O
. O

the O
ch O
##ole O
##ster O
##yl O
est O
##er O
transfer O
protein O
( O
c O
##et O
##p O
) O
media O
##tes O
the O
transfer O
of O
ch O
##ole O
##ster O
##yl O
est O
##ers O
from O
h O
##dl O
to O
other O
lip O
##op O
##rote O
##ins O
and O
is O
a O
key O
participant O
in O
the O
reverse O
transport O
of O
ch O
##ole O
##ster O
##ol O
from O
the O
periphery O
to O
the O
liver O
. O

a O
high O
prevalence O
of O
two O
different O
c O
##et O
##p O
gene O
mutations O
( O
d O
##44 O
##2 O
##g O
, O
5 O
. O
1 O
% O
; O
intro O
##n O
14 O
##g O
a O
, O
0 O
. O
5 O
% O
) O
, O
was O
found O
in O
3 O
, O
46 O
##9 O
men O
of O
j O
##apa O
##nese O
ancestry O
in O
the O
ho O
##no O
##lu O
##lu O
heart O
program O
and O
mutations O
were O
associated O
with O
decreased O
c O
##et O
##p O
( O
- O
35 O
% O
) O
and O
increased O
h O
##dl O
ch O
##ol O
levels O
( O
+ O
10 O
% O
for O
d O
##44 O
##2 O
##g O
) O
. O

however O
, O
the O
overall O
prevalence O
of O
definite O
ch B-Disease
##d I-Disease
was O
21 O
% O
in O
men O
with O
mutations O
and O
16 O
% O
in O
men O
without O
mutations O
. O

the O
relative O
risk O
( O
r O
##r O
) O
of O
ch B-Disease
##d I-Disease
was O
1 O
. O

43 O
in O
men O
with O
mutations O
( O
p O
[UNK] O
. O
05 O
) O
; O
after O
adjustment O
for O
ch B-Disease
##d I-Disease
risk O
factors O
, O
the O
r O
##r O
was O
1 O
. O

55 O
( O
p O
= O
. O
02 O
) O
; O
after O
additional O
adjustment O
for O
h O
##dl O
levels O
, O
the O
r O
##r O
was O
1 O
. O

68 O
( O
p O
= O
. O
00 O
##8 O
) O
. O

similar O
r O
##r O
values O
were O
obtained O
for O
the O
d O
##44 O
##2 O
##g O
mutation O
alone O
. O

increased O
ch B-Disease
##d I-Disease
in O
men O
with O
mutations O
was O
primarily O
observed O
for O
h O
##dl O
ch O
##ol O
41 O
- O
60 O
mg O
/ O
d O
##l O
; O
for O
h O
##dl O
ch O
##ol O
[UNK] O
60 O
mg O
/ O
d O
##l O
men O
with O
and O
without O
mutations O
had O
low O
ch B-Disease
##d I-Disease
prevalence O
. O

thus O
, O
genetic O
c B-Disease
##et I-Disease
##p I-Disease
deficiency I-Disease
appears O
to O
be O
an O
independent O
risk O
factor O
for O
ch B-Disease
##d I-Disease
, O
primarily O
due O
to O
increased O
ch B-Disease
##d I-Disease
prevalence O
in O
men O
with O
the O
d O
##44 O
##2 O
##g O
mutation O
and O
h O
##dl O
ch O
##ole O
##ster O
##ol O
between O
41 O
and O
60 O
mg O
/ O
d O
##l O
. O

the O
findings O
suggest O
that O
both O
h O
##dl O
concentration O
and O
the O
dynamics O
of O
ch O
##ole O
##ster O
##ol O
transport O
through O
h O
##dl O
( O
i O
. O
e O
. O
, O
reverse O
ch O
##ole O
##ster O
##ol O
transport O
) O
determine O
the O
anti O
- O
at O
##her O
##ogenic O
##ity O
of O
the O
h O
##dl O
fraction O
. O

mapping O
the O
ho O
##mo O
##log O
of O
the O
human O
r O
##b O
##1 O
gene O
to O
chromosome O
14 O
of O
higher O
p O
##rima O
##tes O
. O

the O
r O
##b O
##1 O
gene O
has O
been O
implicated O
with O
re B-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
and O
is O
located O
on O
human O
chromosome O
( O
ch O
##r O
) O
13 O
##q O
##14 O
. O

2 O
2 O
. O

a O
unique O
sequence O
human O
r O
##b O
##1 O
co O
##sm O
##id O
d O
##na O
probe O
has O
been O
used O
to O
local O
##ize O
this O
region O
on O
a O
##pes O
ch O
##r O
14 O
by O
the O
fish O
technique O
. O

the O
conservation O
of O
the O
r O
##b O
##1 O
gene O
in O
higher O
p O
##rima O
##tes O
at O
the O
corresponding O
equivalent O
chromosome O
lo O
##cus O
( O
14 O
##q O
##14 O
) O
of O
the O
human O
may O
serve O
as O
a O
phylogenetic O
marker O
to O
further O
trace O
the O
evolutionary O
pathway O
of O
human O
descent O
. O

w B-Disease
##isk I-Disease
##ott I-Disease
- I-Disease
al I-Disease
##dric I-Disease
##h I-Disease
syndrome I-Disease
: O
no O
strict O
g O
##eno O
##type O
- O
p O
##hen O
##otype O
correlation O
##s O
but O
cluster O
##ing O
of O
miss O
##ense O
mutations O
in O
the O
amino O
- O
terminal O
part O
of O
the O
was O
##p O
gene O
product O
. O

the O
w B-Disease
##isk I-Disease
##ott I-Disease
- I-Disease
al I-Disease
##dric I-Disease
##h I-Disease
syndrome I-Disease
protein O
( O
was O
##p O
) O
gene O
was O
found O
to O
be O
m O
##uta O
##ted O
in O
patients O
presenting O
with O
was B-Disease
and O
in O
patients O
showing O
x B-Disease
- I-Disease
linked I-Disease
th I-Disease
##rom I-Disease
##bo I-Disease
##cy I-Disease
##top I-Disease
##enia I-Disease
. O

mutation O
analysis O
in O
19 O
families O
of O
g O
##erman O
, O
s O
##wi O
##ss O
and O
t O
##ur O
##kis O
##h O
descent O
by O
single O
- O
strand O
conform O
##ation O
p O
##oly O
##mor O
##phism O
and O
se O
##quencing O
resulted O
in O
the O
detection O
of O
seven O
novel O
and O
10 O
known O
mutations O
. O

a O
striking O
cluster O
##ing O
of O
miss O
##ense O
mutations O
in O
the O
first O
four O
ex O
##ons O
contrasted O
with O
a O
random O
distribution O
of O
nonsense O
mutations O
. O

more O
than O
85 O
% O
of O
all O
known O
miss O
##ense O
mutations O
were O
localized O
in O
the O
amino O
- O
terminal O
stretch O
of O
the O
was O
##p O
gene O
product O
; O
this O
region O
contained O
a O
mutation O
##al O
hot O
spot O
at O
co O
##don O
86 O
. O

no O
g O
##eno O
##type O
- O
p O
##hen O
##otype O
correlation O
emerged O
after O
a O
comparison O
of O
the O
identified O
mutations O
with O
the O
resulting O
clinical O
picture O
for O
a O
classical O
was B-Disease
p O
##hen O
##otype O
. O

a O
substitution O
at O
co O
##don O
86 O
resulted O
in O
an O
extremely O
variable O
expression O
of O
the O
disease O
in O
a O
large O
s O
##wi O
##ss O
family O
. O

an O
extended O
ho O
##mology O
search O
revealed O
a O
distant O
relationship O
of O
this O
stretch O
to O
the O
v O
##as O
##od O
##ila O
##tor O
- O
stimulate O
##d O
p O
##hos O
##ph O
##op O
##rote O
##in O
( O
v O
##as O
##p O
) O
, O
which O
is O
involved O
in O
the O
maintenance O
of O
c O
##yt O
##o O
- O
architecture O
by O
interacting O
with O
act O
##in O
- O
like O
fi O
##lam O
##ents O
. O
. O

influence O
of O
p O
##ax O
##6 O
gene O
dos O
##age O
on O
development O
: O
over O
##ex O
##press O
##ion O
causes O
severe O
eye B-Disease
abnormal I-Disease
##ities I-Disease
. O

an B-Disease
##iri I-Disease
##dia I-Disease
in O
man O
and O
small O
eye O
in O
mice O
are O
semi B-Disease
##dom I-Disease
##ina I-Disease
##nt I-Disease
developmental I-Disease
disorders I-Disease
caused O
by O
mutations O
within O
the O
paired O
box O
gene O
p O
##ax O
##6 O
. O

whereas O
he O
##tero O
##zy O
##got O
##es O
suffer O
from O
i B-Disease
##ris I-Disease
h I-Disease
##y I-Disease
##pop I-Disease
##lasia I-Disease
, O
ho O
##mo O
##zy O
##go O
##us O
mice O
lack O
eyes O
and O
nasal O
ca O
##vi O
##ties O
and O
exhibit O
brain B-Disease
abnormal I-Disease
##ities I-Disease
. O

to O
investigate O
the O
role O
of O
gene O
dos O
##age O
in O
more O
detail O
, O
we O
have O
generated O
yeast O
artificial O
chromosome O
trans O
##genic O
mice O
carrying O
the O
human O
p O
##ax O
##6 O
lo O
##cus O
. O

when O
crossed O
onto O
the O
small O
eye O
background O
, O
the O
trans O
##gene O
rescue O
##s O
the O
mutant O
p O
##hen O
##otype O
. O

striking O
##ly O
, O
mice O
carrying O
multiple O
copies O
on O
a O
wild O
- O
type O
background O
show O
specific O
developmental B-Disease
abnormal I-Disease
##ities I-Disease
of I-Disease
the I-Disease
eye I-Disease
, O
but O
not O
of O
other O
tissues O
expressing O
the O
gene O
. O

thus O
, O
at O
least O
five O
different O
eye O
p O
##hen O
##otype O
##s O
are O
associated O
with O
changes O
in O
p O
##ax O
##6 O
expression O
. O

we O
provide O
evidence O
that O
not O
only O
reduced O
, O
but O
also O
increased O
levels O
of O
transcription O
##al O
regulator O
##s O
can O
cause O
developmental B-Disease
defects I-Disease
. O
. O

he O
##tero O
##di O
##mer O
formation O
and O
activity O
in O
the O
human O
enzyme O
gal O
##act O
##ose O
- O
1 O
- O
phosphate O
u O
##rid O
##yl O
##yl O
##tra O
##ns O
##fer O
##ase O
. O

one O
of O
the O
fundamental O
questions O
concerning O
expression O
and O
function O
of O
dim O
##eric O
enzymes O
involves O
the O
impact O
of O
naturally O
occurring O
mutations O
on O
subunit O
assembly O
and O
he O
##tero O
##di O
##mer O
activity O
. O

this O
question O
is O
of O
particular O
interest O
for O
the O
human O
enzyme O
gal O
##act O
##ose O
- O
l O
- O
phosphate O
u O
##rid O
##yl O
##yl O
- O
transfer O
##ase O
( O
gal O
##t O
) O
, O
imp O
##air O
##ment O
of O
which O
results O
in O
the O
inherited B-Disease
metabolic I-Disease
disorder I-Disease
gal B-Disease
##act I-Disease
##ose I-Disease
##mia I-Disease
, O
because O
many O
if O
not O
most O
patients O
studied O
to O
date O
are O
compound O
he O
##tero O
##zy O
##got O
##es O
rather O
than O
true O
molecular O
ho O
##mo O
##zy O
##got O
##es O
. O

further O
##more O
, O
the O
broad O
range O
of O
p O
##hen O
##otypic O
severity O
observed O
in O
these O
patients O
raises O
the O
possibility O
that O
all O
##eli O
##c O
combination O
, O
not O
just O
all O
##eli O
##c O
constitution O
, O
may O
play O
some O
role O
in O
determining O
outcome O
. O

in O
the O
work O
described O
here O
##in O
, O
we O
have O
selected O
two O
distinct O
naturally O
occurring O
null O
mutations O
of O
gal O
##t O
, O
q O
##18 O
##8 O
##r O
and O
r O
##33 O
##3 O
##w O
, O
and O
asked O
the O
questions O
( O
i O
) O
what O
are O
the O
impacts O
of O
these O
mutations O
on O
subunit O
assembly O
, O
and O
( O
ii O
) O
if O
he O
##tero O
##di O
##mers O
do O
form O
, O
are O
they O
active O
? O

to O
answer O
these O
questions O
, O
we O
have O
established O
a O
yeast O
system O
for O
the O
co O
##ex O
##press O
##ion O
of O
e O
##pit O
##ope O
- O
tag O
##ged O
all O
##ele O
##s O
of O
human O
gal O
##t O
and O
investigated O
both O
the O
extent O
of O
specific O
gal O
##t O
subunit O
interactions O
and O
the O
activity O
of O
defined O
he O
##tero O
##di O
##mer O
pools O
. O

we O
have O
found O
that O
both O
ho O
##mo O
##di O
##mers O
and O
he O
##tero O
##di O
##mers O
do O
form O
involving O
each O
of O
the O
mutant O
subunit O
##s O
tested O
and O
that O
both O
he O
##tero O
##di O
##mer O
pools O
retain O
substantial O
en O
##zy O
##matic O
activity O
. O

these O
results O
are O
significant O
not O
only O
in O
terms O
of O
their O
implications O
for O
further O
##ing O
our O
understanding O
of O
gal B-Disease
##act I-Disease
##ose I-Disease
##mia I-Disease
and O
gal O
##t O
ho O
##lo O
##en O
##zy O
##me O
structure O
- O
function O
relationships O
but O
also O
because O
the O
system O
described O
may O
serve O
as O
a O
model O
for O
similar O
studies O
of O
other O
complexes O
composed O
of O
multiple O
subunit O
##s O
. O
. O

c O
##lea O
##vage O
of O
hunting O
##tin O
by O
a O
##pop O
##ain O
, O
a O
pro O
##ap O
##op O
##to O
##tic O
c O
##ys O
##tein O
##e O
pro O
##te O
##ase O
, O
is O
m O
##od O
##ulated O
by O
the O
p O
##oly O
##g O
##lut O
##amine O
tract O
. O

a O
##pop O
##tosis O
has O
recently O
been O
recognized O
as O
a O
mode O
of O
cell O
death O
in O
hunting B-Disease
##ton I-Disease
disease I-Disease
( O
h B-Disease
##d I-Disease
) O
. O

a O
##pop O
##ain O
, O
a O
human O
counterpart O
of O
the O
ne O
##mat O
##ode O
c O
##ys O
##tein O
##e O
pro O
##te O
##ase O
death O
- O
gene O
product O
, O
c O
##ed O
- O
3 O
, O
has O
a O
key O
role O
in O
pro O
##te O
##oly O
##tic O
events O
leading O
to O
a O
##pop O
##tosis O
. O

here O
we O
show O
that O
a O
##pop O
##to O
##tic O
extract O
##s O
and O
a O
##pop O
##ain O
itself O
specifically O
c O
##lea O
##ve O
the O
h B-Disease
##d I-Disease
gene O
product O
, O
hunting O
##tin O
. O

the O
rate O
of O
c O
##lea O
##vage O
increases O
with O
the O
length O
of O
the O
hunting O
##tin O
p O
##oly O
##g O
##lut O
##amine O
tract O
, O
providing O
an O
explanation O
for O
the O
gain O
- O
of O
- O
function O
associated O
with O
ca O
##g O
expansion O
. O

our O
results O
show O
that O
hunting O
##tin O
is O
c O
##lea O
##ved O
by O
c O
##ys O
##tein O
##e O
pro O
##te O
##ases O
and O
suggest O
that O
h B-Disease
##d I-Disease
might O
be O
a O
disorder B-Disease
of I-Disease
inappropriate I-Disease
a I-Disease
##pop I-Disease
##tosis I-Disease
. O
. O

the O
5 O
' O
end O
of O
the O
br O
##ca O
##1 O
gene O
lies O
within O
a O
du O
##plicate O
##d O
region O
of O
human O
chromosome O
17 O
##q O
##21 O
. O

to O
begin O
to O
address O
the O
hypothesis O
that O
abnormal O
regulation O
of O
the O
breast B-Disease
/ I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
su O
##s O
##ce O
##pt O
##ibility O
gene O
br O
##ca O
##1 O
is O
a O
critical O
step O
in O
s O
##poradic O
breast O
/ O
o O
##var O
##ian O
tumor O
##ige O
##nes O
##is O
, O
we O
have O
determined O
the O
detailed O
structure O
of O
the O
br O
##ca O
##1 O
g O
##eno O
##mic O
region O
. O

we O
show O
that O
this O
region O
of O
the O
genome O
contains O
a O
tandem O
du O
##plication O
of O
approximately O
30 O
k O
##ilo O
##base O
##s O
, O
which O
results O
in O
two O
copies O
of O
br O
##ca O
##1 O
ex O
##ons O
1 O
and O
2 O
, O
of O
ex O
##ons O
1 O
and O
3 O
of O
the O
adjacent O
1 O
##a O
##1 O
- O
3 O
##b O
gene O
and O
of O
the O
previously O
reported O
295 O
base O
pair O
inter O
##genic O
region O
. O

sequence O
analysis O
of O
the O
du O
##plicate O
##d O
ex O
##ons O
of O
br O
##ca O
##1 O
and O
1 O
##a O
##1 O
- O
3 O
##b O
and O
flank O
##ing O
g O
##eno O
##mic O
d O
##na O
reveals O
maintenance O
of O
the O
intro O
##n O
- O
ex O
##on O
structure O
and O
a O
high O
degree O
of O
n O
##uc O
##leo O
##tide O
sequence O
identity O
, O
suggesting O
that O
these O
are O
non O
- O
processed O
pseudo O
##gene O
##s O
and O
that O
the O
du O
##plication O
is O
a O
recent O
event O
in O
evolutionary O
terms O
. O

we O
also O
show O
that O
a O
processed O
pseudo O
##gene O
of O
the O
acidic O
rib O
##oso O
##mal O
p O
##hos O
##ph O
##op O
##rote O
##in O
p O
##1 O
( O
a O
##rp O
##p O
##1 O
) O
is O
inserted O
directly O
upstream O
of O
pseudo O
- O
br O
##ca O
##1 O
ex O
##on O
1 O
##a O
. O

we O
believe O
that O
these O
findings O
could O
not O
only O
con O
##found O
br O
##ca O
##1 O
mutation O
analysis O
, O
but O
could O
have O
implications O
for O
the O
normal O
and O
abnormal O
regulation O
of O
br O
##ca O
##1 O
transcription O
, O
translation O
and O
function O
. O
. O

del O
##eti O
##on O
of O
small O
nuclear O
rib O
##on O
##uc O
##leo O
##p O
##rote O
##in O
p O
##oly O
##pe O
##pt O
##ide O
n O
( O
s O
##n O
##rp O
##n O
) O
in O
p B-Disease
##rade I-Disease
##r I-Disease
- I-Disease
will I-Disease
##i I-Disease
syndrome I-Disease
detected O
by O
flu O
##ores O
##cence O
in O
sit O
##u O
hybrid O
##ization O
: O
two O
si O
##bs O
with O
the O
typical O
p O
##hen O
##otype O
without O
a O
c O
##yt O
##ogen O
##etic O
del O
##eti O
##on O
in O
chromosome O
15 O
##q O
. O

the O
small O
nuclear O
rib O
##on O
##uc O
##leo O
##p O
##rote O
##in O
p O
##oly O
##pe O
##pt O
##ide O
n O
( O
s O
##n O
##rp O
##n O
) O
gene O
is O
regarded O
as O
one O
of O
the O
candidates O
for O
p B-Disease
##rade I-Disease
##r I-Disease
- I-Disease
will I-Disease
##i I-Disease
syndrome I-Disease
( O
p B-Disease
##ws I-Disease
) O
. O

we O
describe O
two O
si O
##bs O
with O
typical O
p B-Disease
##ws I-Disease
presenting O
del O
##eti O
##on O
of O
s O
##n O
##rp O
##n O
detected O
by O
flu O
##ores O
##cence O
in O
sit O
##u O
hybrid O
##ization O
( O
fish O
) O
. O

neither O
a O
c O
##yt O
##ogen O
##etic O
##ally O
detect O
##able O
15 O
##q O
##12 O
del O
##eti O
##on O
nor O
a O
del O
##eti O
##on O
for O
the O
d O
##15 O
##s O
##11 O
, O
d O
##15 O
##s O
##10 O
, O
and O
g O
##ab O
##rb O
##3 O
co O
##sm O
##id O
probe O
##s O
were O
found O
in O
either O
patient O
. O

this O
implies O
a O
smaller O
del O
##eti O
##on O
limited O
to O
the O
p B-Disease
##ws I-Disease
critical O
region O
. O

fish O
with O
a O
s O
##n O
##rp O
##n O
probe O
will O
permit O
analysis O
of O
p B-Disease
##ws I-Disease
patients O
with O
limited O
del O
##eti O
##ons O
not O
detect O
##able O
with O
other O
probe O
##s O
. O
. O

expression O
of O
the O
von B-Disease
hip I-Disease
##pel I-Disease
- I-Disease
l I-Disease
##inda I-Disease
##u I-Disease
disease I-Disease
t I-Disease
##umour I-Disease
suppress O
##or O
gene O
during O
human O
em O
##b O
##ryo O
##genesis O
. O

the O
von B-Disease
hip I-Disease
##pel I-Disease
- I-Disease
l I-Disease
##inda I-Disease
##u I-Disease
( I-Disease
v I-Disease
##hl I-Disease
) I-Disease
disease I-Disease
product O
is O
thought O
to O
down O
- O
regulate O
transcription O
by O
ant O
##agon O
##izing O
el O
##ong O
##in O
- O
enhanced O
transcription O
##al O
el O
##ong O
##ation O
. O

g O
##er O
##m O
##line O
v B-Disease
##hl I-Disease
gene O
mutations O
pre O
##dis O
##pose O
to O
the O
development O
of O
re B-Disease
##tina I-Disease
##l I-Disease
, I-Disease
c I-Disease
##ere I-Disease
##bella I-Disease
##r I-Disease
and I-Disease
spinal I-Disease
ha I-Disease
##eman I-Disease
##gio I-Disease
##blast I-Disease
##oma I-Disease
##s I-Disease
, O
re B-Disease
##nal I-Disease
cell I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
and O
p B-Disease
##ha I-Disease
##eo I-Disease
##ch I-Disease
##rom I-Disease
##oc I-Disease
##yt I-Disease
##oma I-Disease
. O

in O
addition O
, O
so O
##matic O
in O
##act O
##ivation O
of O
the O
v B-Disease
##hl I-Disease
gene O
is O
frequent O
in O
s B-Disease
##poradic I-Disease
re I-Disease
##nal I-Disease
cell I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
and O
ha B-Disease
##eman I-Disease
##gio I-Disease
##blast I-Disease
##oma I-Disease
. O

regulation O
of O
trans O
##cript O
el O
##ong O
##ation O
is O
an O
important O
control O
mechanism O
for O
gene O
expression O
and O
the O
v B-Disease
##hl I-Disease
gene O
might O
modify O
the O
expression O
of O
pro O
##to O
- O
on O
##co O
##gene O
##s O
and O
growth O
suppress O
##or O
genes O
during O
em O
##b O
##ryo O
##genesis O
. O

we O
therefore O
investigated O
the O
expression O
of O
v B-Disease
##hl I-Disease
m O
##rna O
during O
human O
em O
##b O
##ryo O
##genesis O
by O
in O
sit O
##u O
hybrid O
##ization O
studies O
at O
4 O
, O
6 O
and O
10 O
weeks O
post O
conception O
. O

although O
v B-Disease
##hl I-Disease
m O
##rna O
was O
expressed O
in O
all O
three O
g O
##er O
##m O
layers O
, O
strong O
expression O
was O
noted O
in O
the O
central O
nervous O
system O
, O
kidney O
##s O
, O
test O
##is O
and O
lung O
. O

within O
the O
kidney O
, O
v B-Disease
##hl I-Disease
m O
##rna O
was O
differential O
##ly O
expressed O
within O
re O
##nal O
tub O
##ules O
suggesting O
that O
the O
v B-Disease
##hl I-Disease
gene O
product O
may O
have O
a O
specific O
role O
in O
kidney O
development O
. O

two O
alternatively O
s O
##p O
##lice O
##d O
v B-Disease
##hl I-Disease
m O
##rna O
##s O
characterized O
by O
inclusion O
( O
is O
##of O
##orm O
i O
) O
or O
exclusion O
( O
is O
##of O
##orm O
ii O
) O
of O
ex O
##on O
2 O
are O
trans O
##cribed O
in O
adult O
tissues O
. O

to O
investigate O
if O
the O
two O
is O
##of O
##orms O
are O
differential O
##ly O
expressed O
during O
em O
##b O
##ryo O
##genesis O
, O
v B-Disease
##hl I-Disease
m O
##rna O
was O
reverse O
trans O
##cribed O
from O
13 O
f O
##etal O
tissues O
( O
8 O
- O
10 O
weeks O
g O
##esta O
##tion O
) O
. O

the O
quantitative O
distribution O
of O
v B-Disease
##hl I-Disease
m O
##rna O
within O
f O
##etal O
tissues O
reflected O
that O
seen O
by O
in O
sit O
##u O
hybrid O
##ization O
and O
the O
ratio O
of O
the O
two O
v B-Disease
##hl I-Disease
is O
##of O
##orms O
was O
similar O
between O
tissues O
. O

although O
the O
genes O
regulated O
by O
the O
v B-Disease
##hl I-Disease
gene O
product O
have O
not O
yet O
been O
identified O
, O
our O
findings O
are O
compatible O
with O
the O
hypothesis O
that O
v B-Disease
##hl I-Disease
- O
mediated O
control O
of O
transcription O
##al O
el O
##ong O
##ation O
may O
have O
a O
role O
in O
normal O
human O
development O
. O
. O

genetic O
he O
##tero O
##gene O
##ity O
in O
hereditary B-Disease
breast I-Disease
cancer I-Disease
: O
role O
of O
br O
##ca O
##1 O
and O
br O
##ca O
##2 O
. O

the O
common O
hereditary O
forms O
of O
breast B-Disease
cancer I-Disease
have O
been O
largely O
attributed O
to O
the O
inheritance O
of O
mutations O
in O
the O
br O
##ca O
##1 O
or O
br O
##ca O
##2 O
genes O
. O

however O
, O
it O
is O
not O
yet O
clear O
what O
proportion O
of O
hereditary B-Disease
breast I-Disease
cancer I-Disease
is O
explained O
by O
br O
##ca O
##1 O
and O
br O
##ca O
##2 O
or O
by O
some O
other O
unidentified O
su O
##s O
##ce O
##pt O
##ibility O
gene O
( O
s O
) O
. O

we O
describe O
the O
proportion O
of O
hereditary B-Disease
breast I-Disease
cancer I-Disease
explained O
by O
br O
##ca O
##1 O
or O
br O
##ca O
##2 O
in O
a O
sample O
of O
north O
am O
##eric O
##an O
hereditary B-Disease
breast I-Disease
cancer I-Disease
##s I-Disease
and O
assess O
the O
evidence O
for O
additional O
su O
##s O
##ce O
##pt O
##ibility O
genes O
that O
may O
con O
##fer O
hereditary B-Disease
breast I-Disease
or I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
risk O
. O

twenty O
- O
three O
families O
were O
identified O
through O
two O
high O
- O
risk O
breast B-Disease
cancer I-Disease
research O
programs O
. O

genetic O
analysis O
was O
undertaken O
to O
establish O
link O
##age O
between O
the O
breast B-Disease
or I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
cases O
and O
markers O
on O
chromosome O
##s O
17 O
##q O
( O
br O
##ca O
##1 O
) O
and O
13 O
##q O
( O
br O
##ca O
##2 O
) O
. O

mutation O
analysis O
in O
the O
br O
##ca O
##1 O
and O
br O
##ca O
##2 O
genes O
was O
also O
undertaken O
in O
all O
families O
. O

the O
pattern O
of O
hereditary B-Disease
cancer I-Disease
in O
14 O
( O
61 O
% O
) O
of O
the O
23 O
families O
studied O
was O
attributed O
to O
br O
##ca O
##1 O
by O
a O
combination O
of O
link O
##age O
and O
mutation O
analyses O
. O

no O
families O
were O
attributed O
to O
br O
##ca O
##2 O
. O

five O
families O
( O
22 O
% O
) O
provided O
evidence O
against O
link O
##age O
to O
both O
br O
##ca O
##1 O
and O
br O
##ca O
##2 O
. O

no O
br O
##ca O
##1 O
or O
br O
##ca O
##2 O
mutations O
were O
detected O
in O
these O
five O
families O
. O

the O
br O
##ca O
##1 O
or O
br O
##ca O
##2 O
status O
of O
four O
families O
( O
17 O
% O
) O
could O
not O
be O
determined O
. O

br O
##ca O
##1 O
and O
br O
##ca O
##2 O
probably O
explain O
the O
majority O
of O
hereditary B-Disease
breast I-Disease
cancer I-Disease
that O
exists O
in O
the O
north O
am O
##eric O
##an O
population O
. O

however O
, O
one O
or O
more O
additional O
genes O
may O
yet O
be O
found O
that O
explain O
some O
proportion O
of O
hereditary B-Disease
breast I-Disease
cancer I-Disease
. O
. O

an O
intro O
##nic O
mutation O
in O
a O
la O
##ria O
##t O
branch O
##point O
sequence O
is O
a O
direct O
cause O
of O
an O
inherited B-Disease
human I-Disease
disorder I-Disease
( O
fish B-Disease
- I-Disease
eye I-Disease
disease I-Disease
) O
. O

the O
first O
step O
in O
the O
s O
##p O
##licing O
of O
an O
intro O
##n O
from O
nuclear O
precursor O
##s O
of O
m O
##rna O
results O
in O
the O
formation O
of O
a O
la O
##ria O
##t O
structure O
. O

a O
distinct O
intro O
##nic O
n O
##uc O
##leo O
##tide O
sequence O
, O
known O
as O
the O
branch O
##point O
region O
, O
plays O
a O
central O
role O
in O
this O
process O
. O

we O
here O
describe O
a O
point O
mutation O
in O
such O
a O
sequence O
. O

three O
sisters O
were O
shown O
to O
suffer O
from O
fish B-Disease
- I-Disease
eye I-Disease
disease I-Disease
( O
fed B-Disease
) O
, O
a O
disorder O
which O
is O
caused O
by O
mutations O
in O
the O
gene O
coding O
for O
le O
##ci O
##thin O
ch O
##ole O
##ster O
##ol O
a O
##cy O
##lt O
##ran O
##s O
##fer O
##ase O
( O
l O
##cat O
) O
. O

se O
##quencing O
of O
the O
l O
##cat O
gene O
of O
all O
three O
pro O
##band O
##s O
revealed O
compound O
he O
##tero O
##zy O
##gos O
##ity O
for O
a O
miss O
##ense O
mutation O
in O
ex O
##on O
4 O
which O
is O
reported O
to O
under O
##lie O
the O
fed B-Disease
p O
##hen O
##otype O
, O
and O
a O
point O
mutation O
located O
in O
intro O
##n O
4 O
( O
i O
##v O
##s O
##4 O
t O
- O
22 O
##c O
) O
. O

by O
performing O
in O
v O
##it O
##ro O
expression O
of O
l O
##cat O
mini O
##gene O
##s O
and O
reverse O
trans O
##cript O
##ase O
p O
##c O
##r O
on O
m O
##rna O
isolated O
from O
le O
##uk O
##ocytes O
of O
the O
patient O
, O
this O
gene O
defect O
was O
shown O
to O
cause O
a O
null O
all O
##ele O
as O
the O
result O
of O
complete O
intro O
##n O
retention O
. O

in O
conclusion O
, O
we O
demonstrated O
that O
a O
point O
mutation O
in O
a O
la O
##ria O
##t O
branch O
##point O
consensus O
sequence O
causes O
a O
null O
all O
##ele O
in O
a O
patient O
with O
fed B-Disease
. O

in O
addition O
, O
our O
finding O
illustrate O
##s O
the O
importance O
of O
this O
sequence O
for O
normal O
human O
m O
##rna O
processing O
. O

finally O
, O
this O
report O
provides O
a O
widely O
applicable O
strategy O
which O
ensures O
fast O
and O
effective O
screening O
for O
intro O
##nic O
defects O
that O
under O
##lie O
differential O
gene O
expression O
. O
. O

mutations O
associated O
with O
variant O
p O
##hen O
##otype O
##s O
in O
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
. O

we O
have O
identified O
14 O
families O
with O
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
( O
a B-Disease
- I-Disease
t I-Disease
) O
in O
which O
mutation O
of O
the O
at O
##m O
gene O
is O
associated O
with O
a O
less O
severe O
clinical O
and O
cellular O
p O
##hen O
##otype O
( O
approximately O
10 O
% O
- O
15 O
% O
of O
a B-Disease
- I-Disease
t I-Disease
families O
identified O
in O
the O
united O
kingdom O
) O
. O

in O
10 O
of O
these O
families O
, O
all O
the O
ho O
##mo O
##zy O
##got O
##es O
have O
a O
137 O
- O
b O
##p O
insertion O
in O
their O
c O
##dn O
##a O
caused O
by O
a O
point O
mutation O
in O
a O
sequence O
resembling O
a O
s O
##p O
##lice O
- O
donor O
site O
. O

the O
second O
a B-Disease
- I-Disease
t I-Disease
all O
##ele O
has O
a O
different O
mutation O
in O
each O
patient O
. O

we O
show O
that O
the O
less O
severe O
p O
##hen O
##otype O
in O
these O
patients O
is O
caused O
by O
some O
degree O
of O
normal O
s O
##p O
##licing O
, O
which O
occurs O
as O
an O
alternative O
product O
from O
the O
insertion O
- O
containing O
all O
##ele O
. O

the O
level O
of O
the O
137 O
- O
b O
##p O
p O
##c O
##r O
product O
containing O
the O
insertion O
was O
lowest O
in O
two O
patients O
who O
showed O
a O
later O
onset O
of O
c B-Disease
##ere I-Disease
##bella I-Disease
##r I-Disease
at I-Disease
##ax I-Disease
##ia I-Disease
. O

a O
further O
four O
families O
who O
do O
not O
have O
this O
insertion O
have O
been O
identified O
. O

mutations O
detected O
in O
two O
of O
four O
of O
these O
are O
miss O
##ense O
mutations O
, O
normally O
rare O
in O
a B-Disease
- I-Disease
t I-Disease
patients O
. O

the O
demonstration O
of O
mutations O
giving O
rise O
to O
a O
slightly O
mild O
##er O
p O
##hen O
##otype O
in O
a B-Disease
- I-Disease
t I-Disease
raises O
the O
interesting O
question O
of O
what O
range O
of O
p O
##hen O
##otype O
##s O
might O
occur O
in O
individuals O
in O
whom O
both O
mutations O
are O
mild O
##er O
. O

one O
possibility O
might O
be O
that O
individuals O
who O
are O
compound O
he O
##tero O
##zy O
##got O
##es O
for O
at O
##m O
mutations O
are O
more O
common O
than O
we O
realize O
. O
. O

mutation O
of O
the O
v O
##hl O
gene O
is O
associated O
exclusively O
with O
the O
development O
of O
non B-Disease
- I-Disease
p I-Disease
##ap I-Disease
##illa I-Disease
##ry I-Disease
re I-Disease
##nal I-Disease
cell I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
##s I-Disease
. O

to O
define O
the O
possible O
role O
of O
the O
v B-Disease
##hl I-Disease
gene O
in O
the O
development O
of O
s B-Disease
##poradic I-Disease
re I-Disease
##nal I-Disease
cell I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
##s I-Disease
, O
91 O
different O
par B-Disease
##en I-Disease
##chy I-Disease
##mal I-Disease
t I-Disease
##umour I-Disease
##s I-Disease
of I-Disease
the I-Disease
kidney I-Disease
have O
been O
investigated O
for O
mutation O
of O
the O
v B-Disease
##hl I-Disease
gene O
by O
single O
strand O
conform O
##ation O
p O
##oly O
##mor O
##phism O
( O
s O
##s O
##c O
##p O
) O
and O
/ O
or O
he O
##tero O
##du O
##plex O
( O
h O
##d O
) O
techniques O
. O

chromosome O
3 O
##p O
del O
##eti O
##on O
was O
detected O
in O
98 O
per O
cent O
of O
non B-Disease
- I-Disease
p I-Disease
##ap I-Disease
##illa I-Disease
##ry I-Disease
re I-Disease
##nal I-Disease
cell I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
##s I-Disease
and O
in O
25 O
per O
cent O
of O
ch O
##rom O
##op O
##ho O
##be O
re B-Disease
##nal I-Disease
cell I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
##s I-Disease
. O

in O
22 O
of O
the O
43 O
non B-Disease
- I-Disease
p I-Disease
##ap I-Disease
##illa I-Disease
##ry I-Disease
re I-Disease
##nal I-Disease
cell I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
##s I-Disease
, O
abnormal O
##ly O
mi O
##grating O
d O
##na O
bands O
were O
detected O
by O
s O
##s O
##c O
##p O
and O
/ O
or O
h O
##d O
analysis O
. O

no O
mobility O
shift O
was O
seen O
in O
any O
of O
the O
23 O
ch O
##rom O
##op O
##ho O
##be O
re B-Disease
##nal I-Disease
cell I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
##s I-Disease
. O

in O
addition O
, O
15 O
p B-Disease
##ap I-Disease
##illa I-Disease
##ry I-Disease
re I-Disease
##nal I-Disease
cell I-Disease
t I-Disease
##umour I-Disease
##s I-Disease
and O
ten O
re B-Disease
##nal I-Disease
on I-Disease
##co I-Disease
##cy I-Disease
##tom I-Disease
##as I-Disease
, O
which O
are O
characterized O
by O
genetic O
changes O
other O
than O
loss O
of O
chromosome O
3 O
##p O
sequences O
, O
were O
anal O
##ys O
##ed O
for O
mutation O
of O
the O
v B-Disease
##hl I-Disease
gene O
. O

none O
of O
these O
t B-Disease
##umour I-Disease
##s I-Disease
showed O
abnormal O
migration O
patterns O
. O

the O
results O
indicate O
that O
mutation O
of O
the O
v B-Disease
##hl I-Disease
gene O
is O
associated O
exclusively O
with O
the O
development O
of O
non B-Disease
- I-Disease
p I-Disease
##ap I-Disease
##illa I-Disease
##ry I-Disease
re I-Disease
##nal I-Disease
cell I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
. O
. O

the O
em B-Disease
##ery I-Disease
- I-Disease
d I-Disease
##re I-Disease
##if I-Disease
##uss I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
protein O
, O
em O
##eri O
##n O
, O
is O
a O
nuclear O
membrane O
protein O
. O

a O
large O
fragment O
of O
em O
##eri O
##n O
c O
##dn O
##a O
was O
prepared O
by O
p O
##c O
##r O
and O
expressed O
as O
a O
re O
##comb O
##ina O
##nt O
protein O
in O
es O
##cher O
##ichi O
##a O
co O
##li O
. O

using O
this O
as O
im O
##mu O
##no O
##gen O
, O
we O
prepared O
a O
panel O
of O
12 O
mon O
##oc O
##lon O
##al O
antibodies O
which O
recognise O
at O
least O
four O
different O
e O
##pit O
##ope O
##s O
on O
em O
##eri O
##n O
in O
order O
to O
ensure O
that O
em O
##eri O
##n O
can O
be O
distinguished O
from O
non O
- O
specific O
cross O
- O
react O
##ing O
proteins O
. O

all O
the O
ma O
##bs O
recognised O
a O
34 O
k O
##da O
protein O
in O
all O
tissues O
tested O
, O
though O
minor O
em O
##eri O
##n O
- O
related O
bands O
were O
also O
detected O
in O
some O
tissues O
. O

im O
##mu O
##no O
##f O
##lu O
##ores O
##cence O
micro O
##sco O
##py O
showed O
that O
em O
##eri O
##n O
is O
located O
at O
the O
nuclear O
rim O
in O
all O
tissues O
examined O
. O

a O
muscle O
bio O
##psy O
from O
an O
em B-Disease
##ery I-Disease
- I-Disease
d I-Disease
##re I-Disease
##if I-Disease
##uss I-Disease
muscular I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
em B-Disease
##d I-Disease
##m I-Disease
) O
patient O
showed O
complete O
absence O
of O
em O
##eri O
##n O
by O
both O
western O
b O
##lot O
##ting O
and O
im O
##mu O
##no O
##his O
##to O
##chemistry O
, O
suggesting O
a O
simple O
diagnostic O
anti O
##body O
test O
for O
ed B-Disease
##m I-Disease
##d I-Disease
families O
. O

bio O
##chemical O
fraction O
##ation O
of O
brain O
and O
liver O
tissues O
showed O
that O
em O
##eri O
##n O
was O
present O
in O
nuclei O
pu O
##rified O
by O
cent O
##ri O
##fu O
##gation O
through O
65 O
% O
su O
##c O
##rose O
and O
was O
absent O
from O
soluble O
fraction O
##s O
( O
post O
- O
100 O
, O
000 O
g O
) O
. O

from O
these O
results O
, O
together O
with O
sequence O
and O
structural O
ho O
##mo O
##logies O
between O
em O
##eri O
##n O
, O
thy O
##mo O
##po O
##iet O
##ins O
and O
the O
nuclear O
la O
##mina O
- O
associated O
protein O
, O
lap O
##2 O
, O
we O
suggest O
that O
em O
##eri O
##n O
will O
prove O
to O
be O
one O
member O
of O
a O
family O
of O
inner O
nuclear O
membrane O
proteins O
. O
. O

mutation O
of O
m O
##sh O
##3 O
in O
end B-Disease
##ome I-Disease
##tri I-Disease
##al I-Disease
cancer I-Disease
and O
evidence O
for O
its O
functional O
role O
in O
he O
##tero O
##du O
##plex O
repair O
. O

many O
human O
t B-Disease
##umour I-Disease
##s I-Disease
have O
length O
alterations O
in O
repetitive O
sequence O
elements O
. O

although O
this O
micro B-Disease
##sat I-Disease
##elli I-Disease
##te I-Disease
instability I-Disease
has O
been O
attributed O
to O
mutations O
in O
four O
d O
##na O
mi O
##sma O
##tch O
repair O
genes O
in O
hereditary B-Disease
non I-Disease
##pol I-Disease
##y I-Disease
##po I-Disease
##sis I-Disease
color I-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
( O
h B-Disease
##n I-Disease
##p I-Disease
##cc I-Disease
) O
kind O
##red O
##s O
, O
many O
s B-Disease
##poradic I-Disease
t I-Disease
##umour I-Disease
##s I-Disease
exhibit O
instability O
but O
no O
detect O
##able O
mutations O
in O
these O
genes O
. O

it O
is O
therefore O
of O
interest O
to O
identify O
other O
genes O
that O
contribute O
to O
this O
instability O
. O

in O
yeast O
, O
mutations O
in O
several O
genes O
, O
including O
r O
##th O
and O
m O
##sh O
##3 O
, O
cause O
micro O
##sat O
##elli O
##te O
instability O
. O

thus O
, O
we O
screened O
16 O
end B-Disease
##ome I-Disease
##tri I-Disease
##al I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
##s I-Disease
with O
micro O
##sat O
##elli O
##te O
instability O
for O
alterations O
in O
f O
##en O
##1 O
( O
the O
human O
ho O
##mo O
##log O
of O
r O
##th O
) O
and O
in O
m O
##sh O
##3 O
( O
re O
##fs O
12 O
- O
14 O
) O
. O

although O
we O
found O
no O
f O
##en O
##1 O
mutations O
, O
a O
frames O
##hi O
##ft O
mutation O
in O
m O
##sh O
##3 O
was O
observed O
in O
an O
end B-Disease
##ome I-Disease
##tri I-Disease
##al I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
and O
in O
an O
end B-Disease
##ome I-Disease
##tri I-Disease
##al I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
cell O
line O
. O

extract O
##s O
of O
the O
cell O
line O
were O
def O
##icient O
in O
repair O
of O
d O
##na O
substrates O
containing O
mi O
##sma O
##tches O
or O
extra O
n O
##uc O
##leo O
##tide O
##s O
. O

introducing O
chromosome O
5 O
, O
encoding O
the O
m O
##sh O
##3 O
gene O
, O
into O
the O
mutant O
cell O
line O
increased O
the O
stability O
of O
some O
but O
not O
all O
micro O
##sat O
##elli O
##tes O
. O

extract O
##s O
of O
these O
cells O
repaired O
certain O
substrates O
containing O
extra O
n O
##uc O
##leo O
##tide O
##s O
, O
but O
were O
def O
##icient O
in O
repair O
of O
those O
containing O
mi O
##sma O
##tches O
or O
other O
extra O
n O
##uc O
##leo O
##tide O
##s O
. O

a O
subsequent O
search O
revealed O
a O
second O
gene O
mutation O
in O
h O
##hua O
cells O
, O
a O
miss O
##ense O
mutation O
in O
the O
m O
##sh O
##6 O
gene O
. O

together O
the O
data O
suggest O
that O
the O
m O
##sh O
##3 O
gene O
en O
##codes O
a O
product O
that O
functions O
in O
repair O
of O
some O
but O
not O
all O
pre O
- O
mutation O
##al O
intermediate O
##s O
, O
its O
mutation O
in O
t B-Disease
##umour I-Disease
##s I-Disease
can O
result O
in O
g O
##eno O
##mic O
instability O
and O
, O
as O
in O
yeast O
, O
m O
##sh O
##3 O
and O
m O
##sh O
##6 O
are O
partially O
redundant O
for O
mi O
##sma O
##tch O
repair O
. O
. O

comparative O
genome O
mapping O
of O
the O
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
region O
in O
mouse O
, O
rat O
, O
and O
s O
##yrian O
ha O
##ms O
##ter O
. O

ch O
##rom O
##oso O
##mal O
locations O
of O
the O
at O
##m O
( O
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
( O
at B-Disease
) O
- O
m O
##uta O
##ted O
) O
and O
a O
##cat O
##1 O
( O
mitochondrial O
ace O
##to O
##ace O
##ty O
##l O
- O
co O
##a O
th O
##iol O
##ase O
) O
genes O
in O
mouse O
, O
rat O
, O
and O
s O
##yrian O
ha O
##ms O
##ter O
were O
determined O
by O
direct O
r O
- O
band O
##ing O
fish O
. O

both O
genes O
were O
co O
##loc O
##ali O
##zed O
to O
the O
c O
- O
d O
band O
of O
mouse O
chromosome O
9 O
, O
the O
pro O
##ximal O
end O
of O
q O
##24 O
. O

1 O
of O
rat O
chromosome O
8 O
, O
and O
q O
##a O
##4 O
- O
q O
##a O
##5 O
of O
s O
##yrian O
ha O
##ms O
##ter O
chromosome O
12 O
. O

the O
regions O
in O
the O
mouse O
and O
rat O
were O
ho O
##mo O
##log O
##ous O
to O
human O
chromosome O
11 O
##q O
. O

fine O
genetic O
link O
##age O
mapping O
of O
the O
mouse O
at B-Disease
region O
was O
performed O
using O
the O
inter O
##sp O
##ec O
##ific O
back O
##cross O
mice O
. O

at O
##m O
, O
a O
##cat O
##1 O
, O
and O
n O
##pa O
##t O
, O
which O
is O
a O
new O
gene O
isolated O
from O
the O
at O
region O
, O
and O
12 O
flank O
##ing O
micro O
##sat O
##elli O
##te O
d O
##na O
markers O
were O
examined O
. O

no O
re O
##comb O
##ination O
##s O
were O
found O
among O
the O
at O
##m O
, O
n O
##pa O
##t O
, O
a O
##cat O
##1 O
, O
and O
d O
##9 O
##mit O
##6 O
lo O
##ci O
, O
and O
these O
lo O
##ci O
were O
mapped O
2 O
. O

0 O
cm O
di O
##stal O
to O
d O
##9 O
##mit O
##9 O
##9 O
and O
1 O
. O

3 O
cm O
pro O
##ximal O
to O
d O
##9 O
##mit O
##10 O
##2 O
. O

comparison O
of O
the O
link O
##age O
map O
of O
mouse O
chromosome O
9 O
( O
mm O
##u O
##9 O
) O
and O
that O
of O
human O
chromosome O
11 O
( O
h O
##sa O
##11 O
) O
indicates O
that O
there O
is O
a O
ch O
##rom O
##oso O
##mal O
rear O
##rang O
##ement O
due O
to O
an O
in O
##version O
between O
et O
##s O
##1 O
and O
at O
##m O
- O
n O
##pa O
##t O
- O
a O
##cat O
##1 O
and O
that O
the O
in O
##version O
of O
mm O
##u O
##9 O
originated O
from O
the O
ch O
##rom O
##oso O
##mal O
break O
##age O
at O
the O
boundary O
between O
g O
##ria O
##4 O
and O
at O
##m O
- O
n O
##pa O
##t O
- O
a O
##cat O
##1 O
on O
h O
##sa O
##11 O
. O

this O
type O
of O
in O
##version O
appeared O
to O
be O
conserved O
in O
the O
three O
rode O
##nt O
species O
, O
mouse O
, O
rat O
, O
and O
s O
##yrian O
ha O
##ms O
##ter O
, O
using O
additional O
comparative O
mapping O
data O
with O
the O
r O
##ck O
gene O

an O
animal O
model O
for O
nor B-Disease
##rie I-Disease
disease I-Disease
( O
n B-Disease
##d I-Disease
) O
: O
gene O
targeting O
of O
the O
mouse O
n B-Disease
##d I-Disease
gene O
. O

in O
order O
to O
el O
##uc O
##ida O
##te O
the O
cellular O
and O
molecular O
processes O
which O
are O
involved O
in O
nor B-Disease
##rie I-Disease
disease I-Disease
( O
n B-Disease
##d I-Disease
) O
, O
we O
have O
used O
gene O
targeting O
technology O
to O
generate O
n B-Disease
##d I-Disease
mutant O
mice O
. O

the O
m O
##uri O
##ne O
ho O
##mo O
##logue O
of O
the O
n B-Disease
##d I-Disease
gene O
was O
clone O
##d O
and O
shown O
to O
en O
##code O
a O
p O
##oly O
##pe O
##pt O
##ide O
that O
shares O
94 O
% O
of O
the O
amino O
acid O
sequence O
with O
its O
human O
counterpart O
. O

r O
##na O
in O
sit O
##u O
hybrid O
##ization O
revealed O
expression O
in O
re O
##tina O
, O
brain O
and O
the O
o O
##lf O
##actor O
##y O
bulb O
and O
e O
##pit O
##hel O
##ium O
of O
2 O
week O
old O
mice O
. O

hem O
##iz O
##y O
##go O
##us O
mice O
carrying O
a O
replacement O
mutation O
in O
ex O
##on O
2 O
of O
the O
n B-Disease
##d I-Disease
gene O
developed O
re O
##tro O
##lent O
##al O
structures O
in O
the O
v O
##it O
##re O
##ous O
body O
and O
showed O
an O
overall O
di O
##sor O
##gan O
##ization O
of O
the O
re O
##tina O
##l O
gang O
##lion O
cell O
layer O
. O

the O
outer O
p O
##lex O
##iform O
layer O
disappears O
occasionally O
, O
resulting O
in O
a O
j O
##ux O
##ta O
##posed O
inner O
and O
outer O
nuclear O
layer O
. O

at O
the O
same O
regions O
, O
the O
outer O
segments O
of O
the O
photo O
##re O
##ceptor O
cell O
layer O
are O
no O
longer O
present O
. O

these O
o O
##cular O
findings O
are O
consistent O
with O
observations O
in O
n B-Disease
##d I-Disease
patients O
and O
the O
generated O
mouse O
line O
provides O
a O
faithful O
model O
for O
study O
of O
early O
path O
##ogenic O
events O
in O
this O
severe O
x B-Disease
- I-Disease
linked I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
ne I-Disease
##uro I-Disease
##logical I-Disease
disorder I-Disease
. O
. O

the O
hybrid O
p O
##ax O
##3 O
- O
f O
##kh O
##r O
fusion O
protein O
of O
al B-Disease
##ve I-Disease
##olar I-Disease
r I-Disease
##hab I-Disease
##dom I-Disease
##yo I-Disease
##sar I-Disease
##com I-Disease
##a I-Disease
transforms O
fi O
##bro O
##blast O
##s O
in O
culture O
. O

p B-Disease
##ediatric I-Disease
al I-Disease
##ve I-Disease
##olar I-Disease
r I-Disease
##hab I-Disease
##dom I-Disease
##yo I-Disease
##sar I-Disease
##com I-Disease
##a I-Disease
is O
characterized O
by O
a O
ch O
##rom O
##oso O
##mal O
trans O
##location O
that O
f O
##uses O
parts O
of O
the O
p O
##ax O
##3 O
and O
f O
##kh O
##r O
genes O
. O

p O
##ax O
##3 O
codes O
for O
a O
transcription O
##al O
regulator O
that O
controls O
developmental O
programs O
, O
and O
f O
##kh O
##r O
codes O
for O
a O
fork O
##head O
- O
winged O
he O
##lix O
protein O
, O
also O
a O
likely O
transcription O
factor O
. O

the O
p O
##ax O
##3 O
- O
f O
##kh O
##r O
fusion O
product O
retains O
the O
d O
##na O
binding O
domains O
of O
the O
p O
##ax O
##3 O
protein O
and O
the O
put O
##ative O
act O
##iva O
##tor O
domain O
of O
the O
f O
##kh O
##r O
protein O
. O

the O
p O
##ax O
##3 O
- O
f O
##kh O
##r O
protein O
has O
been O
shown O
to O
function O
as O
a O
transcription O
##al O
act O
##iva O
##tor O
. O

using O
the O
r O
##cas O
re O
##tro O
##vir O
##al O
vector O
, O
we O
have O
introduced O
the O
p O
##ax O
##3 O
- O
f O
##kh O
##r O
gene O
into O
chicken O
em O
##b O
##ryo O
fi O
##bro O
##blast O
##s O
. O

expression O
of O
the O
p O
##ax O
##3 O
- O
f O
##kh O
##r O
protein O
in O
these O
cells O
leads O
to O
transformation O
the O
cells O
become O
enlarged O
, O
grow O
tightly O
packed O
and O
in O
multiple O
layers O
, O
and O
acquire O
the O
ability O
for O
anchor O
##age O
- O
independent O
growth O
. O

this O
cellular O
transformation O
in O
v O
##it O
##ro O
will O
facilitate O
studies O
on O
the O
mechanism O
of O
p O
##ax O
##3 O
- O
f O
##kh O
##r O
- O
induced O
on O
##co O
##genesis O
. O
. O

so O
##matic O
- O
cell O
selection O
is O
a O
major O
de O
##ter O
##mina O
##nt O
of O
the O
blood O
- O
cell O
p O
##hen O
##otype O
in O
he O
##tero O
##zy O
##got O
##es O
for O
glucose O
- O
6 O
- O
phosphate O
de O
##hy O
##dr O
##ogen O
##ase O
mutations O
causing O
severe O
enzyme B-Disease
deficiency I-Disease
. O

x O
- O
chromosome O
in O
##act O
##ivation O
in O
mammals O
is O
regarded O
as O
an O
essentially O
random O
process O
, O
but O
the O
resulting O
so O
##matic O
- O
cell O
mosaic O
##ism O
creates O
the O
opportunity O
for O
cell O
selection O
. O

in O
most O
people O
with O
red O
- O
blood O
- O
cell O
glucose B-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
de I-Disease
##hy I-Disease
##dr I-Disease
##ogen I-Disease
##ase I-Disease
( I-Disease
g I-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
) I-Disease
deficiency I-Disease
, O
the O
enzyme O
- O
def O
##icient O
p O
##hen O
##otype O
is O
only O
moderately O
expressed O
in O
n O
##uc O
##lea O
##ted O
cells O
. O

however O
, O
in O
a O
small O
subset O
of O
hem O
##iz O
##y O
##go O
##us O
males O
who O
suffer O
from O
chronic B-Disease
non I-Disease
##sp I-Disease
##her I-Disease
##oc I-Disease
##ytic I-Disease
hem I-Disease
##oly I-Disease
##tic I-Disease
an I-Disease
##emia I-Disease
, O
the O
underlying O
mutations O
( O
designated O
class O
i O
) O
cause O
more O
- O
severe O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
, O
and O
this O
might O
provide O
an O
opportunity O
for O
selection O
in O
he O
##tero O
##zy O
##go O
##us O
females O
during O
development O
. O

in O
order O
to O
test O
this O
possibility O
we O
have O
analyzed O
four O
he O
##tero O
##zy O
##got O
##es O
for O
class O
i O
g O
##6 O
##p O
##d O
mutations O
two O
with O
g O
##6 O
##p O
##d O
port O
##ici O
( O
117 O
##8 O
##g O
- O
- O
[UNK] O
a O
) O
and O
two O
with O
g O
##6 O
##p O
##d O
bar O
##i O
( O
118 O
##7 O
##c O
- O
- O
[UNK] O
t O
) O
. O

we O
found O
that O
in O
fraction O
##ated O
blood O
cell O
types O
( O
including O
er O
##yt O
##hr O
##oid O
, O
my O
##elo O
##id O
, O
and O
l O
##ymph O
##oid O
cell O
lineage O
##s O
) O
there O
was O
a O
significant O
excess O
of O
g O
##6 O
##p O
##d O
- O
normal O
cells O
. O

the O
significant O
con O
##cor O
##dance O
that O
we O
have O
observed O
in O
the O
degree O
of O
im O
##bal O
##ance O
in O
the O
different O
blood O
- O
cell O
lineage O
##s O
indicates O
that O
a O
selective O
mechanism O
is O
likely O
to O
operate O
at O
the O
level O
of O
p O
##lu O
##rip O
##ote O
##nt O
blood O
stem O
cells O
. O

thus O
, O
it O
appears O
that O
severe O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
affects O
adverse O
##ly O
the O
proliferation O
or O
the O
survival O
of O
n O
##uc O
##lea O
##ted O
blood O
cells O
and O
that O
this O
p O
##hen O
##otypic O
characteristic O
is O
critical O
during O
hem O
##ato O
##po O
##ies O
##is O
. O
. O

analysis O
of O
me O
##iot O
##ic O
segregation O
, O
using O
single O
- O
sperm O
typing O
: O
me O
##iot O
##ic O
drive O
at O
the O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
lo O
##cus O
. O

me O
##iot O
##ic O
drive O
at O
the O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
) O
lo O
##cus O
has O
recently O
been O
suggested O
as O
being O
responsible O
for O
maintaining O
the O
frequency O
, O
in O
the O
human O
population O
, O
of O
d B-Disease
##m I-Disease
chromosome O
##s O
capable O
of O
expansion O
to O
the O
disease O
state O
. O

in O
order O
to O
test O
this O
hypothesis O
, O
we O
have O
studied O
samples O
of O
single O
sperm O
from O
three O
individuals O
he O
##tero O
##zy O
##go O
##us O
at O
the O
d B-Disease
##m I-Disease
lo O
##cus O
, O
each O
with O
one O
all O
##ele O
larger O
and O
one O
all O
##ele O
smaller O
than O
19 O
c O
##t O
##g O
repeats O
. O

to O
guard O
against O
the O
possible O
problem O
of O
differential O
p O
##c O
##r O
am O
##p O
##lification O
rates O
based O
on O
the O
lengths O
of O
the O
all O
##ele O
##s O
, O
the O
sperm O
were O
also O
typed O
at O
another O
closely O
linked O
marker O
whose O
all O
##ele O
size O
was O
unrelated O
to O
the O
all O
##ele O
size O
at O
the O
d B-Disease
##m I-Disease
lo O
##cus O
. O

using O
statistical O
models O
specifically O
designed O
to O
study O
single O
- O
sperm O
segregation O
data O
, O
we O
find O
no O
evidence O
of O
me O
##iot O
##ic O
segregation O
distortion O
. O

the O
upper O
limit O
of O
the O
two O
- O
sided O
95 O
% O
confidence O
interval O
for O
the O
estimate O
of O
the O
common O
segregation O
probability O
for O
the O
three O
donors O
is O
at O
or O
below O
. O

51 O
##5 O
for O
all O
models O
considered O
, O
and O
no O
statistical O
##ly O
significant O
difference O
from O
. O

5 O
is O
detected O
in O
any O
of O
the O
models O
. O

this O
suggests O
that O
any O
greater O
amount O
of O
segregation O
distortion O
at O
the O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
lo O
##cus O
must O
result O
from O
events O
following O
sperm O
e O
##ja O
##cula O
##tion O
. O

l O
##pp O
, O
the O
preferred O
fusion O
partner O
gene O
of O
h O
##m O
##gic O
in O
lip B-Disease
##oma I-Disease
##s I-Disease
, O
is O
a O
novel O
member O
of O
the O
l O
##im O
protein O
gene O
family O
. O

a O
major O
c O
##yt O
##ogen O
##etic O
subgroup O
of O
lip B-Disease
##oma I-Disease
##s I-Disease
is O
characterized O
by O
re O
##current O
chromosome O
a O
##ber O
##rations O
, O
mainly O
trans O
##location O
##s O
, O
that O
involve O
chromosome O
segment O
12 O
##q O
##13 O
- O
q O
##15 O
. O

multiple O
chromosome O
##s O
have O
been O
found O
as O
the O
trans O
##location O
partners O
of O
chromosome O
12 O
but O
3 O
##q O
##27 O
- O
q O
##28 O
is O
prefer O
##ential O
##ly O
involved O
. O

in O
previous O
studies O
, O
it O
has O
been O
shown O
that O
the O
high O
mobility O
group O
( O
h O
##m O
##g O
) O
protein O
gene O
h O
##m O
##gic O
at O
12 O
##q O
##15 O
is O
consistently O
rear O
##ranged O
as O
a O
consequence O
of O
these O
trans O
##location O
##s O
. O

here O
, O
we O
report O
the O
identification O
and O
characterization O
of O
the O
chromosome O
3 O
- O
derived O
trans O
##location O
partner O
gene O
, O
which O
we O
have O
designated O
l O
##pp O
( O
lip B-Disease
##oma I-Disease
preferred O
partner O
gene O
) O
. O

using O
3 O
- O
race O
analysis O
of O
h O
##m O
##gic O
fusion O
trans O
##cripts O
in O
lip B-Disease
##oma I-Disease
cell O
line O
l O
##i O
- O
501 O
/ O
s O
##v O
##40 O
, O
e O
##ct O
##op O
##ic O
genetic O
sequences O
were O
obtained O
, O
which O
by O
cash O
( O
chromosome O
assignment O
using O
so O
##matic O
cell O
hybrid O
##s O
) O
and O
fish O
( O
flu O
##ores O
##cence O
in O
sit O
##u O
hybrid O
##ization O
) O
analysis O
were O
found O
to O
originate O
from O
chromosome O
segment O
3 O
##q O
##27 O
- O
q O
##28 O
. O

in O
northern O
b O
##lot O
analysis O
, O
an O
m O
##rna O
of O
over O
10 O
k O
##b O
was O
detected O
by O
these O
e O
##ct O
##op O
##ic O
sequences O
in O
a O
variety O
of O
human O
tissues O
but O
not O
in O
brain O
and O
peripheral O
blood O
le O
##uk O
##ocytes O
. O

upon O
partial O
c O
##dn O
##a O
c O
##lon O
##ing O
, O
features O
of O
the O
genetic O
organization O
of O
l O
##pp O
were O
established O
. O

the O
gene O
was O
found O
to O
span O
a O
g O
##eno O
##mic O
region O
of O
over O
400 O
k O
##b O
. O

n O
##uc O
##leo O
##tide O
sequence O
analysis O
of O
a O
composite O
c O
##dn O
##a O
of O
l O
##pp O
revealed O
an O
open O
reading O
frame O
of O
1836 O
n O
##uc O
##leo O
##tide O
##s O
encoding O
a O
pro O
##line O
- O
rich O
protein O
containing O
a O
le O
##uc O
##ine O
- O
zipper O
motif O
in O
its O
amino O
- O
terminal O
region O
and O
three O
l O
##im O
domains O
in O
its O
car O
##box O
##y O
- O
terminal O
region O
. O

the O
l O
##pp O
- O
encoded O
protein O
should O
be O
classified O
as O
a O
novel O
member O
of O
the O
group O
3 O
proteins O
of O
the O
l O
##im O
protein O
gene O
family O
. O

using O
reverse O
trans O
##cript O
##ase O
combined O
with O
polymer O
##ase O
chain O
reactions O
in O
the O
analysis O
of O
a O
number O
of O
lip B-Disease
##oma I-Disease
cell O
lines O
and O
primary B-Disease
lip I-Disease
##oma I-Disease
##s I-Disease
, O
it O
appeared O
that O
l O
##pp O
is O
frequently O
rear O
##ranged O
also O
in O
cases O
without O
a O
c O
##yt O
##ogen O
##etic O
##ally O
detect O
##able O
involvement O
of O
3 O
##q O
##27 O
- O
q O
##28 O
. O

two O
alternative O
h O
##m O
##gic O
/ O
l O
##pp O
hybrid O
trans O
##cripts O
have O
been O
detected O
; O
the O
difference O
between O
them O
is O
mainly O
the O
presence O
of O
either O
two O
or O
three O
l O
##im O
domains O
in O
the O
predicted O
h O
##m O
##gi O
- O
c O
/ O
l O
##pp O
fusion O
proteins O
. O
. O

absence O
of O
disease O
p O
##hen O
##otype O
and O
inter O
##gene O
##ration O
##al O
stability O
of O
the O
ca O
##g O
repeat O
in O
trans O
##genic O
mice O
expressing O
the O
human O
hunting B-Disease
##ton I-Disease
disease I-Disease
trans O
##cript O
. O

the O
mutation O
underlying O
hunting B-Disease
##ton I-Disease
disease I-Disease
( O
h B-Disease
##d I-Disease
) O
is O
ca O
##g O
expansion O
in O
the O
first O
ex O
##on O
of O
the O
h B-Disease
##d I-Disease
gene O
. O

in O
order O
to O
investigate O
the O
role O
of O
ca O
##g O
expansion O
in O
the O
path O
##ogen O
##esis O
of O
h B-Disease
##d I-Disease
, O
we O
have O
produced O
trans O
##genic O
mice O
containing O
the O
full O
length O
human O
h B-Disease
##d I-Disease
c O
##dn O
##a O
with O
44 O
ca O
##g O
repeats O
. O

by O
1 O
year O
, O
these O
mice O
have O
no O
behavioral B-Disease
abnormal I-Disease
##ities I-Disease
and O
m O
##or O
##ph O
##ometric O
analysis O
at O
6 O
( O
one O
animal O
) O
and O
9 O
( O
two O
animals O
) O
months O
age O
revealed O
no O
changes O
. O

despite O
high O
levels O
of O
m O
##rna O
expression O
, O
there O
was O
no O
evidence O
of O
the O
h B-Disease
##d I-Disease
gene O
product O
in O
any O
of O
these O
trans O
##genic O
mice O
. O

in O
v O
##it O
##ro O
trans O
##fect O
##ion O
studies O
indicated O
that O
the O
inclusion O
of O
120 O
b O
##p O
of O
the O
5 O
u O
##tr O
in O
the O
c O
##dn O
##a O
construct O
and O
the O
presence O
of O
a O
frames O
##hi O
##ft O
mutation O
at O
n O
##uc O
##leo O
##tide O
234 O
##9 O
prevented O
expression O
of O
the O
h B-Disease
##d I-Disease
c O
##dn O
##a O
. O

these O
findings O
suggest O
that O
the O
path O
##ogen O
##esis O
of O
h B-Disease
##d I-Disease
is O
not O
mediated O
through O
d O
##na O
- O
protein O
interaction O
and O
that O
presence O
of O
the O
r O
##na O
trans O
##cript O
with O
an O
expanded O
ca O
##g O
repeat O
is O
insufficient O
to O
cause O
the O
disease O
. O

rather O
, O
translation O
of O
the O
ca O
##g O
is O
crucial O
for O
the O
path O
##ogen O
##esis O
of O
h B-Disease
##d I-Disease
. O

in O
contrast O
to O
that O
seen O
in O
humans O
, O
the O
ca O
##g O
repeat O
in O
these O
mice O
was O
remarkably O
stable O
in O
97 O
me O
##ios O
##es O
. O

this O
suggests O
that O
g O
##eno O
##mic O
sequences O
may O
play O
a O
critical O
role O
in O
in O
##f O
##lue O
##ncing O
repeat O
instability O
. O
. O

fish O
studies O
in O
a O
patient O
with O
s B-Disease
##poradic I-Disease
an I-Disease
##iri I-Disease
##dia I-Disease
and O
t O
( O
7 O
; O
11 O
) O
( O
q O
##31 O
. O
2 O
; O
p O
##13 O
) O
. O

a O
2 O
year O
old O
female O
presenting O
with O
bilateral B-Disease
s I-Disease
##poradic I-Disease
an I-Disease
##iri I-Disease
##dia I-Disease
was O
found O
to O
have O
an O
apparently O
balanced O
re O
##ci O
##p O
##ro O
##cal O
trans O
##location O
with O
a O
chromosome O
11 O
break O
##point O
within O
band O
p O
##13 O
. O

flu O
##ores O
##cence O
in O
sit O
##u O
hybrid O
##isation O
( O
fish O
) O
studies O
with O
di O
##stal O
11 O
##p O
##13 O
specific O
co O
##sm O
##ids O
showed O
that O
the O
chromosome O
11 O
break O
##point O
lay O
between O
the O
an B-Disease
##iri I-Disease
##dia I-Disease
( O
p O
##ax O
##6 O
) O
lo O
##cus O
and O
a O
region O
approximately O
100 O
k O
##b O
di O
##stal O
to O
p O
##ax O
##6 O
defined O
by O
the O
co O
##sm O
##id O
f O
##o O
##21 O
##21 O
. O

although O
this O
patient O
did O
not O
have O
a O
detect O
##able O
del O
##eti O
##on O
within O
p O
##ax O
##6 O
, O
her O
an B-Disease
##iri I-Disease
##dia I-Disease
may O
have O
resulted O
from O
a O
disruption O
of O
the O
di O
##stal O
ch O
##roma O
##tin O
domain O
containing O
either O
enhance O
##rs O
or O
regulator O
##s O
for O
p O
##ax O
##6 O
. O

this O
case O
may O
therefore O
be O
another O
example O
of O
an B-Disease
##iri I-Disease
##dia I-Disease
caused O
by O
a O
position O
effect O
as O
recently O
described O
in O
two O
f B-Disease
##ami I-Disease
##lial I-Disease
an I-Disease
##iri I-Disease
##dia I-Disease
patients O
in O
which O
the O
p O
##hen O
##otype O
co O
##se O
##g O
##re O
##gated O
with O
chromosome B-Disease
abnormal I-Disease
##ities I-Disease
with O
11 O
##p O
##13 O
break O
##points O
. O
. O

muscle O
expression O
of O
glucose B-Disease
- I-Disease
6 I-Disease
- I-Disease
phosphate I-Disease
de I-Disease
##hy I-Disease
##dr I-Disease
##ogen I-Disease
##ase I-Disease
deficiency I-Disease
in O
different O
variants O
. O

muscle O
expression O
of O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
deficiency I-Disease
has O
been O
investigated O
in O
me O
##dit O
##er O
##rane O
##an O
, O
seat O
##tle O
- O
like O
and O
a O
- O
variants O
. O

g O
##6 O
##p O
##d O
activity O
was O
detected O
in O
samples O
obtained O
from O
bio O
##ps O
##ies O
on O
the O
q O
##uad O
##rice O
##ps O
muscle O
of O
seven O
males O
and O
one O
female O
. O

the O
type O
of O
genetic O
variant O
was O
determined O
by O
molecular O
analysis O
of O
d O
##na O
, O
extracted O
from O
blood O
samples O
. O

all O
variants O
showed O
the O
enzyme O
defect O
in O
muscle O
. O

a O
statistical O
##ly O
significant O
relationship O
was O
found O
in O
the O
activity O
of O
g O
##6 O
##p O
##d O
between O
er O
##yt O
##hr O
##ocytes O
and O
muscle O
of O
the O
male O
subjects O
( O
r O
= O
0 O
. O
96 O
##8 O
; O
p O
= O
0 O
. O
000 O
##0 O
##8 O
) O
. O

the O
equation O
for O
the O
best O
fit O
line O
was O
y O
= O
0 O
. O

390 O
##x O
+ O
0 O
. O

198 O
198 O
. O

the O
results O
suggest O
that O
, O
for O
a O
given O
variant O
, O
the O
extent O
of O
the O
enzyme O
defect O
in O
muscle O
may O
be O
determined O
, O
using O
this O
equation O
, O
from O
the O
g O
##6 O
##p O
##d O
activity O
of O
er O
##yt O
##hr O
##ocytes O

gene O
therapy O
for O
p B-Disease
##hen I-Disease
##yl I-Disease
##ket I-Disease
##on I-Disease
##uria I-Disease
. O

classical O
p B-Disease
##hen I-Disease
##yl I-Disease
##ket I-Disease
##on I-Disease
##uria I-Disease
( O
p B-Disease
##ku I-Disease
) O
is O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
disorder I-Disease
caused O
by O
a O
deficiency B-Disease
of I-Disease
he I-Disease
##pa I-Disease
##tic I-Disease
p I-Disease
##hen I-Disease
##yla I-Disease
##lani I-Disease
##ne I-Disease
h I-Disease
##ydro I-Disease
##xy I-Disease
##lase I-Disease
( O
p O
##ah O
) O
. O

limitations O
of O
the O
current O
diet O
##ary O
treatment O
for O
p B-Disease
##ku I-Disease
have O
led O
to O
the O
development O
of O
potential O
treatments O
based O
on O
so O
##matic O
gene O
transfer O
. O

three O
different O
vector O
systems O
have O
been O
examined O
. O

vectors O
derived O
from O
a O
re O
##comb O
##ina O
##nt O
re O
##tro O
##virus O
or O
a O
d O
##na O
/ O
protein O
complex O
can O
efficiently O
trans O
##du O
##ce O
the O
p O
##ah O
c O
##dn O
##a O
into O
p B-Disease
##ah I-Disease
- I-Disease
def I-Disease
##icient I-Disease
he O
##pa O
##to O
##cy O
##tes O
in O
v O
##it O
##ro O
, O
but O
the O
application O
of O
these O
vector O
systems O
is O
presently O
limited O
by O
their O
low O
trans O
##duction O
efficiency O
in O
v O
##ivo O
. O

in O
contrast O
, O
a O
vector O
derived O
from O
a O
re O
##comb O
##ina O
##nt O
ad O
##eno O
##virus O
can O
restore O
10 O
% O
- O
80 O
% O
of O
normal O
he O
##pa O
##tic O
p O
##ah O
activity O
into O
p B-Disease
##ah I-Disease
- I-Disease
def I-Disease
##icient I-Disease
mice O
, O
which O
completely O
normal O
##izes O
serum O
p O
##hen O
##yla O
##lani O
##ne O
levels O
. O

this O
treatment O
is O
trans O
##ient O
and O
cannot O
be O
effectively O
re O
- O
administered O
due O
to O
the O
presence O
of O
neutral O
##izing O
antibodies O
directed O
against O
the O
re O
##comb O
##ina O
##nt O
ad O
##eno O
##vir O
##al O
vector O
. O

however O
, O
these O
findings O
suggest O
that O
p B-Disease
##ku I-Disease
can O
be O
completely O
corrected O
by O
so O
##matic O
gene O
therapy O
, O
and O
provide O
some O
direction O
for O
the O
future O
development O
of O
ad O
##eno O
##vir O
##al O
vectors O
. O
. O

ex O
##on O
- O
intro O
##n O
structure O
of O
the O
human O
ne O
##uron O
##al O
ni O
##cot O
##ini O
##c O
ace O
##ty O
##l O
##cho O
##line O
receptor O
alpha O
4 O
subunit O
( O
ch O
##rna O
##4 O
) O
. O

the O
human O
ne O
##uron O
##al O
ni O
##cot O
##ini O
##c O
ace O
##ty O
##l O
##cho O
##line O
receptor O
alpha O
4 O
subunit O
gene O
( O
ch O
##rna O
##4 O
) O
is O
located O
in O
the O
candidate O
region O
for O
three O
different O
p O
##hen O
##otype O
##s O
ben B-Disease
##ign I-Disease
f I-Disease
##ami I-Disease
##lial I-Disease
neon I-Disease
##ata I-Disease
##l I-Disease
con I-Disease
##vu I-Disease
##ls I-Disease
##ions I-Disease
, O
auto B-Disease
##so I-Disease
##mal I-Disease
dominant I-Disease
no I-Disease
##cturnal I-Disease
frontal I-Disease
lobe I-Disease
e I-Disease
##pile I-Disease
##psy I-Disease
, O
and O
low O
- O
voltage O
e O
##eg O
. O

recently O
, O
a O
miss O
##ense O
mutation O
in O
trans O
##me O
##mb O
##rane O
domain O
2 O
of O
ch O
##rna O
##4 O
was O
found O
to O
be O
associated O
with O
auto B-Disease
##so I-Disease
##mal I-Disease
dominant I-Disease
no I-Disease
##cturnal I-Disease
frontal I-Disease
lobe I-Disease
e I-Disease
##pile I-Disease
##psy I-Disease
in O
one O
extended O
p O
##ed O
##ig O
##ree O
. O

we O
have O
determined O
the O
g O
##eno O
##mic O
organization O
of O
ch O
##rna O
##4 O
, O
which O
consists O
of O
six O
ex O
##ons O
distributed O
over O
approximately O
17 O
k O
##b O
of O
g O
##eno O
##mic O
d O
##na O
. O

the O
n O
##uc O
##leo O
##tide O
sequence O
obtained O
from O
the O
g O
##eno O
##mic O
regions O
adjacent O
to O
the O
ex O
##on O
boundaries O
enabled O
us O
to O
develop O
a O
set O
of O
prime O
##r O
pairs O
for O
p O
##c O
##r O
am O
##p O
##lification O
of O
the O
complete O
coding O
region O
. O

the O
sequence O
analysis O
provides O
the O
basis O
for O
a O
comprehensive O
mutation O
screening O
of O
ch O
##rna O
##4 O
in O
the O
above O
- O
mentioned O
p O
##hen O
##otype O
##s O
and O
possibly O
in O
other O
types O
of O
id B-Disease
##io I-Disease
##pathic I-Disease
e I-Disease
##pile I-Disease
##ps I-Disease
##ies I-Disease
. O
. O

ash O
##ken O
##azi O
j O
##ew O
##ish O
population O
frequencies O
for O
common O
mutations O
in O
br O
##ca O
##1 O
and O
br O
##ca O
##2 O
. O

br O
##ca O
##1 O
and O
br O
##ca O
##2 O
are O
the O
two O
major O
identified O
causes O
of O
inherited B-Disease
breast I-Disease
cancer I-Disease
, O
with O
mutations O
in O
either O
gene O
con O
##fer O
##ring O
up O
to O
80 O
- O
90 O
% O
lifetime O
risk O
of O
breast B-Disease
cancer I-Disease
in O
carrier O
females O
. O

mutations O
in O
br O
##ca O
##1 O
account O
for O
approximately O
45 O
% O
of O
f B-Disease
##ami I-Disease
##lial I-Disease
breast I-Disease
cancer I-Disease
and O
90 O
% O
of O
inherited B-Disease
breast I-Disease
/ I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
, O
whereas O
mutations O
in O
br O
##ca O
##2 O
account O
for O
a O
comparable O
percentage O
of O
inherited B-Disease
breast I-Disease
cancer I-Disease
cases O
. O

over O
85 O
distinct O
br O
##ca O
##1 O
mutations O
and O
a O
growing O
list O
of O
br O
##ca O
##2 O
mutations O
have O
been O
identified O
, O
with O
the O
majority O
resulting O
in O
protein O
t O
##run O
##cation O
. O

a O
specific O
br O
##ca O
##1 O
mutation O
, O
185 O
##dela O
##g O
, O
has O
a O
reported O
increased O
carrier O
frequency O
of O
approximately O
0 O
. O

9 O
% O
in O
the O
ash O
##ken O
##azi O
j O
##ew O
##ish O
population O
, O
but O
is O
also O
found O
in O
rare O
non O
- O
j O
##ew O
##ish O
patients O
with O
a O
different O
ha O
##p O
##lot O
##ype O
. O

the O
61 O
##7 O
##4 O
##del O
##t O
mutation O
in O
br O
##ca O
##2 O
was O
recently O
identified O
as O
a O
frequent O
mutation O
in O
8 O
out O
of O
107 O
ash O
##ken O
##azi O
j O
##ew O
##ish O
women O
diagnosed O
with O
breast B-Disease
cancer I-Disease
by O
age O
50 O
( O
re O
##f O
. O
8 O
) O
, O
as O
well O
as O
in O
three O
ash O
##ken O
##azi O
male B-Disease
breast I-Disease
cancer I-Disease
patients O
. O

we O
have O
conducted O
a O
large O
- O
scale O
population O
study O
to O
investigate O
the O
prevalence O
of O
specific O
br O
##ca O
##1 O
and O
br O
##ca O
##2 O
mutations O
in O
ash O
##ken O
##azi O
j O
##ew O
##ish O
individuals O
who O
were O
un O
##sel O
##ec O
##ted O
for O
breast B-Disease
cancer I-Disease
. O

br O
##ca O
##1 O
mutation O
screening O
on O
approximately O
3 O
, O
000 O
ash O
##ken O
##azi O
j O
##ew O
##ish O
samples O
determined O
a O
carrier O
frequency O
of O
1 O
. O

09 O
% O
for O
the O
185 O
##dela O
##g O
mutation O
and O
0 O
. O

13 O
% O
for O
the O
53 O
##8 O
##2 O
##ins O
##c O
mutation O
. O

br O
##ca O
##2 O
analysis O
on O
3 O
, O
08 O
##5 O
individuals O
from O
the O
same O
population O
showed O
a O
carrier O
frequency O
of O
1 O
. O

52 O
% O
for O
the O
61 O
##7 O
##4 O
##del O
##t O
mutation O
. O

this O
expanded O
population O
- O
based O
study O
confirms O
that O
the O
br O
##ca O
##1 O
185 O
##dela O
##g O
mutation O
and O
the O
br O
##ca O
##2 O
61 O
##7 O
##4 O
##del O
##t O
mutation O
constitute O
the O
two O
most O
frequent O
mutation O
all O
##ele O
##s O
pre O
##dis O
##po O
##sing O
to O
hereditary B-Disease
breast I-Disease
cancer I-Disease
among O
the O
ash O
##ken O
##azi O
##m O
, O
and O
suggests O
a O
relatively O
lower O
pen O
##et O
##rance O
for O
the O
61 O
##7 O
##4 O
##del O
##t O
mutation O
in O
br O
##ca O
##2 O

dual O
roles O
of O
at O
##m O
in O
the O
cellular O
response O
to O
radiation O
and O
in O
cell O
growth O
control O
. O

the O
gene O
m O
##uta O
##ted O
in O
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
( O
at B-Disease
) O
patients O
, O
denoted O
at O
##m O
, O
en O
##codes O
a O
put O
##ative O
protein O
or O
lip O
##id O
kinase O
. O

to O
el O
##uc O
##ida O
##te O
the O
functions O
of O
at O
##m O
, O
we O
disrupted O
the O
mouse O
at O
##m O
gene O
through O
ho O
##mo O
##log O
##ous O
re O
##comb O
##ination O
in O
mice O
. O

consistent O
with O
cellular O
defects O
of O
at B-Disease
patients O
, O
the O
at O
##m O
- O
/ O
- O
cells O
are O
h O
##yper O
##sen O
##sitive O
to O
gamma O
- O
i O
##rra O
##diation O
and O
defect O
##ive O
in O
cell O
- O
cycle O
arrest O
following O
radiation O
, O
co O
##rrel O
##ating O
with O
a O
defect O
##ive O
up O
- O
regulation O
of O
p O
##53 O
. O

in O
addition O
, O
at O
##m O
- O
/ O
- O
mouse O
thy O
##mo O
##cy O
##tes O
are O
more O
resistant O
to O
a O
##pop O
##tosis O
induced O
by O
gamma O
- O
i O
##rra O
##diation O
than O
normal O
thy O
##mo O
##cy O
##tes O
. O

at O
##m O
- O
/ O
- O
fi O
##bro O
##blast O
##s O
are O
in O
##ef O
##ficient O
in O
g O
##1 O
to O
s O
- O
phase O
progression O
following O
serum O
stimulation O
and O
se O
##nes O
##ce O
after O
only O
a O
few O
passages O
in O
culture O
. O

they O
have O
an O
increased O
con O
##st O
##it O
##utive O
level O
of O
p O
##21 O
##c O
##p O
##1 O
/ O
wa O
##f O
##1 O
. O

the O
at O
##m O
protein O
is O
therefore O
critical O
both O
for O
cellular O
responses O
to O
ion O
##izing O
radiation O
and O
for O
normal O
cell O
- O
cycle O
progression O
. O

at O
##m O
+ O
/ O
- O
fi O
##bro O
##blast O
##s O
and O
thy O
##mo O
##cy O
##tes O
showed O
intermediate O
##ly O
defect O
##ive O
responses O
to O
i O
##rra O
##diation O
but O
no O
growth O
defect O
, O
suggesting O
that O
the O
increased O
cancer B-Disease
risk O
of O
at B-Disease
he O
##tero O
##zy O
##got O
##es O
could O
be O
at O
##tri O
##but O
##able O
to O
poor O
check O
##point O
function O
. O
. O

targeted O
disruption O
of O
at O
##m O
leads O
to O
growth B-Disease
re I-Disease
##tar I-Disease
##dation I-Disease
, O
ch B-Disease
##rom I-Disease
##oso I-Disease
##mal I-Disease
fragment I-Disease
##ation I-Disease
during I-Disease
me I-Disease
##ios I-Disease
##is I-Disease
, O
immune B-Disease
defects I-Disease
, O
and O
thy B-Disease
##mic I-Disease
l I-Disease
##ymph I-Disease
##oma I-Disease
. O

at O
##m O
, O
the O
gene O
m O
##uta O
##ted O
in O
the O
inherited B-Disease
human I-Disease
disease I-Disease
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
, O
is O
a O
member O
of O
a O
family O
of O
kinase O
##s O
involved O
in O
d O
##na O
metabolism O
and O
cell O
- O
cycle O
check O
##point O
control O
. O

to O
help O
c O
##lar O
##ify O
the O
physiological O
roles O
of O
the O
at O
##m O
protein O
, O
we O
disrupted O
the O
at O
##m O
gene O
in O
mice O
through O
ho O
##mo O
##log O
##ous O
re O
##comb O
##ination O
. O

initial O
evaluation O
of O
the O
at O
##m O
knockout O
animals O
indicates O
that O
in O
##act O
##ivation O
of O
the O
mouse O
at O
##m O
gene O
re O
##cre O
##ates O
much O
of O
the O
p O
##hen O
##otype O
of O
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
. O

the O
ho O
##mo O
##zy O
##go O
##us O
mutant O
( O
at O
##m O
- O
/ O
- O
) O
mice O
are O
viable O
, O
growth O
- O
re O
##tar O
##ded O
, O
and O
in O
##fer O
##tile O
. O

the O
in B-Disease
##fer I-Disease
##tility I-Disease
of O
at O
##m O
- O
/ O
- O
mice O
results O
from O
me O
##iot O
##ic O
failure O
. O

me O
##ios O
##is O
is O
arrested O
at O
the O
z O
##y O
##got O
##ene O
/ O
p O
##ach O
##yte O
##ne O
stage O
of O
prop O
##has O
##e O
i O
as O
a O
result O
of O
abnormal O
ch O
##rom O
##oso O
##mal O
s O
##yna O
##psis O
and O
subsequent O
chromosome O
fragment O
##ation O
. O

immune B-Disease
defects I-Disease
also O
are O
evident O
in O
at O
##m O
- O
/ O
- O
mice O
, O
including O
reduced O
numbers O
of O
b O
##22 O
##0 O
+ O
c O
##d O
##43 O
- O
pre O
- O
b O
cells O
, O
thy O
##mo O
##cy O
##tes O
, O
and O
peripheral O
t O
cells O
, O
as O
well O
as O
functional O
imp O
##air O
##ment O
of O
t O
- O
cell O
- O
dependent O
immune O
responses O
. O

the O
c O
##ere O
##bella O
of O
at O
##m O
- O
/ O
- O
mice O
appear O
normal O
by O
his O
##to O
##log O
##ic O
examination O
at O
3 O
to O
4 O
months O
and O
the O
mice O
have O
no O
gross O
behavioral B-Disease
abnormal I-Disease
##ities I-Disease
. O

the O
majority O
of O
mutant O
mice O
rapidly O
develop O
thy B-Disease
##mic I-Disease
l I-Disease
##ymph I-Disease
##oma I-Disease
##s I-Disease
and O
die O
before O
4 O
months O
of O
age O
. O

these O
findings O
indicate O
that O
the O
at O
##m O
gene O
product O
plays O
an O
essential O
role O
in O
a O
diverse O
group O
of O
cellular O
processes O
, O
including O
me O
##ios O
##is O
, O
the O
normal O
growth O
of O
so O
##matic O
tissues O
, O
immune O
development O
, O
and O
tumor B-Disease
suppression O
. O
. O

c O
##lon O
##ing O
and O
characterization O
of O
human O
very O
- O
long O
- O
chain O
a O
##cy O
##l O
- O
co O
##a O
de O
##hy O
##dr O
##ogen O
##ase O
c O
##dn O
##a O
, O
ch O
##rom O
##oso O
##mal O
assignment O
of O
the O
gene O
and O
identification O
in O
four O
patients O
of O
nine O
different O
mutations O
within O
the O
v O
##l O
##ca O
##d O
gene O
. O

very O
- O
long O
- O
chain O
a O
##cy O
##l O
- O
co O
##a O
de O
##hy O
##dr O
##ogen O
##ase O
( O
v O
##l O
##ca O
##d O
) O
is O
one O
of O
four O
straight O
- O
chain O
a O
##cy O
##l O
- O
co O
##a O
de O
##hy O
##dr O
##ogen O
##ase O
( O
a O
##c O
##d O
) O
enzymes O
, O
which O
are O
all O
nuclear O
encoded O
mitochondrial O
fl O
##av O
##op O
##rote O
##ins O
cat O
##aly O
##zing O
the O
initial O
step O
in O
fatty O
acid O
beta O
- O
oxidation O
. O

we O
have O
used O
the O
very O
fast O
, O
rapid O
am O
##p O
##lification O
of O
c O
##dn O
##a O
ends O
( O
race O
) O
based O
strategy O
to O
obtain O
the O
sequence O
of O
c O
##dn O
##as O
encoding O
human O
v O
##l O
##ca O
##d O
from O
place O
##nta O
and O
fi O
##bro O
##blast O
##s O
. O

alignment O
of O
the O
predicted O
amino O
acid O
sequence O
of O
human O
v O
##l O
##ca O
##d O
with O
those O
of O
the O
other O
human O
a O
##c O
##d O
enzymes O
revealed O
extensive O
sequence O
ho O
##mology O
. O

more O
##over O
, O
human O
v O
##l O
##ca O
##d O
and O
human O
a O
##cy O
##l O
- O
co O
##a O
o O
##xi O
##das O
##e O
showed O
extensive O
sequence O
ho O
##mology O
co O
##rro O
##bor O
##ating O
the O
notion O
that O
these O
genes O
are O
evolution O
##arily O
related O
. O

southern O
b O
##lot O
analysis O
of O
g O
##eno O
##mic O
d O
##na O
from O
hybrid O
cell O
lines O
was O
used O
to O
local O
##ize O
the O
v O
##l O
##ca O
##d O
gene O
to O
human O
chromosome O
17 O
##p O
##11 O
. O

2 O
- O
p O
##11 O
. O

131 O
##0 O
##5 O
. O

using O
northern O
and O
western O
b O
##lot O
analysis O
to O
investigate O
the O
tissue O
specific O
distribution O
of O
v O
##l O
##ca O
##d O
m O
##rna O
and O
protein O
in O
several O
human O
tissues O
we O
showed O
that O
v O
##l O
##ca O
##d O
is O
most O
abundant O
in O
heart O
and O
skeletal O
muscle O
. O

this O
agrees O
well O
with O
the O
fact O
that O
cardiac O
and O
muscle O
symptoms O
are O
characteristic O
for O
patients O
with O
v B-Disease
##l I-Disease
##ca I-Disease
##d I-Disease
deficiency I-Disease
. O

northern O
b O
##lot O
analysis O
and O
se O
##quencing O
of O
clone O
##d O
p O
##c O
##r O
am O
##plified O
v O
##l O
##ca O
##d O
c O
##dn O
##a O
from O
four O
unrelated O
patients O
with O
v B-Disease
##l I-Disease
##ca I-Disease
##d I-Disease
deficiency I-Disease
showed O
that O
v O
##l O
##ca O
##d O
m O
##rna O
was O
und O
##ete O
##ct O
##able O
in O
one O
patient O
and O
that O
the O
other O
three O
have O
mutations O
in O
both O
v O
##l O
##ca O
##d O
all O
##ele O
##s O
. O

western O
b O
##lot O
analysis O
of O
patient O
fi O
##bro O
##blast O
##s O
showed O
that O
the O
identified O
mutations O
result O
in O
severely O
reduced O
amounts O
of O
v O
##l O
##ca O
##d O
protein O
. O

molecular O
bases O
of O
combined B-Disease
sub I-Disease
##to I-Disease
##tal I-Disease
def I-Disease
##ici I-Disease
##encies I-Disease
of I-Disease
c I-Disease
##6 I-Disease
and I-Disease
c I-Disease
##7 I-Disease
: O
their O
effects O
in O
combination O
with O
other O
c B-Disease
##6 I-Disease
and I-Disease
c I-Disease
##7 I-Disease
def I-Disease
##ici I-Disease
##encies I-Disease
. O

combined B-Disease
sub I-Disease
##to I-Disease
##tal I-Disease
deficiency I-Disease
of I-Disease
c I-Disease
##6 I-Disease
and I-Disease
c I-Disease
##7 I-Disease
, O
in O
which O
both O
proteins O
are O
expressed O
at O
very O
low O
levels O
, O
has O
been O
observed O
in O
ho O
##mo O
##zy O
##go O
##us O
form O
in O
two O
families O
. O

a O
defect O
at O
the O
5 O
s O
##p O
##lice O
donor O
site O
of O
intro O
##n O
15 O
of O
the O
c O
##6 O
gene O
explains O
the O
low O
molecular O
weight O
of O
the O
c O
##6 O
protein O
and O
is O
probably O
responsible O
for O
its O
low O
expressed O
concentration O
. O

the O
c O
##7 O
defect O
is O
more O
en O
##igma O
##tic O
the O
protein O
is O
of O
normal O
molecular O
weight O
, O
low O
circulating O
concentration O
, O
and O
altered O
is O
##oe O
##lect O
##ric O
point O
. O

an O
a O
##rg O
[UNK] O
se O
##r O
co O
##don O
substitution O
in O
ex O
##on O
11 O
is O
the O
only O
molecular O
alter O
##ation O
within O
the O
mature O
c O
##7 O
protein O
. O

these O
defects O
are O
associated O
with O
a O
characteristic O
set O
of O
p O
##oly O
##morphic O
d O
##na O
markers O
in O
the O
c O
##6 O
/ O
c O
##7 O
region O
, O
forming O
a O
distinct O
ha O
##p O
##lot O
##ype O
. O

the O
ha O
##p O
##lot O
##ype O
has O
been O
found O
in O
combination O
with O
a O
number O
of O
other O
ha O
##p O
##lot O
##ype O
##s O
containing O
defect O
##ive O
genes O
that O
lead O
either O
to O
c B-Disease
##6 I-Disease
or I-Disease
c I-Disease
##7 I-Disease
deficiency I-Disease
, O
but O
with O
different O
consequences O
. O

where O
it O
is O
combined O
with O
a O
c B-Disease
##6 I-Disease
- I-Disease
def I-Disease
##icient I-Disease
gene O
, O
the O
serum O
c O
##7 O
levels O
can O
be O
surprisingly O
high O
, O
possibly O
because O
there O
is O
no O
c O
##6 O
generating O
c O
##5 O
##6 O
to O
consume O
the O
c O
##7 O
. O

in O
contrast O
, O
where O
the O
c O
##7 O
genes O
are O
both O
defect O
##ive O
( O
but O
still O
partially O
functional O
) O
, O
there O
may O
be O
a O
profound O
deficit O
of O
circulating O
c O
##7 O
because O
there O
is O
ample O
c O
##6 O
to O
produce O
c O
##5 O
##6 O
and O
consume O
the O
already O
small O
amount O
of O
c O
##7 O
. O

each O
molecular O
defect O
has O
also O
been O
found O
in O
isolation O
and O
has O
the O
expected O
effect O
. O
. O

genetic O
bases O
of O
human O
complement B-Disease
c I-Disease
##7 I-Disease
deficiency I-Disease
. O

complement B-Disease
c I-Disease
##7 I-Disease
deficiency I-Disease
( O
c B-Disease
##7 I-Disease
##d I-Disease
) O
is O
associated O
frequently O
with O
re O
##current O
bacterial B-Disease
infections I-Disease
, O
especially O
men B-Disease
##ing I-Disease
##itis I-Disease
caused O
by O
ne B-Disease
##isse I-Disease
##ria I-Disease
men I-Disease
##ing I-Disease
##iti I-Disease
##dis I-Disease
. O

we O
report O
in O
this O
work O
the O
molecular O
bases O
of O
c B-Disease
##7 I-Disease
##d I-Disease
in O
two O
unrelated O
j O
##apa O
##nese O
males O
. O

we O
used O
ex O
##on O
- O
specific O
p O
##c O
##r O
/ O
single O
- O
strand O
conform O
##ation O
p O
##oly O
##mor O
##phism O
analysis O
as O
a O
screening O
step O
for O
mutations O
. O

subsequent O
direct O
se O
##quencing O
of O
the O
target O
ex O
##ons O
identified O
ho O
##mo O
##zy O
##go O
##us O
mutations O
in O
ex O
##on O
16 O
of O
case O
1 O
and O
in O
ex O
##on O
15 O
of O
case O
2 O
. O

the O
mutation O
of O
case O
1 O
was O
a O
ho O
##mo O
##zy O
##go O
##us O
t O
to O
a O
trans O
##version O
at O
n O
##uc O
##leo O
##tide O
225 O
##0 O
, O
the O
third O
n O
##uc O
##leo O
##tide O
of O
the O
co O
##don O
t O
##gt O
for O
c O
##ys O
##7 O
##28 O
, O
leading O
to O
a O
stop O
co O
##don O
t O
##ga O
( O
c O
##7 O
##28 O
##x O
) O
. O

in O
case O
2 O
, O
a O
ho O
##mo O
##zy O
##go O
##us O
2 O
- O
b O
##p O
del O
##eti O
##on O
( O
213 O
##7 O
##del O
##t O
##g O
/ O
213 O
##8 O
##del O
##gt O
/ O
213 O
##9 O
##del O
##t O
##g O
) O
caused O
a O
frames O
##hi O
##ft O
, O
generating O
a O
premature O
termination O
co O
##don O
4 O
to O
6 O
n O
##uc O
##leo O
##tide O
##s O
downstream O
. O

family O
study O
in O
case O
1 O
confirmed O
the O
genetic O
nature O
of O
the O
defect O
. O

more O
##over O
, O
we O
detected O
a O
novel O
p O
##oly O
##mor O
##phism O
in O
intro O
##n O
11 O
that O
presumably O
is O
linked O
to O
the O
mutation O
responsible O
for O
c B-Disease
##7 I-Disease
##d I-Disease
in O
case O
1 O
. O

our O
results O
indicate O
that O
the O
path O
##ogen O
##esis O
of O
c B-Disease
##7 I-Disease
##d I-Disease
is O
he O
##tero O
##gene O
##ous O
like O
most O
of O
the O
other O
def B-Disease
##ici I-Disease
##encies I-Disease
of I-Disease
complement I-Disease
components I-Disease
. O
. O

hp B-Disease
##rt I-Disease
- I-Disease
a I-Disease
##p I-Disease
##rt I-Disease
- I-Disease
def I-Disease
##icient I-Disease
mice O
are O
not O
a O
model O
for O
les B-Disease
##ch I-Disease
- I-Disease
n I-Disease
##y I-Disease
##han I-Disease
syndrome I-Disease
. O

complete B-Disease
h I-Disease
##y I-Disease
##pox I-Disease
##ant I-Disease
##hine I-Disease
- I-Disease
g I-Disease
##uan I-Disease
##ine I-Disease
p I-Disease
##hos I-Disease
##ph I-Disease
##ori I-Disease
##bos I-Disease
##yl I-Disease
- I-Disease
transfer I-Disease
##ase I-Disease
( I-Disease
hp I-Disease
##rt I-Disease
) I-Disease
deficiency I-Disease
in O
humans O
results O
in O
the O
les B-Disease
##ch I-Disease
- I-Disease
n I-Disease
##y I-Disease
##han I-Disease
syndrome I-Disease
which O
is O
characterized O
, O
among O
other O
features O
, O
by O
com O
##pu O
##lsive O
self O
- O
in O
##ju O
##rious O
behavior O
. O

hp B-Disease
##rt I-Disease
- I-Disease
def I-Disease
##icient I-Disease
mice O
generated O
using O
mouse O
em O
##b O
##ryo O
##nic O
stem O
cells O
exhibit O
none O
of O
the O
behavioral O
symptoms O
associated O
with O
the O
les B-Disease
##ch I-Disease
- I-Disease
n I-Disease
##y I-Disease
##han I-Disease
syndrome I-Disease
. O

administration O
of O
drugs O
that O
in O
##hibit O
ad O
##eni O
##ne O
p O
##hos O
##ph O
##ori O
##bos O
##yl O
##tra O
##ns O
##fer O
##ase O
( O
a O
##p O
##rt O
) O
in O
hp B-Disease
##rt I-Disease
- I-Disease
def I-Disease
##icient I-Disease
mice O
has O
produced O
the O
suggestion O
that O
deficiency B-Disease
of I-Disease
a I-Disease
##p I-Disease
##rt I-Disease
in O
combination O
with O
hp B-Disease
##rt I-Disease
- I-Disease
deficiency I-Disease
in O
mice O
may O
lead O
to O
self O
- O
m O
##uti O
##lation O
behavior O
[ O
c O
. O
l O
. O
w O
##u O
and O
d O
. O
w O
. O
melt O
##on O
( O
1993 O
) O
nature O
gene O
##t O
. O
3 O
, O
235 O
- O
240 O
] O
. O

to O
test O
this O
proposition O
, O
we O
bred O
hp B-Disease
##rt I-Disease
- I-Disease
a I-Disease
##p I-Disease
##rt I-Disease
- I-Disease
def I-Disease
##icient I-Disease
mice O
. O

although O
the O
do O
##ub O
##ly O
- O
def O
##icient O
mice O
ex O
##cre O
##te O
ad O
##eni O
##ne O
and O
its O
highly O
ins O
##ol O
##ub O
##le O
derivative O
, O
2 O
, O
8 O
- O
di O
##hy O
##dr O
##ox O
##ya O
##den O
##ine O
, O
which O
are O
also O
associated O
with O
human O
a B-Disease
##p I-Disease
##rt I-Disease
deficiency I-Disease
, O
additional O
abnormal O
##ities O
or O
any O
self O
- O
in O
##ju O
##rious O
behavior O
were O
not O
detected O
. O

thus O
, O
a B-Disease
##p I-Disease
##rt I-Disease
- I-Disease
hp I-Disease
##rt I-Disease
- I-Disease
def I-Disease
##icient I-Disease
mice O
, O
which O
are O
devoid O
of O
any O
pu O
##rine O
salvage O
pathways O
, O
show O
no O
novel O
p O
##hen O
##otype O
and O
are O
not O
a O
model O
for O
the O
behavioral B-Disease
abnormal I-Disease
##ities I-Disease
associated O
with O
the O
les B-Disease
##ch I-Disease
- I-Disease
n I-Disease
##y I-Disease
##han I-Disease
syndrome I-Disease
as O
previously O
suggested O

so O
##matic O
alterations O
of O
the O
d O
##p O
##c O
##4 O
gene O
in O
human O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
##s I-Disease
in O
v O
##ivo O
. O

background O
[UNK] O
aims O
the O
chromosome O
region O
18 O
##q O
##21 O
has O
been O
shown O
to O
be O
frequently O
deleted O
in O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
##s I-Disease
, O
and O
such O
frequent O
all O
##eli O
##c O
loss O
is O
a O
hall O
##mark O
of O
the O
presence O
of O
a O
tumor O
- O
suppress O
##or O
gene O
. O

the O
d O
##p O
##c O
##4 O
gene O
, O
which O
is O
located O
at O
18 O
##q O
##21 O
, O
has O
been O
identified O
as O
a O
tumor O
- O
suppress O
##or O
gene O
from O
examination O
of O
pan B-Disease
##cre I-Disease
##atic I-Disease
cancer I-Disease
##s I-Disease
. O

the O
aim O
of O
the O
present O
study O
was O
to O
determine O
if O
it O
might O
also O
be O
altered O
in O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
##s I-Disease
. O

methods O
mutation O
analyses O
of O
the O
d O
##p O
##c O
##4 O
gene O
were O
performed O
on O
complementary O
d O
##na O
samples O
from O
31 O
primary O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
specimens O
using O
a O
combination O
of O
polymer O
##ase O
chain O
reaction O
, O
single O
- O
strand O
conform O
##ation O
p O
##oly O
##mor O
##phism O
, O
and O
d O
##na O
se O
##quencing O
. O

results O
four O
miss O
##ense O
mutations O
producing O
amino O
acid O
substitution O
##s O
and O
a O
so O
##matic O
12 O
- O
base O
pair O
del O
##eti O
##on O
in O
the O
coding O
region O
of O
the O
d O
##p O
##c O
##4 O
gene O
were O
detected O
in O
the O
31 O
cancer B-Disease
##s I-Disease
( O
16 O
% O
; O
5 O
of O
31 O
) O
. O

conclusions O
the O
d O
##p O
##c O
##4 O
gene O
may O
play O
a O
role O
as O
a O
tumor O
- O
suppress O
##or O
gene O
in O
a O
fraction O
of O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
##s I-Disease
; O
however O
, O
while O
all O
##eli O
##c O
loss O
at O
18 O
##q O
##21 O
is O
very O
often O
seen O
in O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
##s I-Disease
, O
only O
a O
minority O
show O
d O
##p O
##c O
##4 O
mutations O
, O
suggesting O
that O
there O
might O
be O
another O
tumor O
- O
suppress O
##or O
gene O
in O
this O
chromosome O
region O
. O
. O

p O
##le O
##iot O
##ropic O
defects O
in O
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
protein O
- O
def O
##icient O
mice O
. O

we O
have O
generated O
a O
mouse O
model O
for O
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
by O
using O
gene O
targeting O
to O
generate O
mice O
that O
do O
not O
express O
the O
at O
##m O
protein O
. O

at O
##m O
- O
def O
##icient O
mice O
are O
re O
##tar O
##ded O
in O
growth O
, O
do O
not O
produce O
mature O
sperm O
, O
and O
exhibit O
severe O
defects O
in O
t O
cell O
mat O
##uration O
while O
going O
on O
to O
develop O
thy B-Disease
##mo I-Disease
##mas I-Disease
. O

at O
##m O
- O
def O
##icient O
fi O
##bro O
##blast O
##s O
grow O
poorly O
in O
culture O
and O
display O
a O
high O
level O
of O
double O
- O
stranded O
chromosome O
breaks O
. O

at O
##m O
- O
def O
##icient O
thy O
##mo O
##cy O
##tes O
undergo O
spontaneous O
a O
##pop O
##tosis O
in O
v O
##it O
##ro O
significantly O
more O
than O
controls O
. O

at O
##m O
- O
def O
##icient O
mice O
then O
exhibit O
many O
of O
the O
same O
symptoms O
found O
in O
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
patients O
and O
in O
cells O
derived O
from O
them O
. O

further O
##more O
, O
we O
demonstrate O
that O
the O
at O
##m O
protein O
exists O
as O
two O
discrete O
molecular O
species O
, O
and O
that O
loss O
of O
one O
or O
of O
both O
of O
these O
can O
lead O
to O
the O
development O
of O
the O
disease O
. O
. O

the O
d O
##cc O
protein O
and O
pro O
##gno O
##sis O
in O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
. O

background O
all O
##eli O
##c O
loss O
of O
chromosome O
18 O
##q O
predict O
##s O
a O
poor O
outcome O
in O
patients O
with O
stage B-Disease
ii I-Disease
color I-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
. O

although O
the O
specific O
gene O
inactivated O
by O
this O
all O
##eli O
##c O
loss O
has O
not O
been O
el O
##uc O
##idated O
, O
the O
d O
##cc O
( O
deleted O
in O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
) O
gene O
is O
a O
candidate O
. O

we O
investigated O
whether O
the O
expression O
of O
the O
d O
##cc O
protein O
in O
tumor B-Disease
cells O
is O
a O
pro O
##gno O
##stic O
marker O
in O
color B-Disease
##ec I-Disease
##tal I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
. O

methods O
the O
expression O
of O
d O
##cc O
was O
evaluated O
im O
##mu O
##no O
##his O
##to O
##chemical O
##ly O
in O
132 O
para O
##ffin O
- O
embedded O
samples O
from O
patients O
with O
cu O
##rative O
##ly O
re O
##sect O
##ed O
stage B-Disease
ii I-Disease
and I-Disease
ii I-Disease
##i I-Disease
color I-Disease
##ec I-Disease
##tal I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
##s I-Disease
. O

the O
co O
##x O
proportional O
- O
hazards O
model O
was O
used O
to O
adjust O
for O
co O
##var O
##iate O
##s O
including O
age O
, O
sex O
, O
tumor B-Disease
site O
, O
degree O
of O
tumor B-Disease
differentiation O
, O
and O
use O
of O
ad O
##ju O
##vant O
therapy O
. O

results O
the O
expression O
of O
d O
##cc O
was O
a O
strong O
positive O
predict O
##ive O
factor O
for O
survival O
in O
both O
stage B-Disease
ii I-Disease
and I-Disease
stage I-Disease
ii I-Disease
##i I-Disease
color I-Disease
##ec I-Disease
##tal I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
##s I-Disease
. O

in O
patients O
with O
stage O
ii O
disease O
whose O
tumors B-Disease
expressed O
d O
##cc O
, O
the O
five O
- O
year O
survival O
rate O
was O
94 O
. O

3 O
percent O
, O
whereas O
in O
patients O
with O
d B-Disease
##cc I-Disease
- I-Disease
negative I-Disease
tumors I-Disease
, O
the O
survival O
rate O
was O
61 O
. O

6 O
percent O
( O
p O
[UNK] O
0 O
. O
00 O
##1 O
) O
. O

in O
patients O
with O
stage B-Disease
ii I-Disease
##i I-Disease
disease I-Disease
, O
the O
respective O
survival O
rates O
were O
59 O
. O

3 O
percent O
and O
33 O
. O

2 O
percent O
( O
p O
= O
0 O
. O
03 O
) O
. O

conclusions O
d O
##cc O
is O
a O
pro O
##gno O
##stic O
marker O
in O
patients O
with O
stage B-Disease
ii I-Disease
or I-Disease
stage I-Disease
ii I-Disease
##i I-Disease
color I-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
. O

in O
stage B-Disease
ii I-Disease
color I-Disease
##ec I-Disease
##tal I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
##s I-Disease
, O
the O
absence O
of O
d O
##cc O
identifies O
a O
subgroup O
of O
patients O
with O
lesions O
that O
behave O
like O
stage B-Disease
ii I-Disease
##i I-Disease
cancer I-Disease
##s I-Disease
. O

these O
findings O
may O
thus O
have O
therapeutic O
implications O
in O
this O
group O
of O
patients O

association O
of O
anxiety B-Disease
- I-Disease
related I-Disease
traits I-Disease
with O
a O
p O
##oly O
##mor O
##phism O
in O
the O
se O
##rot O
##oni O
##n O
transport O
##er O
gene O
regulatory O
region O
. O

transport O
##er O
- O
facilitated O
up O
##take O
of O
se O
##rot O
##oni O
##n O
( O
5 O
- O
h O
##ydro O
##xy O
##try O
##pta O
##mine O
or O
5 O
- O
h O
##t O
) O
has O
been O
implicated O
in O
anxiety B-Disease
in O
humans O
and O
animal O
models O
and O
is O
the O
site O
of O
action O
of O
widely O
used O
up O
##take O
- O
in O
##hibit O
##ing O
anti O
##de O
##press O
##ant O
and O
anti O
##an O
##xi O
##ety O
drugs O
. O

human O
5 O
- O
h O
##t O
transport O
##er O
( O
5 O
- O
h O
##tt O
) O
gene O
transcription O
is O
m O
##od O
##ulated O
by O
a O
common O
p O
##oly O
##mor O
##phism O
in O
its O
upstream O
regulatory O
region O
. O

the O
short O
variant O
of O
the O
p O
##oly O
##mor O
##phism O
reduces O
the O
transcription O
##al O
efficiency O
of O
the O
5 O
- O
h O
##tt O
gene O
promoter O
, O
resulting O
in O
decreased O
5 O
- O
h O
##tt O
expression O
and O
5 O
- O
h O
##t O
up O
##take O
in O
l O
##ymph O
##ob O
##last O
##s O
. O

association O
studies O
in O
two O
independent O
samples O
totaling O
50 O
##5 O
individuals O
revealed O
that O
the O
5 O
- O
h O
##tt O
p O
##oly O
##mor O
##phism O
accounts O
for O
3 O
to O
4 O
percent O
of O
total O
variation O
and O
7 O
to O
9 O
percent O
of O
inherited O
variance O
in O
anxiety B-Disease
- I-Disease
related I-Disease
personality I-Disease
traits I-Disease
in O
individuals O
as O
well O
as O
si O
##bs O
##hips O
. O
. O

p O
##hen O
##otypic O
and O
g O
##eno O
##ty O
##pic O
overlap O
between O
ate B-Disease
##los I-Disease
##te I-Disease
##ogen I-Disease
##esis I-Disease
type I-Disease
2 I-Disease
and O
di B-Disease
##ast I-Disease
##rop I-Disease
##hic I-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
. O

mutations O
in O
the O
di B-Disease
##ast I-Disease
##rop I-Disease
##hic I-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
su O
##lf O
##ate O
transport O
##er O
gene O
d O
##t O
##ds O
##t O
have O
been O
associated O
with O
a O
family O
of O
ch B-Disease
##ond I-Disease
##rod I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
##s I-Disease
that O
comprises O
, O
in O
order O
of O
increasing O
severity O
, O
di B-Disease
##ast I-Disease
##rop I-Disease
##hic I-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
( O
d B-Disease
##t I-Disease
##d I-Disease
) O
, O
ate B-Disease
##los I-Disease
##te I-Disease
##ogen I-Disease
##esis I-Disease
type I-Disease
2 I-Disease
( O
a B-Disease
##o I-Disease
##2 I-Disease
) O
, O
and O
a B-Disease
##cho I-Disease
##nd I-Disease
##rogen I-Disease
##esis I-Disease
type I-Disease
1 I-Disease
##b I-Disease
( O
a B-Disease
##c I-Disease
##g I-Disease
##1 I-Disease
##b I-Disease
) O
. O

to O
learn O
more O
about O
the O
molecular O
basis O
of O
d B-Disease
##t I-Disease
##ds I-Disease
##t I-Disease
ch I-Disease
##ond I-Disease
##rod I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
##s I-Disease
and O
about O
g O
##eno O
##type O
- O
p O
##hen O
##otype O
correlation O
##s O
, O
we O
studied O
fi O
##bro O
##blast O
cultures O
of O
three O
new O
patients O
one O
with O
a B-Disease
##o I-Disease
- I-Disease
2 I-Disease
, O
one O
with O
d B-Disease
##t I-Disease
##d I-Disease
, O
and O
one O
with O
an O
intermediate O
p O
##hen O
##otype O
( O
a B-Disease
##o I-Disease
##2 I-Disease
/ O
d B-Disease
##t I-Disease
##d I-Disease
) O
. O

reduced O
incorporation O
of O
in O
##or O
##gan O
##ic O
su O
##lf O
##ate O
into O
mac O
##rom O
##ole O
##cule O
##s O
was O
found O
in O
all O
three O
. O

each O
of O
the O
three O
patients O
was O
found O
to O
be O
he O
##tero O
##zy O
##go O
##us O
for O
a O
c O
##86 O
##2 O
##t O
transition O
predict O
##ing O
a O
r O
##27 O
##9 O
##w O
substitution O
in O
the O
third O
extra O
##cellular O
loop O
of O
d O
##t O
##ds O
##t O
. O

in O
two O
patients O
( O
d B-Disease
##t I-Disease
##d I-Disease
and O
a B-Disease
##o I-Disease
##2 I-Disease
/ O
d B-Disease
##t I-Disease
##d I-Disease
) O
, O
no O
other O
structural O
mutation O
was O
found O
, O
but O
polymer O
##ase O
chain O
reaction O
am O
##p O
##lification O
and O
single O
- O
strand O
conform O
##ation O
p O
##oly O
##mor O
##phism O
analysis O
of O
fi O
##bro O
##blast O
c O
##dn O
##a O
showed O
reduced O
m O
##rna O
levels O
of O
the O
wild O
- O
type O
d O
##t O
##ds O
##t O
all O
##ele O
these O
two O
patients O
may O
be O
compound O
he O
##tero O
##zy O
##got O
##es O
for O
the O
" O
fin O
##nish O
" O
mutation O
( O
as O
yet O
un O
##cha O
##rac O
##ter O
##ized O
at O
the O
d O
##na O
level O
) O
, O
which O
causes O
reduced O
expression O
of O
d O
##t O
##ds O
##t O
. O

the O
third O
patient O
( O
with O
a B-Disease
##o I-Disease
##2 I-Disease
) O
had O
the O
r O
##27 O
##9 O
##w O
mutation O
compound O
##ed O
with O
a O
novel O
mutation O
, O
the O
del O
##eti O
##on O
of O
c O
##yt O
##os O
##ine O
41 O
##8 O
( O
delta O
c O
##41 O
##8 O
) O
, O
predict O
##ing O
a O
frames O
##hi O
##ft O
with O
premature O
termination O
. O

also O
the O
delta O
c O
##41 O
##8 O
all O
##ele O
was O
under O
##re O
##p O
##res O
##ented O
in O
the O
c O
##dn O
##a O
, O
in O
accordance O
with O
previous O
observations O
that O
premature O
stop O
co O
##don O
##s O
reduce O
m O
##rna O
levels O
. O

the O
presence O
of O
the O
d O
##t O
##ds O
##t O
r O
##27 O
##9 O
##w O
mutation O
in O
a O
total O
of O
11 O
patients O
with O
a B-Disease
##o I-Disease
##2 I-Disease
or O
d B-Disease
##t I-Disease
##d I-Disease
emphasizes O
the O
overlap O
between O
these O
conditions O
. O

this O
mutation O
has O
not O
been O
found O
so O
far O
in O
8 O
analyzed O
a B-Disease
##c I-Disease
##g I-Disease
##1 I-Disease
##b I-Disease
patients O
, O
suggesting O
that O
it O
allows O
some O
residual O
activity O
of O
the O
su O
##lf O
##ate O
transport O
##er O
. O
. O

identification O
of O
was O
##p O
mutations O
, O
mutation O
hot O
##sp O
##ots O
and O
g O
##eno O
##type O
- O
p O
##hen O
##otype O
di O
##sp O
##ari O
##ties O
in O
24 O
patients O
with O
the O
w B-Disease
##isk I-Disease
##ott I-Disease
- I-Disease
al I-Disease
##dric I-Disease
##h I-Disease
syndrome I-Disease
. O

the O
w B-Disease
##isk I-Disease
##ott I-Disease
- I-Disease
al I-Disease
##dric I-Disease
##h I-Disease
syndrome I-Disease
( O
was B-Disease
) O
, O
an O
x B-Disease
- I-Disease
linked I-Disease
im I-Disease
##mu I-Disease
##no I-Disease
##de I-Disease
##ficiency I-Disease
disease I-Disease
caused O
by O
mutation O
in O
the O
recently O
isolated O
gene O
encoding O
was B-Disease
protein O
( O
was O
##p O
) O
, O
is O
known O
to O
be O
associated O
with O
extensive O
clinical O
he O
##tero O
##gene O
##ity O
. O

cumulative O
mutation O
data O
have O
revealed O
that O
was O
##p O
g O
##eno O
##type O
##s O
are O
also O
highly O
variable O
among O
was B-Disease
patients O
, O
but O
the O
relationship O
of O
p O
##hen O
##otype O
with O
g O
##eno O
##type O
in O
this O
disease O
remains O
unclear O
. O

to O
address O
this O
issue O
we O
characterized O
was O
##p O
mutations O
in O
24 O
unrelated O
was B-Disease
patients O
, O
including O
18 O
boys O
with O
severe O
classical O
was B-Disease
and O
6 O
boys O
expressing O
mild O
forms O
of O
the O
disease O
, O
and O
then O
examined O
the O
degree O
of O
correlation O
of O
these O
as O
well O
as O
all O
previously O
published O
was O
##p O
mutations O
with O
disease O
severity O
. O

by O
analysis O
of O
these O
compiled O
mutation O
data O
, O
we O
demonstrated O
cluster O
##ing O
of O
was O
##p O
mutations O
within O
the O
four O
most O
n O
- O
terminal O
ex O
##ons O
of O
the O
gene O
and O
also O
identified O
several O
sites O
within O
this O
region O
as O
hot O
##sp O
##ots O
for O
was O
##p O
mutation O
. O

these O
characteristics O
were O
observed O
, O
however O
, O
in O
both O
severe O
and O
mild O
cases O
of O
the O
disease O
. O

similarly O
, O
while O
the O
cumulative O
data O
revealed O
a O
pre O
##dom O
##ina O
##nce O
of O
miss O
##ense O
mutations O
among O
the O
was O
##p O
gene O
lesions O
observed O
in O
boys O
with O
isolated B-Disease
th I-Disease
##rom I-Disease
##bo I-Disease
##cy I-Disease
##top I-Disease
##enia I-Disease
, O
miss O
##ense O
mutations O
were O
not O
exclusively O
associated O
with O
mild O
##er O
was B-Disease
p O
##hen O
##otype O
##s O
, O
but O
also O
comprised O
a O
substantial O
portion O
( O
38 O
% O
) O
of O
the O
was O
##p O
gene O
defects O
found O
in O
patients O
with O
severe O
disease O
. O

these O
findings O
, O
as O
well O
as O
the O
detection O
of O
identical O
was O
##p O
mutations O
in O
patients O
with O
di O
##sp O
##arate O
p O
##hen O
##otype O
##s O
, O
reveal O
a O
lack O
of O
p O
##hen O
##otype O
con O
##cor O
##dance O
with O
g O
##eno O
##type O
in O
was B-Disease
and O
thus O
imply O
that O
p O
##hen O
##otypic O
outcome O
in O
this O
disease O
cannot O
be O
re O
##lia O
##bly O
predicted O
solely O
on O
the O
basis O
of O
was O
##p O
g O
##eno O
##type O
##s O
. O
. O

g O
##er O
##m O
##line O
mutations O
in O
the O
3 O
' O
part O
of O
a B-Disease
##p I-Disease
##c I-Disease
ex O
##on O
15 O
do O
not O
result O
in O
t O
##runcated O
proteins O
and O
are O
associated O
with O
at O
##ten O
##uated O
ad B-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
co I-Disease
##li I-Disease
. O

f B-Disease
##ami I-Disease
##lial I-Disease
ad I-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
( O
f B-Disease
##ap I-Disease
) O
is O
an O
inherited O
pre O
##dis O
##position O
to O
color B-Disease
##ec I-Disease
##tal I-Disease
cancer I-Disease
characterized O
by O
the O
development O
of O
numerous O
ad B-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##ps I-Disease
predominantly O
in O
the O
color O
##ec O
##tal O
region O
. O

g O
##er O
##m O
##line O
mutations O
in O
the O
ad B-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
co I-Disease
##li I-Disease
( O
a B-Disease
##p I-Disease
##c I-Disease
) O
gene O
are O
responsible O
for O
most O
cases O
of O
f B-Disease
##ap I-Disease
. O

mutations O
at O
the O
5 O
end O
of O
a B-Disease
##p I-Disease
##c I-Disease
are O
known O
to O
be O
associated O
with O
a O
relatively O
mild O
form O
of O
the O
disease O
, O
called O
at B-Disease
##ten I-Disease
##uated I-Disease
ad I-Disease
##eno I-Disease
##mat I-Disease
##ous I-Disease
p I-Disease
##oly I-Disease
##po I-Disease
##sis I-Disease
co I-Disease
##li I-Disease
( O
a B-Disease
##ap I-Disease
##c I-Disease
) O
. O

we O
identified O
a O
frames O
##hi O
##ft O
mutation O
in O
the O
3 O
part O
of O
ex O
##on O
15 O
, O
resulting O
in O
a O
stop O
co O
##don O
at O
1862 O
, O
in O
a O
large O
du O
##tch O
kind O
##red O
with O
a B-Disease
##ap I-Disease
##c I-Disease
. O

western O
b O
##lot O
analysis O
of O
l O
##ymph O
##ob O
##last O
##oid O
cell O
lines O
derived O
from O
affected O
family O
members O
from O
this O
kind O
##red O
, O
as O
well O
as O
from O
a O
previously O
reported O
s O
##wi O
##ss O
family O
carrying O
a O
frames O
##hi O
##ft O
mutation O
at O
co O
##don O
1987 O
and O
displaying O
a O
similar O
at O
##ten O
##uated O
p O
##hen O
##otype O
, O
showed O
only O
the O
wild O
- O
type O
a B-Disease
##p I-Disease
##c I-Disease
protein O
. O

our O
study O
indicates O
that O
chain O
- O
terminating O
mutations O
located O
in O
the O
3 O
part O
of O
a B-Disease
##p I-Disease
##c I-Disease
do O
not O
result O
in O
detect O
##able O
t O
##runcated O
p O
##oly O
##pe O
##pt O
##ides O
and O
we O
h O
##y O
##pot O
##hes O
##ize O
that O
this O
is O
likely O
to O
be O
the O
basis O
for O
the O
observed O
a B-Disease
##ap I-Disease
##c I-Disease
p O
##hen O
##otype O
. O
. O

complete O
g O
##eno O
##mic O
sequence O
and O
analysis O
of O
117 O
k O
##b O
of O
human O
d O
##na O
containing O
the O
gene O
br O
##ca O
##1 O
. O

over O
100 O
distinct O
disease O
- O
associated O
mutations O
have O
been O
identified O
in O
the O
breast B-Disease
- I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
su O
##s O
##ce O
##pt O
##ibility O
gene O
br O
##ca O
##1 O
. O

loss O
of O
the O
wild O
- O
type O
all O
##ele O
in O
[UNK] O
90 O
% O
of O
tumors B-Disease
from O
patients O
with O
inherited O
br O
##ca O
##1 O
mutations O
indicates O
tumor B-Disease
suppress O
##ive O
function O
. O

the O
low O
incidence O
of O
so O
##matic O
mutations O
suggests O
that O
br O
##ca O
##1 O
in O
##act O
##ivation O
in O
s O
##poradic O
tumors B-Disease
occurs O
by O
alternative O
mechanisms O
, O
such O
as O
inter O
##st O
##iti O
##al O
ch O
##rom O
##oso O
##mal O
del O
##eti O
##on O
or O
reduced O
transcription O
. O

to O
identify O
possible O
features O
of O
the O
br O
##ca O
##1 O
g O
##eno O
##mic O
region O
that O
may O
contribute O
to O
ch O
##rom O
##oso O
##mal O
instability O
as O
well O
as O
potential O
transcription O
##al O
regulatory O
elements O
, O
a O
117 O
, O
143 O
- O
b O
##p O
d O
##na O
sequence O
encompassing O
br O
##ca O
##1 O
was O
obtained O
by O
random O
se O
##quencing O
of O
four O
co O
##sm O
##ids O
identified O
from O
a O
human O
chromosome O
17 O
specific O
library O
. O

the O
24 O
ex O
##ons O
of O
br O
##ca O
##1 O
span O
an O
81 O
- O
k O
##b O
region O
that O
has O
an O
unusually O
high O
density O
of O
al O
##u O
repetitive O
d O
##na O
( O
41 O
. O
5 O
% O
) O
, O
but O
relatively O
low O
density O
( O
4 O
. O
8 O
% O
) O
of O
other O
repetitive O
sequences O
. O

br O
##ca O
##1 O
intro O
##n O
lengths O
range O
in O
size O
from O
40 O
##3 O
b O
##p O
to O
9 O
. O

2 O
k O
##b O
and O
contain O
the O
in O
##tra O
##genic O
micro O
##sat O
##elli O
##te O
markers O
d O
##17 O
##s O
##13 O
##23 O
, O
d O
##17 O
##s O
##13 O
##22 O
, O
and O
d O
##17 O
##s O
##8 O
##55 O
, O
which O
local O
##ize O
to O
intro O
##ns O
12 O
, O
19 O
, O
and O
20 O
, O
respectively O
. O

in O
addition O
to O
br O
##ca O
##1 O
, O
the O
con O
##ti O
##g O
contains O
two O
complete O
genes O
r O
##ho O
##7 O
, O
a O
member O
of O
the O
r O
##ho O
family O
of O
g O
##t O
##p O
binding O
proteins O
, O
and O
v O
##at O
##1 O
, O
an O
abundant O
membrane O
protein O
of O
ch O
##olin O
##ergic O
s O
##yna O
##ptic O
ve O
##si O
##cles O
. O

partial O
sequences O
of O
the O
1 O
##a O
##1 O
- O
3 O
##b O
b O
- O
box O
protein O
pseudo O
##gene O
and O
if O
##p O
35 O
, O
an O
inter O
##fer O
##on O
induced O
le O
##uc O
##ine O
zipper O
protein O
, O
reside O
within O
the O
con O
##ti O
##g O
. O

an O
l O
##21 O
rib O
##oso O
##mal O
protein O
pseudo O
##gene O
is O
embedded O
in O
br O
##ca O
##1 O
intro O
##n O
13 O
. O

the O
order O
of O
genes O
on O
the O
chromosome O
is O
cent O
##rome O
##re O
- O
1 O
##f O
##p O
35 O
- O
v O
##at O
##1 O
- O
r O
##ho O
##7 O
- O
br O
##ca O
##1 O
- O
1 O
##a O
##1 O
- O
3 O
##b O
- O
te O
##lo O
##mere O

identification O
of O
a O
ring O
protein O
that O
can O
interact O
in O
v O
##ivo O
with O
the O
br O
##ca O
##1 O
gene O
product O
. O

the O
hereditary B-Disease
breast I-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
gene O
, O
br O
##ca O
##1 O
, O
en O
##codes O
a O
large O
p O
##oly O
##pe O
##pt O
##ide O
that O
contains O
the O
c O
##ys O
##tein O
##e O
- O
rich O
ring O
motif O
, O
a O
zinc O
- O
binding O
domain O
found O
in O
a O
variety O
of O
regulatory O
proteins O
. O

here O
we O
describe O
a O
novel O
protein O
that O
interact O
##s O
in O
v O
##ivo O
with O
the O
n O
- O
terminal O
region O
of O
br O
##ca O
##1 O
. O

this O
br O
##ca O
##1 O
- O
associated O
ring O
domain O
( O
bar O
##d O
##1 O
) O
protein O
contains O
an O
n O
- O
terminal O
ring O
motif O
, O
three O
tandem O
an O
##ky O
##rin O
repeats O
, O
and O
a O
c O
- O
terminal O
sequence O
with O
significant O
ho O
##mology O
to O
the O
phylogenetic O
##ally O
conserved O
br O
##ct O
domains O
that O
lie O
near O
the O
c O
terminus O
of O
br O
##ca O
##1 O
. O

the O
bar O
##d O
##1 O
/ O
br O
##ca O
##1 O
interaction O
is O
disrupted O
by O
br O
##ca O
##1 O
miss O
##ense O
mutations O
that O
se O
##g O
##re O
##gate O
with O
breast B-Disease
cancer I-Disease
su O
##s O
##ce O
##pt O
##ibility O
, O
indicating O
that O
bar O
##d O
##1 O
may O
be O
involved O
in O
media O
##ting O
t B-Disease
##umour I-Disease
suppression O
by O
br O
##ca O
##1 O
. O
. O

detection O
of O
he O
##tero O
##zy O
##go O
##us O
mutations O
in O
br O
##ca O
##1 O
using O
high O
density O
o O
##li O
##gon O
##uc O
##leo O
##tide O
array O
##s O
and O
two O
- O
colour O
flu O
##ores O
##cence O
analysis O
. O

the O
ability O
to O
scan O
a O
large O
gene O
rapidly O
and O
accurately O
for O
all O
possible O
he O
##tero O
##zy O
##go O
##us O
mutations O
in O
large O
numbers O
of O
patient O
samples O
will O
be O
critical O
for O
the O
future O
of O
medicine O
. O

we O
have O
designed O
high O
- O
density O
array O
##s O
consisting O
of O
over O
96 O
, O
600 O
o O
##li O
##gon O
##uc O
##leo O
##tide O
##s O
20 O
- O
n O
##uc O
##leo O
##tide O
##s O
( O
n O
##t O
) O
in O
length O
to O
screen O
for O
a O
wide O
range O
of O
he O
##tero O
##zy O
##go O
##us O
mutations O
in O
the O
3 O
. O

45 O
- O
k O
##ilo O
##base O
##s O
( O
k O
##b O
) O
ex O
##on O
11 O
of O
the O
hereditary B-Disease
breast I-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
gene O
br O
##ca O
##1 O
. O

reference O
and O
test O
samples O
were O
co O
- O
hybrid O
##ized O
to O
these O
array O
##s O
and O
differences O
in O
hybrid O
##ization O
patterns O
q O
##uant O
##itated O
by O
two O
- O
colour O
analysis O
. O

fourteen O
of O
fifteen O
patient O
samples O
with O
known O
mutations O
were O
accurately O
diagnosed O
, O
and O
no O
false O
positive O
mutations O
were O
identified O
in O
20 O
control O
samples O
. O

eight O
single O
n O
##uc O
##leo O
##tide O
p O
##oly O
##mor O
##phism O
##s O
were O
also O
readily O
detected O
. O

d O
##na O
chip O
- O
based O
ass O
##ays O
may O
provide O
a O
valuable O
new O
technology O
for O
high O
- O
through O
##put O
cost O
- O
efficient O
detection O
of O
genetic O
alterations O
. O

auto O
##so O
##mal O
dominant O
primary O
h B-Disease
##yper I-Disease
##par I-Disease
##athy I-Disease
##roid I-Disease
##ism I-Disease
and I-Disease
jaw I-Disease
tumor I-Disease
syndrome I-Disease
associated O
with O
re B-Disease
##nal I-Disease
ha I-Disease
##mart I-Disease
##oma I-Disease
##s I-Disease
and O
c B-Disease
##ys I-Disease
##tic I-Disease
kidney I-Disease
disease I-Disease
: O
link O
##age O
to O
1 O
##q O
##21 O
- O
q O
##32 O
and O
loss O
of O
the O
wild O
type O
all O
##ele O
in O
re B-Disease
##nal I-Disease
ha I-Disease
##mart I-Disease
##oma I-Disease
##s I-Disease
. O

hereditary B-Disease
h I-Disease
##yper I-Disease
##par I-Disease
##athy I-Disease
##roid I-Disease
##ism I-Disease
- I-Disease
jaw I-Disease
tumor I-Disease
syndrome I-Disease
( O
hp B-Disease
##t I-Disease
- I-Disease
j I-Disease
##t I-Disease
) O
is O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
dominant I-Disease
disease I-Disease
( O
o O
##mi O
##m O
145 O
##00 O
##1 O
) O
that O
has O
recently O
been O
mapped O
to O
ch O
##rom O
##oso O
##mal O
region O
1 O
##q O
##21 O
- O
q O
##32 O
( O
h O
##rp O
##t O
##2 O
) O
. O

here O
we O
report O
two O
families O
with O
hp B-Disease
##t I-Disease
- I-Disease
j I-Disease
##t I-Disease
syndrome I-Disease
in O
which O
adult B-Disease
re I-Disease
##nal I-Disease
ha I-Disease
##mart I-Disease
##oma I-Disease
##s I-Disease
or O
c B-Disease
##ys I-Disease
##tic I-Disease
kidney I-Disease
disease I-Disease
were O
prominent O
associated O
features O
, O
possibly O
representing O
a O
new O
p O
##hen O
##otypic O
variant O
of O
the O
hp B-Disease
##t I-Disease
- I-Disease
j I-Disease
##t I-Disease
syndrome I-Disease
. O

in O
the O
first O
family O
, O
re B-Disease
##nal I-Disease
lesions I-Disease
were O
present O
in O
five O
out O
of O
six O
affected O
individuals O
, O
whereas O
hp B-Disease
##t I-Disease
and O
j B-Disease
##t I-Disease
were O
seen O
in O
four O
and O
two O
cases O
, O
respectively O
. O

in O
the O
second O
family O
, O
j B-Disease
##t I-Disease
was O
found O
in O
three O
of O
the O
five O
affected O
individuals O
and O
two O
affected O
members O
also O
exhibited O
p B-Disease
##oly I-Disease
##cy I-Disease
##stic I-Disease
kidney I-Disease
disease I-Disease
. O

the O
possibility O
of O
the O
latter O
co O
##se O
##g O
##re O
##gating O
as O
a O
separate O
auto O
##so O
##mal O
dominant O
gene O
can O
not O
be O
ruled O
out O
. O

a O
sex O
- O
dependent O
pen O
##et O
##rance O
of O
primary B-Disease
hp I-Disease
##t I-Disease
, O
resulting O
in O
predominantly O
male O
- O
affected O
cases O
was O
evident O
in O
the O
two O
families O
. O

twenty O
micro O
##sat O
##elli O
##te O
markers O
in O
the O
h O
##rp O
##t O
##2 O
region O
were O
typed O
, O
in O
addition O
to O
markers O
in O
the O
multiple B-Disease
end I-Disease
##oc I-Disease
##rine I-Disease
neo I-Disease
##p I-Disease
##lasia I-Disease
( I-Disease
men I-Disease
) I-Disease
types I-Disease
1 I-Disease
and I-Disease
2 I-Disease
regions O
at O
11 O
##q O
##13 O
and O
10 O
##q O
##11 O
. O

the O
disease O
in O
these O
two O
kind O
##red O
##s O
was O
linked O
to O
five O
markers O
in O
the O
1 O
##q O
##21 O
- O
q O
##32 O
region O
( O
log O
##ari O
##th O
##m O
- O
of O
- O
odds O
scores O
3 O
. O
2 O
- O
4 O
2 O
- O
4 O
. O
2 O
) O
, O
whereas O
link O
##age O
to O
the O
men B-Disease
##1 I-Disease
and O
men B-Disease
##2 I-Disease
regions O
was O
excluded O
. O

me O
##iot O
##ic O
re O
##comb O
##ination O
##s O
detected O
in O
affected O
individuals O
placed O
the O
lo O
##cus O
te O
##lo O
##mer O
##ic O
of O
d O
##1 O
##s O
##21 O
##5 O
, O
thus O
narrowing O
the O
h O
##rp O
##t O
##2 O
region O
from O
[UNK] O
60 O
to O
approximately O
34 O
cent O
##imo O
##rgan O
##s O
. O

loss O
of O
he O
##tero O
##zy O
##gos O
##ity O
was O
studied O
in O
seven O
re B-Disease
##nal I-Disease
ha I-Disease
##mart I-Disease
##oma I-Disease
##s I-Disease
from O
two O
affected O
individuals O
in O
the O
first O
family O
, O
as O
well O
as O
in O
a O
jaw B-Disease
tumor I-Disease
and O
a O
para B-Disease
##thy I-Disease
##roid I-Disease
tumor I-Disease
from O
the O
second O
family O
. O

all O
re B-Disease
##nal I-Disease
ha I-Disease
##mart I-Disease
##oma I-Disease
##s I-Disease
showed O
loss O
of O
he O
##tero O
##zy O
##gos O
##ity O
at O
the O
1 O
##q O
##21 O
- O
q O
##32 O
region O
. O

the O
losses O
in O
##var O
##iably O
involved O
the O
wild O
type O
all O
##ele O
derived O
from O
the O
un O
##af O
##fected O
parent O
, O
suggesting O
the O
in O
##act O
##ivation O
of O
a O
tumor B-Disease
suppress O
##or O
gene O
in O
this O
region O

independent O
origin O
of O
single O
and O
double O
mutations O
in O
the O
human O
glucose O
6 O
- O
phosphate O
de O
##hy O
##dr O
##ogen O
##ase O
gene O
. O

the O
vast O
majority O
of O
both O
p O
##oly O
##morphic O
and O
s O
##poradic O
g O
##6 O
##p O
##d O
variants O
are O
due O
to O
single O
miss O
##ense O
mutations O
. O

in O
the O
four O
p O
##oly O
##morphic O
variants O
that O
have O
two O
point O
mutations O
, O
one O
of O
the O
mutations O
is O
always O
37 O
##6 O
a O
- O
- O
[UNK] O
g O
( O
126 O
as O
##n O
- O
- O
[UNK] O
as O
##p O
) O
, O
which O
on O
its O
own O
gives O
rise O
to O
the O
non O
##de O
##ficient O
p O
##oly O
##morphic O
variant O
, O
g O
##6 O
##p O
##d O
a O
. O

in O
a O
study O
of O
g B-Disease
##6 I-Disease
##p I-Disease
##d I-Disease
def I-Disease
##icient I-Disease
patients O
who O
presented O
with O
clinical O
f B-Disease
##avi I-Disease
##sm I-Disease
in O
spa O
##in O
, O
we O
have O
found O
a O
new O
p O
##oly O
##morphic O
variant O
that O
we O
have O
called O
g O
##6 O
##p O
##d O
ma O
##lag O
##a O
, O
whose O
only O
abnormal O
##ity O
is O
a O
54 O
##2 O
a O
- O
- O
[UNK] O
t O
( O
181 O
as O
##p O
- O
- O
[UNK] O
v O
##al O
) O
mutation O
. O

this O
is O
the O
same O
mutation O
as O
previously O
found O
in O
association O
with O
the O
mutation O
of O
g O
##6 O
##p O
##d O
a O
in O
the O
double O
mutant O
, O
g O
##6 O
##p O
##d O
sa O
##nta O
##mar O
##ia O
. O

g O
##6 O
##p O
##d O
ma O
##lag O
##a O
is O
associated O
with O
enzyme B-Disease
deficiency I-Disease
( O
class O
ii O
##i O
) O
, O
and O
the O
en O
##zy O
##mic O
properties O
of O
g O
##6 O
##p O
##d O
ma O
##lag O
##a O
and O
g O
##6 O
##p O
##d O
sa O
##nta O
##mar O
##ia O
are O
quite O
similar O
, O
indicating O
that O
in O
this O
case O
the O
effects O
of O
the O
two O
mutations O
are O
add O
##itive O
rather O
than O
s O
##yne O
##rg O
##istic O
. O

g O
##6 O
##p O
##d O
sa O
##nta O
##mar O
##ia O
might O
have O
been O
produced O
by O
re O
##comb O
##ination O
between O
g O
##6 O
##p O
##d O
a O
and O
g O
##6 O
##p O
##d O
ma O
##lag O
##a O
; O
however O
ha O
##p O
##lot O
##ype O
analysis O
, O
including O
the O
use O
of O
a O
new O
silent O
p O
##oly O
##mor O
##phism O
, O
suggests O
that O
the O
same O
54 O
##2 O
a O
- O
- O
[UNK] O
t O
mutation O
has O
taken O
place O
independently O
in O
a O
g O
##6 O
##p O
##d O
b O
gene O
to O
give O
g O
##6 O
##p O
##d O
ma O
##lag O
##a O
and O
in O
a O
g O
##6 O
##p O
##d O
a O
gene O
to O
give O
g O
##6 O
##p O
##d O
sa O
##nta O
##mar O
##ia O
. O

these O
findings O
help O
to O
outline O
the O
relationship O
and O
evolution O
of O
mutations O
in O
the O
human O
g O
##6 O
##p O
##d O
lo O
##cus O
. O
. O

br O
##ca O
##1 O
r O
##8 O
##41 O
##w O
: O
a O
strong O
candidate O
for O
a O
common O
mutation O
with O
moderate O
p O
##hen O
##otype O
. O

br O
##ca O
##1 O
mutations O
cause O
increased O
risk O
for O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
, O
frequently O
of O
early O
onset O
. O

many O
different O
mutations O
occur O
in O
br O
##ca O
##1 O
, O
including O
several O
examples O
of O
re O
##current O
mutations O
, O
each O
of O
which O
accounts O
for O
a O
significant O
number O
of O
families O
with O
her O
##ita O
##ble O
cancer B-Disease
pre O
##dis O
##position O
. O

these O
common O
mutations O
have O
an O
et O
##iol O
##ogical O
role O
in O
many O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
cases O
and O
provide O
the O
opportunity O
to O
examine O
g O
##eno O
##type O
- O
p O
##hen O
##otype O
correlation O
##s O
and O
g O
##eno O
##type O
- O
environment O
interactions O
in O
individuals O
with O
the O
identical O
br O
##ca O
##1 O
les O
##ion O
. O

we O
report O
a O
novel O
miss O
##ense O
change O
in O
br O
##ca O
##1 O
, O
264 O
##0 O
c O
- O
- O
[UNK] O
t O
( O
r O
##8 O
##41 O
##w O
) O
, O
found O
in O
3 O
cases O
from O
a O
subject O
group O
of O
305 O
breast B-Disease
and I-Disease
79 I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
cases O
from O
orange O
county O
, O
ca O
. O

these O
are O
consecutive O
, O
population O
- O
based O
cases O
not O
selected O
for O
age O
or O
family O
history O
. O

in O
all O
three O
cases O
, O
there O
is O
a O
strong O
family O
history O
of O
breast B-Disease
, I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
, I-Disease
or I-Disease
other I-Disease
cancer I-Disease
##s I-Disease
possibly O
related O
to O
a O
br O
##ca O
##1 O
defect O
and O
family O
members O
showed O
a O
high O
con O
##cor O
##dance O
of O
cancer B-Disease
incidence O
with O
the O
presence O
of O
r O
##8 O
##41 O
##w O
. O

the O
age O
of O
cancer B-Disease
onset O
was O
not O
always O
distinct O
from O
typical O
s O
##poradic O
cases O
. O

testing O
of O
a O
sample O
of O
41 O
##3 O
unrelated O
individuals O
to O
examine O
the O
hypothesis O
that O
r O
##8 O
##41 O
##w O
might O
be O
a O
rare O
p O
##oly O
##mor O
##phism O
detected O
one O
additional O
instance O
in O
a O
woman O
with O
breast B-Disease
cancer I-Disease
diagnosed O
at O
age O
77 O
years O
, O
and O
cancer B-Disease
in O
one O
parent O
. O

r O
##8 O
##41 O
##w O
is O
likely O
to O
be O
an O
et O
##iol O
##ogical O
##ly O
significant O
les O
##ion O
with O
involvement O
in O
close O
to O
1 O
% O
( O
95 O
% O
confidence O
interval O
of O
0 O
- O
1 O
. O
7 O
% O
) O
of O
all O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
##s I-Disease
in O
this O
population O
. O

at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
: O
founder O
effect O
among O
north O
a O
##f O
##rica O
##n O
j O
##ews O
. O

the O
at O
##m O
gene O
is O
responsible O
for O
the O
auto B-Disease
##so I-Disease
##mal I-Disease
re I-Disease
##cess I-Disease
##ive I-Disease
disorder I-Disease
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
( O
a B-Disease
- I-Disease
t I-Disease
) O
, O
characterized O
by O
c B-Disease
##ere I-Disease
##bella I-Disease
##r I-Disease
de I-Disease
##gene I-Disease
##ration I-Disease
, O
im B-Disease
##mu I-Disease
##no I-Disease
##de I-Disease
##ficiency I-Disease
and O
cancer B-Disease
pre I-Disease
##dis I-Disease
##position I-Disease
. O

a B-Disease
- I-Disease
t I-Disease
carriers O
were O
reported O
to O
be O
moderately O
cancer B-Disease
- I-Disease
prone I-Disease
. O

a O
wide O
variety O
of O
a B-Disease
- I-Disease
t I-Disease
mutations O
, O
most O
of O
which O
are O
unique O
to O
single O
families O
, O
were O
identified O
in O
various O
ethnic O
groups O
, O
pre O
##c O
##lu O
##ding O
carrier O
screening O
with O
mutation O
- O
specific O
ass O
##ays O
. O

however O
, O
a O
single O
mutation O
was O
observed O
in O
32 O
/ O
33 O
defect O
##ive O
at O
##m O
all O
##ele O
##s O
in O
j O
##ew O
##ish O
a B-Disease
- I-Disease
t I-Disease
families O
of O
north O
a O
##f O
##rica O
##n O
origin O
, O
coming O
from O
various O
regions O
of O
m O
##oro O
##cco O
and O
t O
##uni O
##sia O
. O

this O
mutation O
, O
103 O
##c O
- O
- O
[UNK] O
t O
, O
results O
in O
a O
stop O
co O
##don O
at O
position O
35 O
of O
the O
at O
##m O
protein O
. O

in O
keeping O
with O
the O
nature O
of O
this O
mutation O
, O
various O
antibodies O
directed O
against O
the O
at O
##m O
protein O
failed O
to O
defect O
this O
protein O
in O
patient O
cells O
. O

a O
rapid O
carrier O
detection O
ass O
##ay O
detected O
this O
mutation O
in O
three O
out O
of O
48 O
##8 O
at O
##m O
all O
##ele O
##s O
of O
j O
##ew O
##ish O
m O
##oro O
##cca O
##n O
or O
t O
##uni O
##sian O
origin O
. O

this O
founder O
effect O
provides O
a O
unique O
opportunity O
for O
population O
- O
based O
screening O
for O
a B-Disease
- I-Disease
t I-Disease
carriers O
in O
a O
large O
j O
##ew O
##ish O
community O
. O
. O

mutation O
analysis O
of O
br O
##ca O
##1 O
and O
br O
##ca O
##2 O
in O
a O
male B-Disease
breast I-Disease
cancer I-Disease
population O
. O

a O
population O
- O
based O
series O
of O
54 O
male B-Disease
breast I-Disease
cancer I-Disease
cases O
from O
southern O
ca O
##li O
##fo O
##rn O
##ia O
were O
analyzed O
for O
g O
##er O
##m O
- O
line O
mutations O
in O
the O
inherited B-Disease
breast I-Disease
/ I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
genes O
, O
br O
##ca O
##1 O
and O
br O
##ca O
##2 O
. O

nine O
( O
17 O
% O
) O
of O
the O
patients O
had O
a O
family O
history O
of O
breast B-Disease
and I-Disease
/ I-Disease
or I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
in O
at O
least O
one O
first O
- O
degree O
relative O
. O

a O
further O
seven O
( O
13 O
% O
) O
of O
the O
patients O
reported O
breast B-Disease
/ I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
in O
at O
least O
one O
second O
- O
degree O
relative O
and O
in O
no O
first O
- O
degree O
relatives O
. O

no O
g O
##er O
##m O
- O
line O
br O
##ca O
##1 O
mutations O
were O
found O
. O

two O
male B-Disease
breast I-Disease
cancer I-Disease
patients O
( O
4 O
% O
of O
the O
total O
) O
were O
found O
to O
carry O
novel O
t O
##run O
##cating O
mutations O
in O
the O
br O
##ca O
##2 O
gene O
. O

only O
one O
of O
the O
two O
male B-Disease
breast I-Disease
cancer I-Disease
patients O
carrying O
a O
br O
##ca O
##2 O
mutation O
had O
a O
family O
history O
of O
cancer B-Disease
, O
with O
one O
case O
of O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
in O
a O
first O
- O
degree O
relative O
. O

the O
remaining O
eight O
cases O
( O
89 O
% O
) O
of O
male B-Disease
breast I-Disease
cancer I-Disease
with O
a O
family O
history O
of O
breast B-Disease
/ I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
in O
first O
- O
degree O
relatives O
remain O
un O
##ac O
##co O
##unted O
for O
by O
mutations O
in O
either O
the O
br O
##ca O
##1 O
gene O
or O
the O
br O
##ca O
##2 O
gene O
. O
. O

molecular O
basis O
for O
du B-Disease
##arte I-Disease
and I-Disease
los I-Disease
angel I-Disease
##es I-Disease
variant I-Disease
gal I-Disease
##act I-Disease
##ose I-Disease
##mia I-Disease
. O

human O
or O
##yt O
##hr O
##ocytes O
that O
are O
ho O
##mo O
##zy O
##go O
##us O
for O
the O
du B-Disease
##arte I-Disease
enzyme I-Disease
variant I-Disease
of I-Disease
gal I-Disease
##act I-Disease
##ose I-Disease
##mia I-Disease
( O
d O
/ O
d O
) O
have O
a O
characteristic O
is O
##of O
##orm O
on O
is O
##oe O
##lect O
##ric O
focusing O
and O
50 O
% O
reduction O
in O
gal O
##act O
##ose O
- O
1 O
- O
phosphate O
u O
##rid O
##yl O
##tra O
##ns O
##fer O
##ase O
( O
gal O
##t O
) O
enzyme O
activity O
. O

the O
du O
##arte O
bio O
##chemical O
p O
##hen O
##otype O
has O
a O
molecular O
g O
##eno O
##type O
of O
n O
##31 O
##4 O
##d O
/ O
n O
##31 O
##4 O
##d O
. O

the O
characteristic O
du O
##arte O
is O
##of O
##orm O
is O
also O
associated O
with O
a O
variant O
called O
the O
" O
los O
angel O
##es O
( O
la O
) O
p O
##hen O
##otype O
, O
" O
which O
has O
increased O
gal O
##t O
enzyme O
activity O
. O

we O
evaluated O
gal O
##t O
enzyme O
activity O
and O
screened O
the O
gal O
##t O
genes O
of O
145 O
patients O
with O
one O
or O
more O
n O
##31 O
##4 O
##d O
- O
containing O
all O
##ele O
##s O
. O

we O
found O
seven O
with O
the O
la O
bio O
##chemical O
p O
##hen O
##otype O
, O
and O
all O
had O
a O
172 O
##1 O
##c O
- O
- O
[UNK] O
t O
transition O
in O
ex O
##on O
7 O
in O
c O
##is O
with O
the O
n O
##31 O
##4 O
##d O
miss O
##ense O
mutation O
. O

the O
172 O
##1 O
##c O
- O
- O
[UNK] O
t O
transition O
is O
a O
neutral O
p O
##oly O
##mor O
##phism O
for O
le O
##uc O
##ine O
at O
amino O
acid O
218 O
( O
l O
##21 O
##8 O
##l O
) O
. O

in O
p O
##ed O
##ig O
##ree O
analyses O
, O
this O
172 O
##1 O
##c O
- O
- O
[UNK] O
t O
transition O
segregated O
with O
the O
la O
p O
##hen O
##otype O
of O
increased O
gal O
##t O
activity O
in O
three O
different O
bio O
##chemical O
p O
##hen O
##otype O
##s O
( O
la O
/ O
n O
, O
la O
/ O
g O
, O
and O
la O
/ O
d O
) O
. O

to O
determine O
the O
mechanism O
for O
increased O
activity O
of O
the O
la O
variant O
, O
we O
compared O
gal O
##t O
m O
##rna O
, O
protein O
abundance O
, O
and O
enzyme O
thermal O
stability O
in O
l O
##ymph O
##ob O
##last O
cell O
lines O
of O
d O
and O
la O
p O
##hen O
##otype O
##s O
with O
comparable O
g O
##eno O
##type O
##s O
. O

gal O
##t O
protein O
abundance O
was O
increased O
in O
la O
compared O
to O
d O
all O
##ele O
##s O
, O
but O
m O
##rna O
was O
similar O
among O
all O
g O
##eno O
##type O
##s O
. O

when O
la O
/ O
d O
and O
d O
/ O
d O
gal O
##t O
bio O
##chemical O
p O
##hen O
##otype O
##s O
were O
compared O
to O
n O
/ O
n O
gal O
##t O
p O
##hen O
##otype O
##s O
, O
both O
had O
50 O
% O
, O
as O
compared O
to O
21 O
% O
, O
reduction O
in O
gal O
##t O
activity O
in O
the O
wild O
type O
( O
n O
/ O
n O
) O
after O
exposure O
at O
identical O
initial O
enzyme O
activity O
to O
50 O
degrees O
c O
for O
15 O
min O
. O

we O
conclude O
that O
the O
co O
##don O
change O
n O
##31 O
##4 O
##d O
in O
c O
##is O
with O
the O
base O
- O
pair O
transition O
172 O
##1 O
##c O
- O
- O
[UNK] O
t O
produces O
the O
la B-Disease
variant I-Disease
of I-Disease
gal I-Disease
##act I-Disease
##ose I-Disease
##mia I-Disease
and O
that O
this O
n O
##uc O
##leo O
##tide O
change O
increases O
gal O
##t O
activity O
by O
increasing O
gal O
##t O
protein O
abundance O
without O
increasing O
transcription O
or O
decreasing O
thermal O
lab O
##ility O
. O

a O
favorable O
co O
##don O
bias O
for O
the O
m O
##uta O
##ted O
co O
##don O
with O
consequently O
increased O
translation O
rates O
is O
post O
##ulated O
as O
the O
mechanism O
. O
. O

the O
t O
##s O
##g O
##10 O
##1 O
tumor B-Disease
su O
##s O
##ce O
##pt O
##ibility O
gene O
is O
located O
in O
chromosome O
11 O
band O
p O
##15 O
and O
is O
m O
##uta O
##ted O
in O
human O
breast B-Disease
cancer I-Disease
. O

recent O
work O
has O
identified O
a O
mouse O
gene O
( O
t O
##s O
##g O
##10 O
##1 O
) O
whose O
in O
##act O
##ivation O
in O
fi O
##bro O
##blast O
##s O
results O
in O
cellular O
transformation O
and O
the O
ability O
to O
produce O
meta B-Disease
##static I-Disease
tumors I-Disease
in O
nude O
mice O
. O

here O
, O
we O
report O
that O
the O
human O
ho O
##mo O
##log O
, O
t O
##s O
##g O
##10 O
##1 O
, O
which O
we O
isolated O
and O
mapped O
to O
chromosome O
11 O
, O
bands O
15 O
. O

1 O
- O
15 O
1 O
- O
15 O
. O

2 O
, O
a O
region O
proposed O
to O
contain O
tumor B-Disease
suppress O
##or O
gene O
( O
s O
) O
, O
is O
m O
##uta O
##ted O
at O
high O
frequency O
in O
human O
breast B-Disease
cancer I-Disease
. O

in O
7 O
of O
15 O
un O
##culture O
##d O
primary O
human O
breast B-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
##s I-Disease
, O
in O
##tra O
##genic O
del O
##eti O
##ons O
were O
shown O
in O
t O
##s O
##g O
##10 O
##1 O
g O
##eno O
##mic O
d O
##na O
and O
trans O
##cripts O
by O
gel O
and O
sequence O
analysis O
, O
and O
mutations O
affecting O
two O
t O
##s O
##g O
##10 O
##1 O
all O
##ele O
##s O
were O
identified O
in O
four O
of O
these O
cancer B-Disease
##s I-Disease
. O

no O
t O
##s O
##g O
##10 O
##1 O
defects O
were O
found O
in O
matched O
normal O
breast O
tissue O
from O
the O
breast B-Disease
cancer I-Disease
patients O
. O

these O
findings O
strongly O
imp O
##lica O
##te O
t O
##s O
##g O
##10 O
##1 O
mutations O
in O
human O
breast B-Disease
cancer I-Disease

moderate O
inter O
##gene O
##ration O
##al O
and O
so O
##matic O
instability O
of O
a O
55 O
- O
c O
##t O
##g O
repeat O
in O
trans O
##genic O
mice O
. O

my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
( O
d B-Disease
##m I-Disease
) O
is O
associated O
with O
the O
expansion O
of O
a O
( O
c O
##t O
##g O
) O
n O
t O
##rin O
##uc O
##leo O
##tide O
repeat O
in O
the O
3 O
un O
##tra O
##ns O
##lated O
region O
( O
u O
##tr O
) O
of O
the O
d B-Disease
##m I-Disease
protein O
kinase O
gene O
( O
d O
##mp O
##k O
) O
. O

the O
( O
c O
##t O
##g O
) O
n O
repeat O
is O
p O
##oly O
##morphic O
and O
varies O
in O
size O
between O
5 O
and O
37 O
repeats O
in O
un O
##af O
##fected O
individuals O
whereas O
in O
affected O
patients O
there O
are O
between O
50 O
and O
4 O
, O
000 O
c O
##t O
##gs O
. O

the O
size O
of O
the O
( O
c O
##t O
##g O
) O
n O
repeat O
, O
which O
increases O
through O
generations O
, O
generally O
co O
##rrel O
##ates O
with O
clinical O
severity O
and O
age O
of O
onset O
. O

the O
instability O
of O
the O
c O
##t O
##g O
repeat O
appears O
to O
depend O
on O
its O
size O
as O
well O
as O
on O
the O
sex O
of O
the O
transmitting O
parent O
. O

more O
##over O
, O
mit O
##otic O
instability O
analysis O
of O
different O
human O
d B-Disease
##m I-Disease
tissues O
shows O
length O
mosaic O
##ism O
between O
different O
cell O
lineage O
##s O
. O

the O
molecular O
mechanisms O
of O
triple O
##t O
instability O
remain O
el O
##usive O
. O

to O
investigate O
the O
role O
of O
g O
##eno O
##mic O
sequences O
in O
instability O
, O
we O
produced O
trans O
##genic O
mice O
containing O
a O
45 O
- O
k O
##b O
g O
##eno O
##mic O
segment O
with O
a O
55 O
- O
c O
##t O
##g O
repeat O
clone O
##d O
from O
a O
mildly O
affected O
patient O
. O

in O
contrast O
to O
other O
mouse O
models O
containing O
ca O
##g O
repeats O
within O
c O
##dn O
##as O
, O
these O
mice O
showed O
both O
inter O
##gene O
##ration O
##al O
and O
so O
##matic O
repeat O
instability O
. O
. O

miss O
##ense O
mutations O
in O
the O
f O
##as O
gene O
resulting O
in O
auto B-Disease
##im I-Disease
##mu I-Disease
##ne I-Disease
l I-Disease
##ymph I-Disease
##op I-Disease
##rol I-Disease
##ifer I-Disease
##ative I-Disease
syndrome I-Disease
: O
a O
molecular O
and O
im O
##mu O
##nological O
analysis O
. O

programmed O
cell O
death O
( O
or O
a O
##pop O
##tosis O
) O
is O
a O
physiological O
process O
essential O
to O
the O
normal O
development O
and O
home O
##ost O
##atic O
maintenance O
of O
the O
immune O
system O
. O

the O
f O
##as O
/ O
a O
##po O
- O
1 O
receptor O
plays O
a O
crucial O
role O
in O
the O
regulation O
of O
a O
##pop O
##tosis O
, O
as O
demonstrated O
by O
l O
##ymph O
##op O
##rol O
##ifer O
##ation O
in O
m O
##rl O
- O
l O
##p O
##r O
/ O
l O
##p O
##r O
mice O
and O
by O
the O
recently O
described O
auto B-Disease
##im I-Disease
##mu I-Disease
##ne I-Disease
l I-Disease
##ymph I-Disease
##op I-Disease
##rol I-Disease
##ifer I-Disease
##ative I-Disease
syndrome I-Disease
( O
al B-Disease
##ps I-Disease
) O
in O
humans O
, O
both O
of O
which O
are O
due O
to O
mutations O
in O
the O
f O
##as O
gene O
. O

we O
describe O
a O
novel O
family O
with O
al B-Disease
##ps I-Disease
in O
which O
three O
affected O
siblings O
carry O
two O
distinct O
miss O
##ense O
mutations O
on O
both O
the O
f O
##as O
gene O
all O
##ele O
##s O
and O
show O
lack O
of O
f O
##as O
- O
induced O
a O
##pop O
##tosis O
. O

the O
children O
share O
common O
clinical O
features O
including O
s B-Disease
##ple I-Disease
##no I-Disease
##me I-Disease
##gal I-Disease
##y I-Disease
and O
l B-Disease
##ymph I-Disease
##ade I-Disease
##no I-Disease
##pathy I-Disease
, O
but O
only O
one O
developed O
severe O
auto B-Disease
##im I-Disease
##mu I-Disease
##ne I-Disease
manifest I-Disease
##ations I-Disease
. O

in O
all O
three O
siblings O
, O
we O
demonstrated O
the O
presence O
of O
an O
##ergic O
c O
##d O
##3 O
+ O
c O
##d O
##4 O
- O
c O
##d O
##8 O
- O
( O
double O
negative O
, O
[ O
d O
##n O
] O
) O
t O
cells O
; O
more O
##over O
, O
a O
chronic O
l O
##ymph O
##oc O
##yte O
activation O
was O
found O
, O
as O
demonstrated O
by O
the O
presence O
of O
high O
levels O
of O
h O
##la O
- O
d O
##r O
expression O
on O
peripheral O
c O
##d O
##3 O
+ O
cells O
and O
by O
the O
presence O
of O
high O
levels O
of O
serum O
activation O
markers O
such O
as O
soluble O
inter O
##le O
##uki O
##n O
- O
2 O
receptor O
( O
s O
##ll O
- O
2 O
##r O
) O
and O
soluble O
c O
##d O
##30 O
( O
s O
##c O
##d O
##30 O
) O
. O
. O

the O
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
gene O
product O
, O
a O
con O
##st O
##it O
##utive O
##ly O
expressed O
nuclear O
protein O
that O
is O
not O
up O
- O
regulated O
following O
genome O
damage O
. O

the O
product O
of O
the O
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
gene O
( O
at O
##m O
) O
was O
identified O
by O
using O
an O
anti O
##ser O
##um O
developed O
to O
a O
p O
##eptide O
corresponding O
to O
the O
de O
##duced O
amino O
acid O
sequence O
. O

the O
at O
##m O
protein O
is O
a O
single O
, O
high O
- O
molecular O
weight O
protein O
predominantly O
confined O
to O
the O
nucleus O
of O
human O
fi O
##bro O
##blast O
##s O
, O
but O
is O
present O
in O
both O
nuclear O
and O
micro O
##so O
##mal O
fraction O
##s O
from O
human O
l O
##ymph O
##ob O
##last O
cells O
and O
peripheral O
blood O
l O
##ymph O
##ocytes O
. O

at O
##m O
protein O
levels O
and O
local O
##ization O
remain O
constant O
throughout O
all O
stages O
of O
the O
cell O
cycle O
. O

t O
##runcated O
at O
##m O
protein O
was O
not O
detected O
in O
l O
##ymph O
##ob O
##last O
##s O
from O
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
patients O
ho O
##mo O
##zy O
##go O
##us O
for O
mutations O
leading O
to O
premature O
protein O
termination O
. O

exposure O
of O
normal O
human O
cells O
to O
gamma O
- O
i O
##rra O
##diation O
and O
the O
radio O
##mi O
##met O
##ic O
drug O
neo O
##car O
##zin O
##ost O
##ati O
##n O
had O
no O
effect O
on O
at O
##m O
protein O
levels O
, O
in O
contrast O
to O
a O
noted O
rise O
in O
p O
##53 O
levels O
over O
the O
same O
time O
interval O
. O

these O
findings O
are O
consistent O
with O
a O
role O
for O
the O
at O
##m O
protein O
in O
ensuring O
the O
fi O
##delity O
of O
d O
##na O
repair O
and O
cell O
cycle O
regulation O
following O
genome O
damage O
. O
. O

type O
ii O
##i O
co O
##lla O
##gen O
is O
crucial O
for O
co O
##lla O
##gen O
i O
fi O
##bri O
##llo O
##genesis O
and O
for O
normal O
card O
##iovascular O
development O
. O

type O
ii O
##i O
co O
##lla O
##gen O
is O
a O
fi O
##bri O
##llar O
forming O
co O
##lla O
##gen O
comprising O
three O
alpha O
##1 O
( O
ii O
##i O
) O
chains O
and O
is O
expressed O
in O
early O
em O
##b O
##ryo O
##s O
and O
throughout O
em O
##b O
##ryo O
##genesis O
. O

in O
the O
adult O
, O
type O
ii O
##i O
co O
##lla O
##gen O
is O
a O
major O
component O
of O
the O
extra O
##cellular O
matrix O
in O
a O
variety O
of O
internal O
organs O
and O
skin O
. O

mutations O
in O
the O
co O
##l O
##3 O
##a O
##1 O
gene O
have O
been O
implicated O
as O
a O
cause O
of O
type B-Disease
i I-Disease
##v I-Disease
eh I-Disease
##lers I-Disease
- I-Disease
da I-Disease
##n I-Disease
##los I-Disease
syndrome I-Disease
, O
a O
disease O
leading O
to O
a B-Disease
##ort I-Disease
##ic I-Disease
r I-Disease
##up I-Disease
##ture I-Disease
in O
early O
adult O
life O
. O

to O
directly O
study O
the O
role O
of O
co O
##l O
##3 O
##a O
##1 O
in O
development O
and O
disease O
, O
we O
have O
inactivated O
the O
co O
##l O
##3 O
##a O
##1 O
gene O
in O
em O
##b O
##ryo O
##nic O
stem O
cells O
by O
ho O
##mo O
##log O
##ous O
re O
##comb O
##ination O
. O

the O
m O
##uta O
##ted O
all O
##ele O
was O
transmitted O
through O
the O
mouse O
g O
##er O
##m O
line O
and O
ho O
##mo O
##zy O
##go O
##us O
mutant O
animals O
were O
derived O
from O
he O
##tero O
##zy O
##go O
##us O
inter O
##cross O
##es O
. O

about O
10 O
% O
of O
the O
ho O
##mo O
##zy O
##go O
##us O
mutant O
animals O
survived O
to O
adulthood O
but O
have O
a O
much O
shorter O
life O
span O
compared O
with O
wild O
- O
type O
mice O
. O

the O
major O
cause O
of O
death O
of O
mutant O
mice O
was O
r O
##up O
##ture O
of O
the O
major O
blood O
vessels O
, O
similar O
to O
patients O
with O
type B-Disease
i I-Disease
##v I-Disease
eh I-Disease
##lers I-Disease
- I-Disease
da I-Disease
##n I-Disease
##los I-Disease
syndrome I-Disease
. O

ultra O
##st O
##ructural O
analysis O
of O
tissues O
from O
mutant O
mice O
revealed O
that O
type O
ii O
##i O
co O
##lla O
##gen O
is O
essential O
for O
normal O
co O
##lla O
##gen O
i O
fi O
##bri O
##llo O
##genesis O
in O
the O
card O
##iovascular O
system O
and O
other O
organs O
. O
. O

nonsense O
mutation O
in O
ex O
##on O
3 O
of O
the O
pro O
##te O
##oli O
##pid O
protein O
gene O
( O
p O
##l O
##p O
) O
in O
a O
family O
with O
an O
unusual O
form O
of O
p B-Disease
##eli I-Disease
##za I-Disease
##eus I-Disease
- I-Disease
me I-Disease
##rz I-Disease
##bach I-Disease
##er I-Disease
disease I-Disease
. O

we O
report O
a O
g O
- O
- O
[UNK] O
a O
transition O
at O
n O
##uc O
##leo O
##tide O
43 O
##1 O
of O
the O
pro O
##te O
##oli O
##pid O
protein O
gene O
( O
p O
##l O
##p O
) O
results O
in O
a O
nonsense O
co O
##don O
in O
a O
family O
with O
an O
unusual O
form O
of O
p B-Disease
##eli I-Disease
##za I-Disease
##eus I-Disease
- I-Disease
me I-Disease
##rz I-Disease
##bach I-Disease
##er I-Disease
disease I-Disease
( O
pm B-Disease
##d I-Disease
) O
. O

the O
mutation O
, O
which O
creates O
a O
second O
al O
##ui O
restriction O
site O
, O
results O
in O
a O
nonsense O
mutation O
in O
p O
##l O
##p O
. O

the O
clinical O
picture O
resembles O
somewhat O
that O
of O
x B-Disease
- I-Disease
linked I-Disease
spa I-Disease
##stic I-Disease
para I-Disease
##ple I-Disease
##gia I-Disease
( O
s B-Disease
##p I-Disease
##g I-Disease
) O
. O

it O
differs O
from O
this O
and O
both O
the O
classical O
and O
con O
##nat O
##al O
forms O
of O
pm B-Disease
##d I-Disease
in O
that O
it O
is O
relatively O
mild O
in O
form O
, O
onset O
is O
delayed O
beyond O
age O
2 O
years O
, O
n B-Disease
##ys I-Disease
##tag I-Disease
##mus I-Disease
is O
absent O
, O
t B-Disease
##rem I-Disease
##ors I-Disease
are O
prominent O
, O
mental B-Disease
re I-Disease
##tar I-Disease
##dation I-Disease
is O
not O
severe O
, O
some O
patients O
show O
dem B-Disease
##ent I-Disease
##ia I-Disease
or O
personality B-Disease
disorders I-Disease
, O
the O
disease O
is O
progressive O
rather O
than O
static O
in O
some O
, O
and O
several O
females O
show O
signs O
of O
disease O
. O

the O
nonsense O
mutation O
, O
which O
is O
in O
ex O
##on O
3 O
##b O
, O
should O
block O
the O
synthesis O
of O
normal O
p O
##l O
##p O
but O
spare O
d O
##m O
##20 O
, O
the O
is O
##of O
##orm O
whose O
per O
##sistence O
has O
been O
associated O
with O
mild O
forms O
of O
p B-Disease
##l I-Disease
##p I-Disease
- I-Disease
associated I-Disease
disease I-Disease
in O
both O
humans O
and O
mice O
. O
. O

common O
br O
##ca O
##1 O
variants O
and O
su O
##s O
##ce O
##pt O
##ibility O
to O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
in O
the O
general O
population O
. O

most O
multiple O
case O
families O
of O
young O
onset O
breast B-Disease
cancer I-Disease
and O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
are O
thought O
to O
be O
due O
to O
highly O
pen O
##et O
##rant O
mutations O
in O
the O
pre O
##dis O
##po O
##sing O
genes O
br O
##ca O
##1 O
and O
br O
##ca O
##2 O
. O

however O
, O
these O
mutations O
are O
uncommon O
in O
the O
population O
and O
they O
probably O
account O
for O
only O
a O
few O
percent O
of O
all O
breast B-Disease
cancer I-Disease
incidence O
. O

a O
much O
larger O
fraction O
of O
breast B-Disease
cancer I-Disease
might O
, O
in O
principle O
, O
be O
due O
to O
common O
variants O
which O
con O
##fer O
more O
modest O
individual O
risks O
. O

there O
are O
several O
common O
p O
##oly O
##mor O
##phism O
##s O
in O
the O
br O
##ca O
##1 O
gene O
which O
generate O
amino O
acid O
substitution O
##s O
. O

we O
have O
examined O
the O
frequency O
of O
four O
of O
these O
p O
##oly O
##mor O
##phism O
##s O
g O
##ln O
##35 O
##6 O
##ar O
##g O
, O
pro O
##8 O
##7 O
##1 O
##le O
##u O
, O
g O
##lu O
##10 O
##38 O
##gly O
and O
se O
##r O
##16 O
##13 O
##gly O
in O
large O
series O
of O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
cases O
and O
matched O
controls O
. O

due O
to O
strong O
link O
##age O
di O
##se O
##qui O
##li O
##bri O
##um O
, O
these O
four O
sites O
generate O
only O
three O
ha O
##p O
##lot O
##ype O
##s O
with O
a O
frequency O
[UNK] O
1 O
. O

3 O
% O
. O

the O
most O
common O
ha O
##p O
##lot O
##ype O
##s O
, O
defined O
by O
the O
all O
##ele O
##s O
g O
##ln O
##35 O
##6 O
##p O
##ro O
##8 O
##7 O
##1 O
##g O
##lu O
##10 O
##38 O
##ser O
##16 O
##13 O
and O
g O
##ln O
##35 O
##6 O
##le O
##u O
##8 O
##7 O
##1 O
##gly O
##10 O
##38 O
##gly O
##16 O
##13 O
, O
have O
frequencies O
of O
0 O
. O

57 O
and O
0 O
. O

32 O
respectively O
, O
and O
these O
frequencies O
do O
not O
differ O
significantly O
between O
patient O
and O
control O
groups O
. O

thus O
the O
most O
common O
p O
##oly O
##mor O
##phism O
##s O
of O
the O
br O
##ca O
##1 O
gene O
do O
not O
make O
a O
significant O
contribution O
to O
breast B-Disease
or I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
risk O
. O

however O
, O
our O
data O
suggest O
that O
the O
a O
##rg O
##35 O
##6 O
all O
##ele O
may O
have O
a O
different O
g O
##eno O
##type O
distribution O
in O
breast B-Disease
cancer I-Disease
patients O
from O
that O
in O
controls O
( O
a O
##rg O
##35 O
##6 O
ho O
##mo O
##zy O
##got O
##es O
are O
more O
frequent O
in O
the O
control O
groups O
, O
p O
= O
0 O
. O
01 O
) O
, O
indicating O
that O
it O
may O
be O
protective O
against O
breast B-Disease
cancer I-Disease
. O

if O
this O
finding O
can O
be O
confirmed O
, O
it O
may O
provide O
an O
insight O
into O
the O
structural O
features O
of O
the O
br O
##ca O
##1 O
protein O
that O
are O
important O
for O
its O
function O
. O

kn B-Disease
##iest I-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
: O
d O
##r O
. O
w O
. O

kn O
##iest O
, O
his O
patient O
, O
the O
molecular O
defect O
. O

kn B-Disease
##iest I-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
is O
a O
severe O
ch B-Disease
##ond I-Disease
##rod I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
caused O
by O
the O
defect B-Disease
##ive I-Disease
formation I-Disease
of I-Disease
type I-Disease
ii I-Disease
co I-Disease
##lla I-Disease
##gen I-Disease
. O

we O
report O
about O
d O
##r O
. O
kn O
##iest O
, O
who O
first O
described O
the O
condition O
in O
1952 O
, O
and O
his O
patient O
, O
who O
, O
at O
the O
age O
of O
50 O
years O
is O
severely B-Disease
hand I-Disease
##ica I-Disease
##pped I-Disease
with O
short B-Disease
stature I-Disease
, O
restricted B-Disease
joint I-Disease
mobility I-Disease
, O
and O
blind B-Disease
##ness I-Disease
but O
is O
mentally O
alert O
and O
leads O
an O
active O
life O
. O

molecular O
analysis O
of O
the O
patients O
d O
##na O
showed O
a O
single O
base O
( O
g O
) O
del O
##eti O
##on O
involving O
the O
g O
##t O
din O
##uc O
##leo O
##tide O
at O
the O
start O
of O
intro O
##n O
18 O
destroying O
a O
s O
##p O
##lice O
site O
of O
the O
co O
##l O
##2 O
##a O
##1 O
gene O
. O

this O
is O
in O
accordance O
with O
molecular O
findings O
in O
other O
patients O
with O
kn B-Disease
##iest I-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
and O
confirms O
, O
in O
the O
original O
patient O
, O
that O
the O
disorder O
is O
caused O
by O
small O
in O
##frame O
del O
##eti O
##ons O
often O
due O
to O
ex O
##on O
skip O
##ping O
as O
a O
result O
of O
co O
##l O
##2 O
##a O
##1 O
s O
##p O
##lice O
site O
mutations O
. O
. O

c O
##lon O
##ing O
of O
the O
ho O
##mo O
##gent O
##isa O
##te O
1 O
, O
2 O
- O
di O
##ox O
##y O
##gen O
##ase O
gene O
, O
the O
key O
enzyme O
of O
al B-Disease
##ka I-Disease
##pton I-Disease
##uria I-Disease
in O
mouse O
. O

we O
determined O
48 O
amino O
acid O
residues O
from O
five O
p O
##eptide O
##s O
from O
the O
ho O
##mogeneous O
mon O
##omer O
of O
ho O
##mo O
##gent O
##isa O
##te O
1 O
, O
2 O
- O
di O
##ox O
##y O
##gen O
##ase O
( O
h O
##go O
; O
e O
. O
c O
. O
1 O
. O
13 O
. O
11 O
. O
15 O
) O
of O
mouse O
liver O
. O

after O
dig O
##est O
##ion O
with O
try O
##ps O
##in O
, O
p O
##eptide O
##s O
were O
separated O
by O
reversed O
phase O
ch O
##roma O
##tography O
and O
amino O
acid O
sequence O
##d O
. O

the O
de O
##duced O
co O
##don O
sequence O
of O
three O
p O
##eptide O
##s O
was O
used O
to O
derive O
de O
##generate O
##d O
o O
##li O
##go O
##mere O
##s O
. O

by O
combining O
these O
o O
##li O
##gos O
, O
we O
were O
able O
to O
am O
##p O
##lify O
fragments O
from O
100 O
to O
300 O
bases O
( O
b O
) O
from O
mouse O
liver O
c O
##dn O
##a O
by O
polymer O
##ase O
chain O
reaction O
after O
reverse O
transcription O
( O
r O
##t O
- O
p O
##c O
##r O
) O
. O

a O
fragment O
of O
200 O
b O
was O
clone O
##d O
and O
used O
as O
a O
probe O
to O
screen O
a O
mouse O
liver O
c O
##dn O
##a O
library O
. O

one O
clone O
from O
this O
library O
contained O
the O
complete O
c O
##dn O
##a O
- O
insert O
for O
h O
##go O
as O
determined O
by O
se O
##quencing O
. O

the O
c O
##dn O
##a O
en O
##codes O
for O
a O
protein O
of O
50 O
k O
##da O
, O
as O
predicted O
. O

the O
c O
##dn O
##a O
of O
mouse O
h O
##go O
has O
an O
overall O
identity O
of O
41 O
% O
to O
the O
corresponding O
gene O
h O
##m O
##ga O
from O
as O
##per O
##gill O
##us O
. O

sequence O
similarities O
to O
human O
expressed O
sequence O
tags O
( O
est O
) O
clone O
##s O
ranged O
from O
70 O
% O
to O
20 O
% O
. O

the O
positions O
of O
122 O
conserved O
amino O
acids O
could O
be O
determined O
by O
multiple O
sequence O
alignment O
. O

we O
identified O
one O
first O
intro O
##n O
of O
92 O
##8 O
b O
in O
the O
mouse O
gene O
. O

the O
gene O
for O
h O
##go O
seems O
to O
be O
expressed O
in O
various O
tissues O
, O
as O
shown O
by O
r O
##t O
- O
p O
##c O
##r O
on O
different O
c O
##dn O
##as O
. O

fish O
experiments O
with O
the O
whole O
m O
##uri O
##ne O
c O
##dn O
##a O
as O
probe O
clearly O
revealed O
signals O
at O
the O
human O
ch O
##rom O
##oso O
##mal O
band O
3 O
##q O
##13 O
. O

3 O
- O
q O
##21 O
. O

this O
corresponds O
well O
to O
the O
previous O
assignment O
of O
the O
lo O
##cus O
for O
the O
human O
al B-Disease
##ka I-Disease
##pton I-Disease
##uria I-Disease
gene O
( O
a O
##ku O
) O
to O
the O
same O
ch O
##rom O
##oso O
##mal O
region O
by O
multi O
##point O
link O
##age O
analysis O
. O

we O
therefore O
conclude O
that O
the O
h O
##go O
c O
##dn O
##a O
en O
##codes O
the O
gene O
responsible O
for O
al B-Disease
##ka I-Disease
##pton I-Disease
##uria I-Disease
. O

p O
##ten O
, O
a O
put O
##ative O
protein O
t O
##yr O
##os O
##ine O
p O
##hos O
##pha O
##tase O
gene O
m O
##uta O
##ted O
in O
human O
brain B-Disease
, I-Disease
breast I-Disease
, I-Disease
and I-Disease
pro I-Disease
##state I-Disease
cancer I-Disease
. O

mapping O
of O
ho O
##mo O
##zy O
##go O
##us O
del O
##eti O
##ons O
on O
human O
chromosome O
10 O
##q O
##23 O
has O
led O
to O
the O
isolation O
of O
a O
candidate O
tumor B-Disease
suppress O
##or O
gene O
, O
p O
##ten O
, O
that O
appears O
to O
be O
m O
##uta O
##ted O
at O
considerable O
frequency O
in O
human O
cancer B-Disease
##s I-Disease
. O

in O
preliminary O
screens O
, O
mutations O
of O
p O
##ten O
were O
detected O
in O
31 O
% O
( O
13 O
/ O
42 O
) O
of O
g B-Disease
##lio I-Disease
##blast I-Disease
##oma I-Disease
cell O
lines O
and O
x O
##eno O
##gra O
##fts O
, O
100 O
% O
( O
4 O
/ O
4 O
) O
of O
pro B-Disease
##state I-Disease
cancer I-Disease
cell O
lines O
, O
6 O
% O
( O
4 O
/ O
65 O
) O
of O
breast B-Disease
cancer I-Disease
cell O
lines O
and O
x O
##eno O
##gra O
##fts O
, O
and O
17 O
% O
( O
3 O
/ O
18 O
) O
of O
primary B-Disease
g I-Disease
##lio I-Disease
##blast I-Disease
##oma I-Disease
##s I-Disease
. O

the O
predicted O
p O
##ten O
product O
has O
a O
protein O
t O
##yr O
##os O
##ine O
p O
##hos O
##pha O
##tase O
domain O
and O
extensive O
ho O
##mology O
to O
tens O
##in O
, O
a O
protein O
that O
interact O
##s O
with O
act O
##in O
fi O
##lam O
##ents O
at O
focal O
ad O
##hesion O
##s O
. O

these O
ho O
##mo O
##logies O
suggest O
that O
p O
##ten O
may O
suppress O
tumor B-Disease
cell O
growth O
by O
ant O
##agon O
##izing O
protein O
t O
##yr O
##os O
##ine O
kinase O
##s O
and O
may O
regulate O
tumor B-Disease
cell O
invasion O
and O
meta B-Disease
##sta I-Disease
##sis I-Disease
through O
interactions O
at O
focal O
ad O
##hesion O
##s O
. O
. O

he O
##tero O
##gene O
##ity O
in O
s B-Disease
##ch I-Disease
##wart I-Disease
##z I-Disease
- I-Disease
jam I-Disease
##pel I-Disease
ch I-Disease
##ond I-Disease
##rod I-Disease
##ys I-Disease
##tro I-Disease
##phic I-Disease
my I-Disease
##oto I-Disease
##nia I-Disease
. O

the O
s B-Disease
##ch I-Disease
##wart I-Disease
##z I-Disease
- I-Disease
jam I-Disease
##pel I-Disease
syndrome I-Disease
( O
s B-Disease
##j I-Disease
##s I-Disease
; O
ch B-Disease
##ond I-Disease
##rod I-Disease
##ys I-Disease
##tro I-Disease
##phic I-Disease
my I-Disease
##oto I-Disease
##nia I-Disease
; O
m O
##ck O
255 O
, O
800 O
) O
is O
a O
re B-Disease
##cess I-Disease
##ively I-Disease
inherited I-Disease
condition I-Disease
defined O
by O
my B-Disease
##oto I-Disease
##nia I-Disease
, O
short B-Disease
stature I-Disease
, O
and O
bone B-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
. O

genetic O
link O
##age O
between O
s B-Disease
##j I-Disease
##s I-Disease
and O
ch O
##rom O
##oso O
##mal O
region O
1 O
##q O
##36 O
- O
34 O
has O
been O
observed O
in O
several O
families O
, O
but O
the O
gene O
has O
not O
yet O
been O
identified O
. O

we O
studied O
the O
clinical O
and O
radio O
##logical O
features O
in O
81 O
patients O
from O
the O
literature O
and O
5 O
own O
patients O
trying O
to O
identify O
distinct O
subgroup O
##s O
. O

in O
addition O
, O
we O
tested O
genetic O
link O
##age O
to O
the O
s B-Disease
##j I-Disease
##s I-Disease
lo O
##cus O
on O
chromosome O
1 O
in O
one O
family O
with O
two O
affected O
si O
##bs O
. O

we O
found O
that O
a O
group O
of O
patients O
have O
mild O
skeletal O
changes O
which O
may O
be O
secondary O
consequences O
of O
my B-Disease
##oto I-Disease
##nia I-Disease
, O
while O
another O
group O
of O
patients O
appear O
to O
have O
primary O
bone B-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
with O
my B-Disease
##oto I-Disease
##nia I-Disease
. O

within O
this O
latter O
group O
, O
there O
are O
differences O
in O
age O
of O
manifest O
##ation O
, O
clinical O
course O
and O
pattern O
of O
bone O
changes O
. O

we O
tentatively O
is O
##olate O
three O
different O
types O
of O
s B-Disease
##j I-Disease
##s I-Disease
type I-Disease
1 I-Disease
##a I-Disease
, O
usually O
recognized O
in O
childhood O
, O
with O
moderate O
bone B-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
, O
corresponding O
to O
the O
original O
descriptions O
of O
s O
##ch O
##wart O
##z O
, O
jam O
##pel O
and O
a O
##ber O
##feld O
; O
type O
1 O
##b O
, O
similar O
to O
type O
1 O
##a O
but O
recognizable O
at O
birth O
, O
with O
more O
pronounced O
bone B-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
resembling O
kn B-Disease
##iest I-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
; O
and O
type O
2 O
, O
manifest O
at O
birth O
, O
with O
increased O
mortality O
and O
bone B-Disease
d I-Disease
##ys I-Disease
##p I-Disease
##lasia I-Disease
resembling O
p B-Disease
##yle I-Disease
disease I-Disease
. O

genetic O
analysis O
of O
the O
family O
with O
two O
si O
##bs O
affected O
by O
s B-Disease
##j I-Disease
##s I-Disease
type I-Disease
2 I-Disease
showed O
evidence O
against O
link O
##age O
to O
chromosome O
1 O
##p O
##36 O
- O
34 O
. O

conclusions O
s B-Disease
##j I-Disease
##s I-Disease
is O
clinical O
##ly O
and O
radio O
##logical O
##ly O
he O
##tero O
##gene O
##ous O
. O

the O
causes O
of O
he O
##tero O
##gene O
##ity O
are O
not O
known O
yet O
but O
are O
likely O
to O
include O
both O
different O
mutations O
at O
the O
s B-Disease
##j I-Disease
##s I-Disease
lo O
##cus O
on O
chromosome O
1 O
and O
the O
presence O
of O
a O
second O
s B-Disease
##j I-Disease
##s I-Disease
lo O
##cus O
. O

a O
tentative O
clinic O
##o O
- O
radio O
##logical O
classification O
can O
be O
useful O
for O
the O
characterization O
of O
patients O
and O
the O
development O
of O
g O
##eno O
##type O
- O
p O
##hen O
##otype O
correlation O
##s O
. O
. O

a O
clinical O
overview O
of O
w O
##t O
##1 O
gene O
mutations O
. O

mutations O
in O
the O
w O
##t O
##1 O
gene O
were O
anticipated O
to O
explain O
the O
genetic O
basis O
of O
the O
childhood O
kidney B-Disease
cancer I-Disease
, O
w B-Disease
##il I-Disease
##ms I-Disease
t I-Disease
##umour I-Disease
( O
w B-Disease
##t I-Disease
) O
. O

six O
years O
on O
, O
we O
review O
100 O
reports O
of O
in O
##tra O
##genic O
w O
##t O
##1 O
mutations O
and O
examine O
the O
accompanying O
clinical O
p O
##hen O
##otype O
##s O
. O

while O
only O
5 O
% O
of O
s B-Disease
##poradic I-Disease
w I-Disease
##il I-Disease
##ms I-Disease
t I-Disease
##umour I-Disease
##s I-Disease
have O
in O
##tra O
##genic O
w O
##t O
##1 O
mutations O
, O
[UNK] O
90 O
% O
of O
patients O
with O
the O
deny B-Disease
##s I-Disease
- I-Disease
d I-Disease
##rash I-Disease
syndrome I-Disease
( O
re B-Disease
##nal I-Disease
ne I-Disease
##ph I-Disease
##rop I-Disease
##athy I-Disease
, O
go B-Disease
##na I-Disease
##dal I-Disease
an I-Disease
##oma I-Disease
##ly I-Disease
, O
pre B-Disease
##dis I-Disease
##position I-Disease
to I-Disease
w I-Disease
##t I-Disease
) O
carry O
constitutional O
in O
##tra O
##genic O
w O
##t O
##1 O
mutations O
. O

w O
##t O
##1 O
mutations O
have O
also O
been O
reported O
in O
juvenile B-Disease
g I-Disease
##ran I-Disease
##ulos I-Disease
##a I-Disease
cell I-Disease
t I-Disease
##umour I-Disease
, O
non B-Disease
- I-Disease
as I-Disease
##bes I-Disease
##tos I-Disease
related I-Disease
me I-Disease
##so I-Disease
##the I-Disease
##lio I-Disease
##ma I-Disease
, O
des B-Disease
##mo I-Disease
##p I-Disease
##lastic I-Disease
small I-Disease
round I-Disease
cell I-Disease
t I-Disease
##umour I-Disease
and O
, O
most O
recently O
, O
acute B-Disease
my I-Disease
##elo I-Disease
##id I-Disease
le I-Disease
##uke I-Disease
##mia I-Disease
. O
. O

a O
mutation O
in O
auto B-Disease
##so I-Disease
##mal I-Disease
dominant I-Disease
my I-Disease
##oto I-Disease
##nia I-Disease
con I-Disease
##gen I-Disease
##ita I-Disease
affects O
p O
##ore O
properties O
of O
the O
muscle O
chloride O
channel O
. O

auto B-Disease
##so I-Disease
##mal I-Disease
dominant I-Disease
my I-Disease
##oto I-Disease
##nia I-Disease
con I-Disease
##gen I-Disease
##ita I-Disease
is O
an O
inherited B-Disease
disorder I-Disease
of I-Disease
skeletal I-Disease
muscle I-Disease
caused O
by O
mutations O
in O
a O
voltage O
- O
gate O
##d O
c O
##l O
- O
channel O
gene O
( O
c O
##l O
##c O
##n O
##1 O
, O
7 O
##q O
##35 O
) O
. O

here O
, O
we O
report O
that O
a O
mutation O
predict O
##ing O
the O
substitution O
of O
g O
##ly O
230 O
by O
g O
##lut O
##ami O
##c O
acid O
( O
g O
##23 O
##0 O
##e O
) O
between O
segments O
d O
##3 O
and O
d O
##4 O
dramatically O
alter O
##s O
the O
p O
##ore O
properties O
of O
a O
re O
##comb O
##ina O
##nt O
human O
muscle O
c O
##l O
- O
channel O
( O
h O
##ci O
##c O
- O
1 O
) O
expressed O
in O
a O
ma O
##mmal O
##ian O
cell O
line O
( O
t O
##sa O
##20 O
##1 O
) O
. O

the O
g O
##23 O
##0 O
##e O
mutation O
causes O
substantial O
changes O
in O
an O
##ion O
and O
cat O
##ion O
select O
##ivity O
as O
well O
as O
a O
fundamental O
change O
in O
re O
##ct O
##ification O
of O
the O
current O
- O
voltage O
relationship O
. O

whereas O
wild O
- O
type O
channels O
are O
characterized O
by O
pronounced O
inward O
re O
##ct O
##ification O
and O
a O
c O
##l O
[UNK] O
th O
##io O
##cy O
##ana O
##te O
[UNK] O
br O
[UNK] O
no O
( O
3 O
) O
[UNK] O
i O
[UNK] O
ch O
( O
3 O
) O
so O
( O
3 O
) O
select O
##ivity O
, O
g O
##23 O
##0 O
##e O
exhibits O
outward O
re O
##ct O
##ification O
at O
positive O
potential O
##s O
and O
a O
th O
##io O
##cy O
##ana O
##te O
[UNK] O
no O
( O
3 O
) O
[UNK] O
i O
[UNK] O
br O
[UNK] O
c O
##l O
[UNK] O
ch O
( O
3 O
) O
so O
( O
3 O
) O
select O
##ivity O
. O

further O
##more O
, O
the O
cat O
##ion O
- O
to O
- O
an O
##ion O
per O
##me O
##ability O
ratio O
of O
the O
mutant O
is O
much O
greater O
than O
that O
of O
the O
wild O
- O
type O
channel O
. O

voltage O
- O
dependent O
blocks O
by O
in O
##tra O
##cellular O
and O
extra O
##cellular O
i O
##od O
##ide O
help O
to O
distinguish O
two O
distinct O
ion O
binding O
sites O
within O
the O
h O
##c O
##l O
##c O
- O
1 O
conduct O
##ion O
pathway O
. O

both O
binding O
sites O
are O
preserved O
in O
the O
mutant O
but O
have O
decreased O
a O
##ffin O
##ities O
for O
i O
##od O
##ide O
. O

these O
findings O
suggest O
that O
g O
##ly O
230 O
is O
critical O
for O
normal O
ion O
conduct O
##ance O
in O
h O
##c O
##l O
##c O
- O
1 O
and O
that O
this O
residue O
resides O
within O
the O
channel O
p O
##ore O
. O
. O

the O
incidence O
of O
p O
##ax O
##6 O
mutation O
in O
patients O
with O
simple O
an B-Disease
##iri I-Disease
##dia I-Disease
: O
an O
evaluation O
of O
mutation O
detection O
in O
12 O
cases O
. O

twelve O
an B-Disease
##iri I-Disease
##dia I-Disease
patients O
, O
five O
with O
a O
family O
history O
and O
seven O
presumed O
to O
be O
s O
##poradic O
, O
were O
exhaust O
##ively O
screened O
in O
order O
to O
test O
what O
proportion O
of O
people O
with O
an B-Disease
##iri I-Disease
##dia I-Disease
, O
un O
##com O
##plicate O
##d O
by O
associated O
an O
##oma O
##lies O
, O
carry O
mutations O
in O
the O
human O
p O
##ax O
##6 O
gene O
. O

mutations O
were O
detected O
in O
90 O
% O
of O
the O
cases O
. O

three O
mutation O
detection O
techniques O
were O
used O
to O
determine O
if O
one O
method O
was O
superior O
for O
this O
gene O
. O

the O
protein O
t O
##run O
##cation O
test O
( O
p O
##tt O
) O
was O
used O
on O
r O
##t O
- O
p O
##c O
##r O
products O
, O
s O
##s O
##c O
##p O
on O
g O
##eno O
##mic O
p O
##c O
##r O
am O
##p O
##lification O
##s O
, O
and O
chemical O
c O
##lea O
##vage O
of O
mi O
##sma O
##tch O
on O
both O
r O
##t O
- O
p O
##c O
##r O
and O
g O
##eno O
##mic O
am O
##p O
##lification O
##s O
. O

for O
r O
##t O
- O
p O
##c O
##r O
products O
, O
only O
the O
translated O
portion O
of O
the O
gene O
was O
screened O
. O

on O
g O
##eno O
##mic O
products O
ex O
##ons O
1 O
to O
13 O
( O
including O
74 O
##0 O
b O
##p O
of O
the O
3 O
un O
##tra O
##ns O
##lated O
sequence O
and O
all O
intro O
##n O
/ O
ex O
##on O
boundaries O
) O
were O
screened O
, O
as O
was O
a O
ne O
##uro O
##ret O
##ina O
specific O
enhance O
##r O
in O
intro O
##n O
4 O
. O

ten O
of O
the O
possible O
12 O
mutations O
in O
the O
five O
f O
##ami O
##lial O
cases O
and O
five O
of O
the O
s O
##poradic O
patients O
were O
found O
, O
all O
of O
which O
conform O
##ed O
to O
a O
functional O
outcome O
of O
ha O
##p O
##lo O
##ins O
##uff O
##iciency O
. O

five O
were O
s O
##p O
##lice O
site O
mutations O
( O
one O
in O
the O
donor O
site O
of O
intro O
##n O
4 O
, O
two O
in O
the O
donor O
site O
of O
intro O
##n O
6 O
, O
one O
in O
each O
of O
the O
accept O
##or O
sites O
of O
intro O
##ns O
8 O
and O
9 O
) O
and O
five O
were O
nonsense O
mutations O
in O
ex O
##ons O
8 O
, O
9 O
, O
10 O
, O
11 O
, O
and O
12 O
. O

s O
##s O
##c O
##p O
analysis O
of O
individually O
am O
##plified O
ex O
##ons O
, O
with O
which O
nine O
of O
the O
10 O
mutations O
were O
seen O
, O
was O
the O
most O
useful O
detection O
method O
for O
p O
##ax O
##6 O
. O
. O

insulin O
gene O
region O
contributes O
to O
genetic O
su O
##s O
##ce O
##pt O
##ibility O
to O
, O
but O
may O
not O
to O
low O
incidence O
of O
, O
insulin B-Disease
- I-Disease
dependent I-Disease
diabetes I-Disease
me I-Disease
##lli I-Disease
##tus I-Disease
in O
j O
##apa O
##nese O
. O

in O
the O
ca O
##uca O
##sian O
population O
, O
it O
has O
been O
demonstrated O
that O
the O
insulin O
gene O
( O
ins O
) O
region O
contains O
the O
insulin B-Disease
- I-Disease
dependent I-Disease
diabetes I-Disease
me I-Disease
##lli I-Disease
##tus I-Disease
lo O
##cus O
( O
id O
##d O
##m O
##2 O
) O
. O

in O
the O
j O
##apa O
##nese O
population O
, O
however O
, O
there O
has O
been O
no O
report O
demonstrating O
the O
contribution O
of O
id O
##d O
##m O
##2 O
to O
the O
path O
##ogen O
##esis O
of O
id B-Disease
##d I-Disease
##m I-Disease
. O

we O
conducted O
an O
association O
study O
of O
id B-Disease
##d I-Disease
##m I-Disease
in O
a O
large O
number O
of O
j O
##apa O
##nese O
subjects O
with O
multiple O
p O
##oly O
##mor O
##phism O
##s O
in O
ins O
region O
. O

we O
found O
a O
significant O
association O
of O
the O
ins O
region O
with O
id B-Disease
##d I-Disease
##m I-Disease
. O

all O
##ele O
##s O
positively O
associated O
with O
id B-Disease
##d I-Disease
##m I-Disease
in O
ins O
region O
were O
the O
same O
as O
those O
positively O
- O
associated O
with O
id B-Disease
##d I-Disease
##m I-Disease
in O
ca O
##uca O
##sian O
population O
, O
although O
positively O
- O
associated O
all O
##ele O
##s O
are O
very O
common O
( O
all O
##ele O
frequencies O
[UNK] O
0 O
. O
9 O
) O
in O
the O
j O
##apa O
##nese O
general O
population O
. O

these O
data O
suggest O
that O
id O
##d O
##m O
##2 O
is O
involved O
in O
the O
genetic O
su O
##s O
##ce O
##pt O
##ibility O
to O
id B-Disease
##d I-Disease
##m I-Disease
in O
j O
##apa O
##nese O
. O

the O
high O
frequencies O
of O
disease O
- O
associated O
all O
##ele O
##s O
in O
the O
general O
population O
suggest O
that O
id O
##d O
##m O
##2 O
lo O
##cus O
is O
not O
responsible O
for O
the O
low O
incidence O
of O
id B-Disease
##d I-Disease
##m I-Disease
in O
j O
##apa O
##nese O
. O

the O
human O
complement O
c O
##9 O
gene O
: O
identification O
of O
two O
mutations O
causing O
deficiency O
and O
revision O
of O
the O
gene O
structure O
. O

the O
ninth O
component O
of O
human O
complement O
( O
c O
##9 O
) O
is O
the O
last O
of O
the O
terminal O
complement O
components O
creating O
the O
membrane O
attack O
complex O
. O

c O
##9 O
is O
a O
single O
- O
chain O
serum O
protein O
that O
is O
encoded O
by O
a O
gene O
located O
on O
chromosome O
5 O
##p O
. O

deficiency B-Disease
of I-Disease
terminal I-Disease
complement I-Disease
components I-Disease
is O
generally O
associated O
with O
re O
##current O
ne B-Disease
##isse I-Disease
##ria I-Disease
infections I-Disease
. O

we O
studied O
a O
previously O
described O
s O
##wi O
##ss O
family O
with O
inherited B-Disease
c I-Disease
##9 I-Disease
deficiency I-Disease
. O

to O
identify O
the O
genetic O
basis O
of O
c B-Disease
##9 I-Disease
deficiency I-Disease
, O
we O
developed O
an O
approach O
using O
ex O
##on O
- O
specific O
p O
##c O
##r O
and O
direct O
d O
##na O
se O
##quencing O
. O

as O
a O
cause O
of O
c B-Disease
##9 I-Disease
deficiency I-Disease
, O
we O
found O
two O
different O
point O
mutations O
, O
both O
generating O
t O
##ga O
stop O
co O
##don O
##s O
in O
the O
coding O
sequence O
. O

one O
mutation O
, O
a O
c O
to O
a O
exchange O
, O
was O
detected O
in O
ex O
##on O
2 O
at O
c O
##dn O
##a O
position O
166 O
, O
the O
other O
, O
a O
c O
to O
t O
exchange O
, O
was O
located O
in O
ex O
##on O
4 O
( O
c O
##dn O
##a O
position O
46 O
##4 O
) O
. O

in O
family O
studies O
of O
three O
first O
- O
degree O
relatives O
with O
he O
##tero O
##zy O
##go O
##us O
c B-Disease
##9 I-Disease
deficiency I-Disease
, O
we O
demonstrated O
that O
the O
two O
mutations O
are O
se O
##g O
##re O
##gating O
independently O
. O

therefore O
, O
these O
mutations O
are O
sufficient O
to O
explain O
the O
complete O
deficiency O
of O
both O
the O
pro O
##band O
##s O
studied O
. O

d O
##na O
se O
##quencing O
of O
the O
ex O
##on O
- O
intro O
##n O
junction O
##s O
revealed O
a O
number O
of O
revision O
##s O
regarding O
the O
boundaries O
between O
ex O
##ons O
4 O
, O
5 O
, O
and O
6 O
as O
well O
as O
between O
ex O
##ons O
10 O
and O
11 O
. O

no O
additional O
intro O
##ns O
were O
detected O
in O
ex O
##ons O
6 O
and O
10 O
. O

further O
##more O
, O
d O
##na O
marker O
studies O
were O
conducted O
using O
known O
p O
##oly O
##mor O
##phism O
##s O
of O
the O
c O
##6 O
, O
c O
##7 O
, O
and O
c O
##9 O
genes O
, O
confirming O
the O
link O
##age O
of O
the O
observed O
c O
##9 O
mutations O
with O
defined O
ha O
##p O
##lot O
##ype O
##s O
. O
. O

br O
##ca O
##1 O
mutations O
in O
women O
attending O
clinics O
that O
evaluate O
the O
risk O
of O
breast B-Disease
cancer I-Disease
. O

background O
to O
define O
the O
incidence O
of O
br O
##ca O
##1 O
mutations O
among O
patients O
seen O
in O
clinics O
that O
evaluate O
the O
risk O
of O
breast B-Disease
cancer I-Disease
, O
we O
analyzed O
d O
##na O
samples O
from O
women O
seen O
in O
this O
setting O
and O
constructed O
probability O
tables O
to O
provide O
estimates O
of O
the O
likelihood O
of O
finding O
a O
br O
##ca O
##1 O
mutation O
in O
individual O
families O
. O

methods O
clinical O
information O
, O
family O
histories O
, O
and O
blood O
for O
d O
##na O
analysis O
were O
obtained O
from O
26 O
##3 O
women O
with O
breast B-Disease
cancer I-Disease
. O

conform O
##ation O
- O
sensitive O
gel O
electro O
##ph O
##ores O
##is O
and O
d O
##na O
se O
##quencing O
were O
used O
to O
identify O
br O
##ca O
##1 O
mutations O
. O

results O
br O
##ca O
##1 O
mutations O
were O
identified O
in O
16 O
percent O
of O
women O
with O
a O
family O
history O
of O
breast B-Disease
cancer I-Disease
. O

only O
7 O
percent O
of O
women O
from O
families O
with O
a O
history O
of O
breast B-Disease
cancer I-Disease
but O
not O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
had O
br O
##ca O
##1 O
mutations O
. O

the O
rates O
were O
higher O
among O
women O
from O
families O
with O
a O
history O
of O
both O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
. O

among O
family O
members O
, O
an O
average O
age O
of O
less O
than O
55 O
years O
at O
the O
diagnosis O
of O
breast B-Disease
cancer I-Disease
, O
the O
presence O
of O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
, O
the O
presence O
of O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
in O
the O
same O
woman O
, O
and O
ash O
##ken O
##azi O
j O
##ew O
##ish O
ancestry O
were O
all O
associated O
with O
an O
increased O
risk O
of O
detect O
##ing O
a O
br O
##ca O
##1 O
mutation O
. O

no O
association O
was O
found O
between O
the O
presence O
of O
bilateral O
breast B-Disease
cancer I-Disease
or O
the O
number O
of O
breast B-Disease
cancer I-Disease
##s I-Disease
in O
a O
family O
and O
the O
detection O
of O
a O
br O
##ca O
##1 O
mutation O
, O
or O
between O
the O
position O
of O
the O
mutation O
in O
the O
br O
##ca O
##1 O
gene O
and O
the O
presence O
of O
o B-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
in O
a O
family O
. O

conclusions O
among O
women O
with O
breast B-Disease
cancer I-Disease
and O
a O
family O
history O
of O
the O
disease O
, O
the O
percentage O
with O
br O
##ca O
##1 O
coding O
- O
region O
mutations O
is O
less O
than O
the O
45 O
percent O
predicted O
by O
genetic O
- O
link O
##age O
analysis O
. O

these O
results O
suggest O
that O
even O
in O
a O
refer O
##ral O
clinic O
specializing O
in O
screening O
women O
from O
high O
- O
risk O
families O
, O
the O
majority O
of O
tests O
for O
br O
##ca O
##1 O
mutations O
will O
be O
negative O
and O
therefore O
un O
##in O
##form O
##ative O
. O
. O

mutations O
in O
the O
a O
##rg O
##ini O
##ne O
- O
rich O
protein O
gene O
( O
a O
##rp O
) O
in O
pan B-Disease
##cre I-Disease
##atic I-Disease
cancer I-Disease
. O

the O
a O
##rp O
gene O
en O
##codes O
a O
highly O
conserved O
a O
##rg O
##ini O
##ne O
- O
rich O
protein O
from O
ch O
##rom O
##oso O
##mal O
band O
3 O
##p O
##21 O
. O

1 O
1 O
. O

at O
the O
c O
##yt O
##ogen O
##etic O
level O
this O
region O
is O
frequently O
deleted O
in O
a O
variety O
of O
different O
solid B-Disease
tumors I-Disease
, O
although O
not O
in O
pan B-Disease
##cre I-Disease
##atic I-Disease
cancer I-Disease
. O

we O
have O
reported O
the O
presence O
of O
a O
specific O
mutation O
( O
at O
##g O
##50 O
- O
- O
[UNK] O
a O
##gg O
) O
or O
del O
##eti O
##on O
of O
co O
##don O
50 O
of O
the O
a O
##rp O
gene O
in O
different O
tumor B-Disease
types I-Disease
( O
s O
##hr O
##id O
##har O
et O
al O
. O
, O
1996 O
, O
1996 O
##a O
) O
. O

in O
the O
present O
study O
, O
we O
have O
observed O
mutations O
involving O
co O
##don O
50 O
in O
11 O
of O
37 O
pan B-Disease
##cre I-Disease
##atic I-Disease
tumors I-Disease
. O

the O
frequency O
of O
co O
##don O
50 O
mutation O
is O
roughly O
the O
same O
in O
pan B-Disease
##cre I-Disease
##atic I-Disease
tumors I-Disease
as O
in O
the O
other O
types O
of O
tumors B-Disease
previously O
examined O
. O

in O
addition O
, O
we O
have O
detected O
mutations O
at O
co O
##don O
51 O
in O
multiple O
p O
##c O
##r O
sub O
##c O
##lone O
##s O
in O
two O
other O
pan B-Disease
##cre I-Disease
##atic I-Disease
tumors I-Disease
. O

mutations O
in O
the O
a O
##rp O
gene O
are O
thus O
commonly O
observed O
in O
pan B-Disease
##cre I-Disease
##atic I-Disease
cancer I-Disease
, O
as O
well O
as O
many O
other O
cancer B-Disease
##s I-Disease
. O

difficulties O
in O
the O
as O
##cer O
##tain O
##ment O
of O
c B-Disease
##9 I-Disease
deficiency I-Disease
: O
lessons O
to O
be O
drawn O
from O
a O
compound O
he O
##tero O
##zy O
##got O
##e O
c B-Disease
##9 I-Disease
- I-Disease
def I-Disease
##icient I-Disease
subject O
. O

a O
group O
of O
patients O
with O
long O
- O
surviving O
mi O
##sma O
##tched O
kidney O
all O
##og O
##raft O
##s O
were O
investigated O
for O
complement O
function O
using O
ha O
##em O
##oly O
##tic O
ass O
##ays O
in O
a O
##gar O
##ose O
gel O
##s O
. O

one O
patient O
was O
found O
to O
have O
no O
alternative O
pathway O
activity O
but O
a O
low O
normal O
classical O
pathway O
. O

surprisingly O
, O
investigation O
revealed O
that O
the O
patients O
complement O
was O
normal O
for O
all O
components O
except O
c O
##9 O
, O
which O
was O
functional O
##ly O
absent O
. O

the O
patient O
was O
shown O
to O
be O
he O
##tero O
##zy O
##go O
##us O
for O
d O
##na O
markers O
in O
the O
c O
##6 O
, O
c O
##7 O
and O
c O
##9 O
region O
of O
chromosome O
5 O
and O
therefore O
appears O
to O
be O
a O
compound O
he O
##tero O
##zy O
##got O
##e O
for O
two O
un O
##cha O
##rac O
##ter O
##ized O
c B-Disease
##9 I-Disease
deficiency I-Disease
genes O
. O

se O
##rol O
##ogical O
analysis O
by O
el O
##isa O
revealed O
that O
he O
has O
trace O
concentrations O
of O
a O
non O
- O
functional O
c O
##9 O
molecule O
. O

western O
b O
##lot O
analysis O
was O
not O
sufficiently O
sensitive O
to O
permit O
detection O
of O
this O
molecule O
. O

we O
h O
##y O
##pot O
##hes O
##ize O
that O
the O
patient O
is O
he O
##tero O
##zy O
##go O
##us O
for O
a O
complete B-Disease
deficiency I-Disease
of I-Disease
c I-Disease
##9 I-Disease
and O
for O
a O
gene O
directing O
h O
##y O
##po O
##sy O
##nt O
##hesis O
of O
a O
defect O
##ive O
c O
##9 O
. O

we O
also O
suggest O
that O
c B-Disease
##9 I-Disease
deficiency I-Disease
may O
be O
more O
common O
among O
ca O
##uca O
##sian O
##s O
than O
has O
been O
reported O
. O
. O

screening O
for O
es O
##r O
mutations O
in O
breast B-Disease
and I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
patients O
. O

in O
the O
present O
study O
, O
le O
##uk O
##oc O
##yte O
d O
##na O
from O
143 O
patients O
with O
f O
##ami O
##lial O
cluster O
##ing O
of O
breast B-Disease
and I-Disease
/ I-Disease
or I-Disease
o I-Disease
##var I-Disease
##ian I-Disease
cancer I-Disease
and O
t B-Disease
##umour I-Disease
d O
##na O
from O
96 O
breast B-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
##s I-Disease
were O
screened O
for O
base O
mutations O
in O
the O
est O
##rogen O
receptor O
gene O
( O
es O
##r O
) O
. O

three O
patients O
with O
a O
family O
history O
of O
cancer B-Disease
were O
carrying O
a O
g O
##ly O
##16 O
##0 O
##cy O
##s O
g O
##er O
##m O
##line O
substitution O
. O

this O
alter O
##ation O
was O
also O
detected O
in O
eight O
( O
four O
females O
and O
four O
males O
) O
of O
72 O
##9 O
controls O
( O
36 O
##6 O
female O
, O
36 O
##3 O
males O
) O
, O
indicating O
that O
the O
substitution O
probably O
represents O
a O
p O
##oly O
##mor O
##phism O
. O

however O
, O
in O
the O
229 O
female O
controls O
in O
whom O
family O
history O
of O
cancer B-Disease
was O
known O
, O
one O
of O
two O
who O
had O
a O
sister O
with O
breast B-Disease
cancer I-Disease
was O
carrying O
the O
variant O
all O
##ele O
. O

hence O
, O
a O
possible O
clinical O
significance O
of O
the O
g O
##ly O
##cine O
into O
c O
##ys O
##tein O
##e O
cannot O
be O
completely O
ruled O
out O
and O
should O
be O
further O
investigated O
. O

so O
##matic O
mutations O
were O
not O
detected O
in O
any O
of O
the O
t B-Disease
##umour I-Disease
##s I-Disease
studied O
, O
and O
the O
present O
data O
do O
not O
provide O
support O
for O
so O
##matic O
es O
##r O
base O
mutations O
as O
an O
important O
mechanism O
for O
ho O
##rmon O
##al O
therapy O
resistance O
in O
est B-Disease
##rogen I-Disease
receptor I-Disease
- I-Disease
positive I-Disease
breast I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
##s I-Disease
. O
. O

molecular O
bases O
of O
c B-Disease
##7 I-Disease
deficiency I-Disease
: O
three O
different O
defects O
. O

the O
molecular O
basis O
of O
c B-Disease
##7 I-Disease
deficiency I-Disease
has O
been O
investigated O
in O
two O
i O
##ris O
##h O
families O
and O
a O
number O
of O
is O
##rae O
##li O
families O
of O
m O
##oro O
##cca O
##n O
se O
##pha O
##rdi O
##c O
j O
##ew O
##ish O
origin O
. O

ex O
##on O
p O
##c O
##r O
and O
se O
##quencing O
revealed O
a O
he O
##tero O
##zy O
##go O
##us O
point O
mutation O
at O
the O
3 O
s O
##p O
##lice O
accept O
##or O
site O
of O
intro O
##n O
1 O
in O
one O
i O
##ris O
##h O
family O
. O

in O
the O
other O
i O
##ris O
##h O
family O
, O
ex O
##ons O
7 O
and O
8 O
failed O
to O
am O
##p O
##lify O
and O
they O
were O
shown O
to O
be O
deleted O
. O

marker O
ha O
##p O
##lot O
##ype O
studies O
of O
the O
c O
##6 O
and O
c O
##7 O
gene O
region O
and O
southern O
b O
##lot O
##s O
show O
that O
the O
i O
##ris O
##h O
family O
with O
the O
s O
##p O
##lice O
defect O
also O
se O
##g O
##re O
##gate O
for O
the O
del O
##eti O
##on O
, O
which O
is O
not O
easily O
detected O
in O
he O
##tero O
##zy O
##got O
##es O
. O

the O
is O
##rae O
##li O
c B-Disease
##7 I-Disease
- I-Disease
def I-Disease
##icient I-Disease
cases O
all O
share O
a O
c O
##7 O
ha O
##p O
##lot O
##ype O
and O
are O
ho O
##mo O
##zy O
##go O
##us O
for O
a O
mi O
##s O
- O
sense O
mutation O
in O
ex O
##on O
9 O
. O

however O
, O
one O
individual O
is O
he O
##tero O
##zy O
##go O
##us O
for O
markers O
at O
adjacent O
c O
##6 O
lo O
##ci O
, O
showing O
that O
there O
has O
been O
an O
inter O
##genic O
re O
##comb O
##ination O
and O
suggesting O
that O
the O
deficiency O
mutation O
is O
of O
app O
##re O
##cia O
##ble O
antiquity O
. O
. O

molecular O
he O
##tero O
##gene O
##ity O
of O
classical B-Disease
and I-Disease
du I-Disease
##arte I-Disease
gal I-Disease
##act I-Disease
##ose I-Disease
##mia I-Disease
: O
mutation O
analysis O
by O
den O
##at O
##uring O
gradient O
gel O
electro O
##ph O
##ores O
##is O
. O

classical B-Disease
gal I-Disease
##act I-Disease
##ose I-Disease
##mia I-Disease
is O
caused O
by O
one O
common O
miss O
##ense O
mutation O
( O
q O
##18 O
##8 O
##r O
) O
and O
by O
several O
rare O
mutations O
in O
the O
gal O
##act O
##ose O
- O
1 O
- O
phosphate O
u O
##rid O
##yl O
##tra O
##ns O
##fer O
##ase O
( O
gal O
##t O
) O
gene O
. O

the O
most O
common O
variant O
of O
gal O
##t O
, O
the O
du O
##arte O
variant O
, O
occurs O
as O
two O
types O
, O
du O
##arte O
- O
1 O
( O
d O
- O
1 O
) O
and O
du O
##arte O
- O
2 O
( O
d O
- O
2 O
) O
, O
both O
of O
which O
carry O
the O
sequence O
change O
n O
##31 O
##4 O
##d O
. O

d O
- O
1 O
increases O
, O
whereas O
d O
- O
2 O
decreases O
gal O
##t O
activity O
. O

to O
study O
the O
molecular O
genetics O
of O
classical B-Disease
and I-Disease
du I-Disease
##arte I-Disease
gal I-Disease
##act I-Disease
##ose I-Disease
##mia I-Disease
, O
we O
analyzed O
the O
gal O
##t O
mutations O
in O
30 O
families O
with O
classical B-Disease
gal I-Disease
##act I-Disease
##ose I-Disease
##mia I-Disease
, O
in O
10 O
families O
with O
the O
d O
- O
2 O
variant O
and O
in O
3 O
individuals O
carrying O
the O
d O
- O
1 O
all O
##ele O
by O
den O
##at O
##uring O
gradient O
gel O
electro O
##ph O
##ores O
##is O
( O
d O
##gg O
##e O
) O
. O

d O
##gg O
##e O
detected O
59 O
of O
the O
60 O
classical O
gal B-Disease
##act I-Disease
##ose I-Disease
##mia I-Disease
all O
##ele O
##s O
. O

q O
##18 O
##8 O
##r O
accounted O
for O
60 O
% O
, O
k O
##28 O
##5 O
##n O
accounted O
for O
28 O
% O
of O
these O
all O
##ele O
##s O
. O

eight O
novel O
candidate O
gal B-Disease
##act I-Disease
##ose I-Disease
##mia I-Disease
mutations O
were O
found O
. O

on O
all O
d O
- O
2 O
all O
##ele O
##s O
n O
##31 O
##4 O
##d O
occurred O
in O
c O
##is O
with O
two O
intro O
##nic O
sequence O
changes O
, O
on O
the O
d O
- O
1 O
all O
##ele O
##s O
in O
c O
##is O
with O
a O
neutral O
mutation O
in O
ex O
##on O
7 O
. O

we O
conclude O
that O
the O
mutations O
causing O
gal B-Disease
##act I-Disease
##ose I-Disease
##mia I-Disease
are O
highly O
he O
##tero O
##gene O
##ous O
and O
that O
k O
##28 O
##5 O
##n O
is O
a O
second O
common O
gal B-Disease
##act I-Disease
##ose I-Disease
##mia I-Disease
mutation O
in O
our O
population O
. O
. O

isolation O
of O
full O
- O
length O
at O
##m O
c O
##dn O
##a O
and O
correction O
of O
the O
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
cellular O
p O
##hen O
##otype O
. O

a O
gene O
m O
##uta O
##ted O
in O
the O
human O
genetic B-Disease
disorder I-Disease
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
( O
a B-Disease
- I-Disease
t I-Disease
) O
, O
at O
##m O
, O
was O
recently O
identified O
by O
position O
##al O
c O
##lon O
##ing O
. O

at O
##m O
is O
a O
member O
of O
the O
p O
##hos O
##pha O
##ti O
##dy O
##lino O
##si O
##to O
##l O
- O
3 O
- O
kinase O
super O
##family O
, O
some O
of O
which O
are O
protein O
kinase O
##s O
and O
appear O
to O
have O
important O
roles O
in O
cell O
cycle O
control O
and O
radiation O
signal O
trans O
##duction O
. O

we O
describe O
here O
##in O
, O
to O
our O
knowledge O
, O
for O
the O
first O
time O
, O
the O
c O
##lon O
##ing O
of O
a O
full O
- O
length O
c O
##dn O
##a O
for O
at O
##m O
and O
correction O
of O
multiple O
aspects O
of O
the O
radio O
- O
sensitive O
p O
##hen O
##otype O
of O
a B-Disease
- I-Disease
t I-Disease
cells O
by O
trans O
##fect O
##ion O
with O
this O
c O
##dn O
##a O
. O

over O
##ex O
##press O
##ion O
of O
at O
##m O
c O
##dn O
##a O
in O
a B-Disease
- I-Disease
t I-Disease
cells O
enhanced O
the O
survival O
of O
these O
cells O
in O
response O
to O
radiation O
exposure O
, O
decreased O
radiation O
- O
induced O
chromosome O
a O
##ber O
##rations O
, O
reduced O
radio O
- O
resistant O
d O
##na O
synthesis O
, O
and O
partially O
corrected O
defect O
##ive O
cell O
cycle O
check O
##points O
and O
induction O
of O
stress O
- O
activated O
protein O
kinase O
. O

this O
correction O
of O
the O
defects O
in O
a B-Disease
- I-Disease
t I-Disease
cells O
provides O
further O
evidence O
of O
the O
multi O
##p O
##licity O
of O
effect O
##or O
functions O
of O
the O
at O
##m O
protein O
and O
suggests O
possible O
approaches O
to O
gene O
therapy O
. O
. O

fusion O
genes O
resulting O
from O
alternative O
ch O
##rom O
##oso O
##mal O
trans O
##location O
##s O
are O
over O
##ex O
##pressed O
by O
gene O
- O
specific O
mechanisms O
in O
al B-Disease
##ve I-Disease
##olar I-Disease
r I-Disease
##hab I-Disease
##dom I-Disease
##yo I-Disease
##sar I-Disease
##com I-Disease
##a I-Disease
. O

ch O
##rom O
##oso O
##mal O
trans O
##location O
##s O
identified O
in O
hem B-Disease
##ato I-Disease
##po I-Disease
##iet I-Disease
##ic I-Disease
and I-Disease
solid I-Disease
tumors I-Disease
result O
in O
der O
##eg O
##ulated O
expression O
of O
pro O
##toon O
##co O
##gene O
##s O
or O
creation O
of O
ch O
##ime O
##ric O
proteins O
with O
tumor O
##ige O
##nic O
potential O
. O

in O
the O
p O
##ediatric O
solid B-Disease
tumor I-Disease
al B-Disease
##ve I-Disease
##olar I-Disease
r I-Disease
##hab I-Disease
##dom I-Disease
##yo I-Disease
##sar I-Disease
##com I-Disease
##a I-Disease
, O
a O
consistent O
t O
( O
2 O
; O
13 O
) O
( O
q O
##35 O
; O
q O
##14 O
) O
or O
variant O
t O
( O
1 O
; O
13 O
) O
( O
p O
##36 O
; O
q O
##14 O
) O
trans O
##location O
generates O
p O
##ax O
##3 O
- O
f O
##kh O
##r O
or O
p O
##ax O
##7 O
- O
f O
##kh O
##r O
fusion O
proteins O
, O
respectively O
. O

in O
this O
report O
, O
we O
demonstrate O
that O
in O
addition O
to O
functional O
alterations O
these O
trans O
##location O
##s O
are O
associated O
with O
fusion O
product O
over O
##ex O
##press O
##ion O
. O

further O
##more O
, O
p O
##ax O
##3 O
- O
f O
##kh O
##r O
and O
p O
##ax O
##7 O
- O
f O
##kh O
##r O
over O
##ex O
##press O
##ion O
occurs O
by O
distinct O
mechanisms O
. O

transcription O
of O
p O
##ax O
##3 O
- O
f O
##kh O
##r O
is O
increased O
relative O
to O
wild O
- O
type O
p O
##ax O
##3 O
by O
a O
copy O
number O
- O
independent O
process O
. O

in O
contrast O
, O
p O
##ax O
##7 O
- O
f O
##kh O
##r O
over O
##ex O
##press O
##ion O
results O
from O
fusion O
gene O
am O
##p O
##lification O
. O

thus O
, O
gene O
- O
specific O
mechanisms O
were O
selected O
to O
over O
##ex O
##press O
p O
##ax O
##3 O
- O
f O
##kh O
##r O
and O
p O
##ax O
##7 O
- O
f O
##kh O
##r O
in O
al B-Disease
##ve I-Disease
##olar I-Disease
r I-Disease
##hab I-Disease
##dom I-Disease
##yo I-Disease
##sar I-Disease
##com I-Disease
##a I-Disease
, O
presumably O
due O
to O
differences O
in O
regulation O
between O
the O
wild O
- O
type O
lo O
##ci O
. O

we O
post O
##ulate O
that O
these O
over O
##ex O
##press O
##ion O
mechanisms O
ensure O
a O
critical O
level O
of O
gene O
product O
for O
the O
on O
##co O
##genic O
effects O
of O
these O
fusion O
##s O
. O
. O

at O
##m O
and O
p O
##53 O
cooperate O
in O
a O
##pop O
##tosis O
and O
suppression O
of O
tumor O
##ige O
##nes O
##is O
, O
but O
not O
in O
resistance O
to O
acute B-Disease
radiation I-Disease
toxicity I-Disease
. O

mutations O
in O
at O
##m O
and O
p O
##53 O
cause O
the O
human O
cancer B-Disease
- I-Disease
associated I-Disease
diseases I-Disease
at B-Disease
##ax I-Disease
##ia I-Disease
- I-Disease
te I-Disease
##lang I-Disease
##ie I-Disease
##ct I-Disease
##asi I-Disease
##a I-Disease
and O
l B-Disease
##i I-Disease
- I-Disease
f I-Disease
##ra I-Disease
##ume I-Disease
##ni I-Disease
syndrome I-Disease
, O
respectively O
. O

the O
two O
genes O
are O
believed O
to O
interact O
in O
a O
number O
of O
pathways O
, O
including O
regulation O
of O
d O
##na O
damage O
- O
induced O
cell O
- O
cycle O
check O
##points O
, O
a O
##pop O
##tosis O
and O
radiation O
sensitivity O
, O
and O
cellular O
proliferation O
. O

at O
##m O
- O
null O
mice O
, O
as O
well O
as O
those O
null O
for O
p O
##53 O
, O
develop O
mainly O
t B-Disease
- I-Disease
cell I-Disease
l I-Disease
##ymph I-Disease
##oma I-Disease
##s I-Disease
, O
supporting O
the O
view O
that O
these O
genes O
have O
similar O
roles O
in O
thy O
##mo O
##cy O
##te O
development O
. O

to O
study O
the O
interactions O
of O
these O
two O
genes O
on O
an O
organism O
##al O
level O
, O
we O
bred O
mice O
he O
##tero O
##zy O
##go O
##us O
for O
null O
all O
##ele O
##s O
of O
both O
at O
##m O
and O
p O
##53 O
to O
produce O
all O
g O
##eno O
##ty O
##pic O
combinations O
. O

mice O
do O
##ub O
##ly O
null O
for O
at O
##m O
and O
p O
##53 O
exhibited O
a O
dramatic O
acceleration O
of O
t B-Disease
##umour I-Disease
formation O
relative O
to O
sing O
##ly O
null O
mice O
, O
indicating O
that O
both O
genes O
collaborate O
in O
a O
significant O
manner O
to O
prevent O
tumor O
##ige O
##nes O
##is O
. O

with O
respect O
to O
their O
roles O
in O
a O
##pop O
##tosis O
, O
loss O
of O
at O
##m O
rendered O
thy O
##mo O
##cy O
##tes O
only O
partly O
resistant O
to O
i O
##rra O
##diation O
- O
induced O
a O
##pop O
##tosis O
, O
whereas O
additional O
loss O
of O
p O
##53 O
en O
##gen O
##dered O
complete O
resistance O
. O

this O
implies O
that O
the O
i O
##rra O
##diation O
- O
induced O
at O
##m O
and O
p O
##53 O
a O
##pop O
##to O
##tic O
pathways O
are O
not O
completely O
con O
##g O
##rue O
##nt O
. O

finally O
- O
and O
in O
contrast O
to O
prior O
predictions O
- O
at O
##m O
and O
p O
##53 O
do O
not O
appear O
to O
interact O
in O
acute B-Disease
radiation I-Disease
toxicity I-Disease
, O
suggesting O
a O
separate O
at O
##m O
effect O
##or O
pathway O
for O
this O
d O
##na O
damage O
response O
and O
having O
implications O
for O
the O
pro O
##gno O
##sis O
and O
treatment O
of O
human O
t B-Disease
##umour I-Disease
##s I-Disease
. O
. O

t O
##rin O
##uc O
##leo O
##tide O
repeat O
expansion O
at O
the O
my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
lo O
##cus O
reduces O
expression O
of O
d O
##mah O
##p O
. O

my B-Disease
##oto I-Disease
##nic I-Disease
d I-Disease
##ys I-Disease
##tro I-Disease
##phy I-Disease
, O
or O
d B-Disease
##ys I-Disease
##tro I-Disease
##phi I-Disease
##a I-Disease
my I-Disease
##oto I-Disease
##nica I-Disease
( O
d B-Disease
##m I-Disease
) O
, O
is O
an O
auto B-Disease
##so I-Disease
##mal I-Disease
dominant I-Disease
multi I-Disease
##sy I-Disease
##ste I-Disease
##m I-Disease
disorder I-Disease
caused O
by O
the O
expansion O
of O
a O
c O
##t O
##g O
t O
##rin O
##uc O
##leo O
##tide O
repeat O
in O
the O
3 O
un O
##tra O
##ns O
##lated O
region O
of O
the O
d O
##mp O
##k O
protein O
kinase O
gene O
on O
chromosome O
19 O
##q O
##13 O
. O

3 O
( O
re O
##fs O
1 O
- O
3 O
) O
. O

although O
the O
d B-Disease
##m I-Disease
mutation O
was O
identified O
more O
than O
five O
years O
ago O
, O
the O
path O
##ogenic O
mechanisms O
underlying O
this O
most O
prevalent O
form O
of O
hereditary O
adult O
ne B-Disease
##uro I-Disease
##mus I-Disease
##cular I-Disease
disease I-Disease
remain O
el O
##usive O
. O

previous O
work O
from O
our O
laboratory O
demonstrated O
that O
a O
d O
##nas O
##e O
l O
- O
h O
##yper O
##sen O
##sitive O
site O
located O
adjacent O
to O
the O
repeats O
on O
the O
wild O
- O
type O
all O
##ele O
is O
eliminated O
by O
repeat O
expansion O
, O
indicating O
that O
large O
c O
##t O
##g O
- O
repeat O
array O
##s O
may O
be O
associated O
with O
a O
local O
ch O
##roma O
##tin O
environment O
that O
re O
##press O
##es O
gene O
expression O
. O

here O
we O
report O
that O
the O
h O
##yper O
##sen O
##sitive O
site O
contains O
an O
enhance O
##r O
element O
that O
regulate O
##s O
transcription O
of O
the O
adjacent O
d O
##mah O
##p O
home O
##ob O
##ox O
gene O
. O

analysis O
of O
d O
##mah O
##p O
expression O
in O
the O
cells O
of O
d B-Disease
##m I-Disease
patients O
with O
loss O
of O
the O
h O
##yper O
##sen O
##sitive O
site O
revealed O
a O
two O
- O
to O
four O
##fold O
reduction O
in O
steady O
- O
state O
d O
##mah O
##p O
trans O
##cript O
levels O
relative O
to O
wild O
- O
type O
controls O
. O

all O
##ele O
- O
specific O
analysis O
of O
d O
##mah O
##p O
expression O
showed O
that O
steady O
- O
state O
trans O
##cript O
levels O
from O
the O
expanded O
all O
##ele O
were O
greatly O
reduced O
in O
comparison O
to O
those O
from O
the O
wild O
- O
type O
all O
##ele O
. O

together O
, O
these O
results O
demonstrate O
that O
c O
##t O
##g O
- O
repeat O
expansion O
##s O
can O
suppress O
local O
gene O
expression O
and O
imp O
##lica O
##te O
d O
##mah O
##p O
in O
d B-Disease
##m I-Disease
path O
##ogen O
##esis O
. O

con O
##st O
##it O
##utive O
##ly O
met O
##hyl O
##ated O
c O
##p O
##g O
din O
##uc O
##leo O
##tide O
##s O
as O
mutation O
hot O
spots O
in O
the O
re B-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
gene O
( O
r O
##b O
##1 O
) O
. O

a O
wide O
spectrum O
of O
mutations O
, O
ranging O
from O
point O
mutations O
to O
large O
del O
##eti O
##ons O
, O
have O
been O
described O
in O
the O
re B-Disease
##tino I-Disease
##blast I-Disease
##oma I-Disease
gene O
( O
r O
##b O
##1 O
) O
. O

mutations O
have O
been O
found O
throughout O
the O
gene O
; O
however O
, O
these O
genetic O
alterations O
do O
not O
appear O
to O
be O
ho O
##mogeneous O
##ly O
distributed O
. O

in O
particular O
, O
a O
significant O
proportion O
of O
disease O
- O
causing O
mutations O
results O
in O
the O
premature O
termination O
of O
protein O
synthesis O
, O
and O
the O
majority O
of O
these O
mutations O
occur O
as O
c O
- O
- O
[UNK] O
t O
transitions O
at O
c O
##p O
##g O
din O
##uc O
##leo O
##tide O
##s O
( O
c O
##p O
##gs O
) O
. O

such O
re O
##current O
c O
##p O
##g O
mutations O
, O
including O
those O
found O
in O
r O
##b O
##1 O
, O
are O
likely O
the O
result O
of O
the O
de O
##ami O
##nation O
of O
5 O
- O
met O
##hyl O
##cy O
##tos O
##ine O
within O
these O
c O
##p O
##gs O
. O

in O
the O
present O
study O
, O
we O
used O
the O
sodium O
##bis O
##ulf O
##ite O
conversion O
method O
to O
detect O
c O
##yt O
##os O
##ine O
met O
##hyl O
##ation O
in O
representative O
ex O
##ons O
of O
r O
##b O
##1 O
. O

we O
analyzed O
d O
##na O
from O
a O
variety O
of O
tissues O
and O
specifically O
targeted O
c O
##ga O
co O
##don O
##s O
in O
r O
##b O
##1 O
, O
where O
re O
##current O
premature O
termination O
mutations O
have O
been O
reported O
. O

we O
found O
that O
d O
##na O
met O
##hyl O
##ation O
within O
r O
##b O
##1 O
ex O
##ons O
8 O
, O
14 O
, O
25 O
, O
and O
27 O
appeared O
to O
be O
restricted O
to O
c O
##p O
##gs O
, O
including O
six O
c O
##ga O
co O
##don O
##s O
. O

other O
co O
##don O
##s O
containing O
met O
##hyl O
##ated O
c O
##yt O
##os O
##ines O
have O
not O
been O
reported O
to O
be O
m O
##uta O
##ted O
. O

therefore O
, O
disease O
- O
causing O
mutations O
at O
c O
##p O
##gs O
in O
r O
##b O
##1 O
appear O
to O
be O
determined O
by O
several O
factors O
, O
including O
the O
con O
##st O
##it O
##utive O
presence O
of O
d O
##na O
met O
##hyl O
##ation O
at O
c O
##yt O
##os O
##ines O
within O
c O
##p O
##gs O
, O
the O
specific O
co O
##don O
within O
which O
the O
met O
##hyl O
##ated O
c O
##yt O
##os O
##ine O
is O
located O
, O
and O
the O
particular O
region O
of O
the O
gene O
within O
which O
that O
co O
##don O
resides O
. O
. O

the O
von B-Disease
hip I-Disease
##pel I-Disease
- I-Disease
l I-Disease
##inda I-Disease
##u I-Disease
tumor I-Disease
suppress O
##or O
gene O
product O
interact O
##s O
with O
s O
##p O
##1 O
to O
re O
##press O
vascular O
end O
##oth O
##eli O
##al O
growth O
factor O
promoter O
activity O
. O

the O
von B-Disease
hip I-Disease
##pel I-Disease
- I-Disease
l I-Disease
##inda I-Disease
##u I-Disease
tumor I-Disease
suppress O
##or O
gene O
( O
v O
##hl O
) O
has O
a O
critical O
role O
in O
the O
path O
##ogen O
##esis O
of O
clear B-Disease
- I-Disease
cell I-Disease
re I-Disease
##nal I-Disease
cell I-Disease
car I-Disease
##cin I-Disease
##oma I-Disease
( O
r B-Disease
##cc I-Disease
) O
, O
as O
v O
##hl O
mutations O
have O
been O
found O
in O
both O
von B-Disease
hip I-Disease
##pel I-Disease
- I-Disease
l I-Disease
##inda I-Disease
##u I-Disease
disease I-Disease
- I-Disease
associated I-Disease
and I-Disease
s I-Disease
##poradic I-Disease
r I-Disease
##cc I-Disease
##s I-Disease
. O

recent O
studies O
suggest O
that O
vascular O
end O
##oth O
##eli O
##al O
growth O
factor O
( O
ve O
##g O
##f O
) O
m O
##rna O
is O
up O
##re O
##gu O
##lated O
in O
r B-Disease
##cc I-Disease
- I-Disease
and I-Disease
von I-Disease
hip I-Disease
##pel I-Disease
- I-Disease
l I-Disease
##inda I-Disease
##u I-Disease
disease I-Disease
- I-Disease
associated I-Disease
tumors I-Disease
. O

we O
have O
therefore O
assessed O
the O
effect O
of O
the O
v O
##hl O
gene O
product O
on O
ve O
##g O
##f O
expression O
. O

ve O
##g O
##f O
promoter O
- O
l O
##uc O
##ifer O
##ase O
construct O
##s O
were O
trans O
##ient O
##ly O
co O
##tra O
##ns O
##fected O
with O
a O
wild O
- O
type O
v O
##hl O
( O
w O
##t O
- O
v O
##hl O
) O
vector O
in O
several O
cell O
lines O
, O
including O
29 O
##3 O
em O
##b O
##ryo O
##nic O
kidney O
and O
r B-Disease
##cc I-Disease
cell O
lines O
. O

w O
##t O
- O
v O
##hl O
protein O
in O
##hibit O
##ed O
ve O
##g O
##f O
promoter O
activity O
in O
a O
dose O
- O
dependent O
manner O
up O
to O
5 O
- O
to O
10 O
- O
fold O
. O

del O
##eti O
##on O
analysis O
defined O
a O
144 O
- O
b O
##p O
region O
of O
the O
ve O
##g O
##f O
promoter O
necessary O
for O
v O
##hl O
repression O
. O

this O
v O
##hl O
- O
re O
##sp O
##ons O
##ive O
element O
is O
g O
##c O
rich O
and O
specifically O
binds O
the O
transcription O
factor O
s O
##p O
##1 O
in O
crude O
nuclear O
extract O
##s O
. O

in O
d O
##ros O
##op O
##hil O
##a O
cells O
, O
co O
##tra O
##ns O
##fected O
v O
##hl O
re O
##press O
##es O
s O
##p O
##1 O
- O
mediated O
activation O
but O
not O
basal O
activity O
of O
the O
ve O
##g O
##f O
promoter O
. O

we O
next O
demonstrated O
in O
co O
##im O
##mu O
##no O
##p O
##re O
##ci O
##pit O
##ates O
that O
v O
##hl O
and O
s O
##p O
##1 O
were O
part O
of O
the O
same O
complex O
and O
, O
by O
using O
a O
g O
##lut O
##ath O
##ione O
- O
s O
- O
transfer O
##ase O
- O
v O
##hl O
fusion O
protein O
and O
pu O
##rified O
s O
##p O
##1 O
, O
that O
v O
##hl O
and O
s O
##p O
##1 O
directly O
interact O
. O

further O
##more O
, O
end O
##ogen O
##ous O
ve O
##g O
##f O
m O
##rna O
levels O
were O
suppressed O
in O
permanent O
r B-Disease
##cc I-Disease
cell O
lines O
expressing O
w O
##t O
- O
v O
##hl O
, O
and O
nuclear O
run O
- O
on O
studies O
indicated O
that O
v O
##hl O
regulation O
of O
ve O
##g O
##f O
occurs O
at O
least O
partly O
at O
the O
transcription O
##al O
level O
. O

these O
observations O
support O
a O
new O
mechanism O
for O
v O
##hl O
- O
mediated O
transcription O
##al O
repression O
via O
a O
direct O
inhibitor O
##y O
action O
on O
s O
##p O
##1 O
and O
suggest O
that O
loss O
of O
s O
##p O
##1 O
in O
##hibition O
may O
be O
important O
in O
the O
path O
##ogen O
##esis O
of O
von B-Disease
hip I-Disease
##pel I-Disease
- I-Disease
l I-Disease
##inda I-Disease
##u I-Disease
disease I-Disease
and O
r B-Disease
##cc I-Disease
. O
. O

adult B-Disease
onset I-Disease
g I-Disease
##lo I-Disease
##bo I-Disease
##id I-Disease
cell I-Disease
le I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
( O
k B-Disease
##rab I-Disease
##be I-Disease
disease I-Disease
) O
: O
analysis O
of O
gal O
##act O
##osy O
##l O
##cer O
##ami O
##das O
##e O
c O
##dn O
##a O
from O
four O
j O
##apa O
##nese O
patients O
. O

we O
examined O
gal O
##act O
##osy O
##l O
##cer O
##ami O
##das O
##e O
( O
gal O
##c O
) O
c O
##dn O
##a O
in O
four O
j O
##apa O
##nese O
patients O
with O
adult B-Disease
onset I-Disease
g I-Disease
##lo I-Disease
##bo I-Disease
##id I-Disease
cell I-Disease
le I-Disease
##uk I-Disease
##ody I-Disease
##stro I-Disease
##phy I-Disease
( O
k B-Disease
##rab I-Disease
##be I-Disease
disease I-Disease
; O
a B-Disease
##o I-Disease
- I-Disease
g I-Disease
##ld I-Disease
) O
by O
polymer O
##ase O
chain O
reaction O
/ O
single O
- O
strand O
conform O
##ation O
p O
##oly O
##mor O
##phism O
( O
p O
##c O
##r O
- O
s O
##s O
##c O
##p O
) O
analysis O
, O
subsequent O
sequence O
determination O
, O
and O
restriction O
enzyme O
dig O
##est O
##ion O
of O
p O
##c O
##r O
products O
, O
initial O
symptoms O
were O
the O
onset O
of O
slowly O
progressive O
spa B-Disease
##stic I-Disease
para I-Disease
##ple I-Disease
##gia I-Disease
from O
the O
middle O
of O
the O
second O
decade O
, O
and O
all O
patients O
had O
diminished B-Disease
gal I-Disease
##c I-Disease
activity I-Disease
in O
their O
le O
##uk O
##ocytes O
. O

we O
identified O
three O
miss O
##ense O
mutations O
( O
i O
##6 O
##6 O
##m O
, O
g O
##27 O
##0 O
##d O
, O
l O
##6 O
##18 O
##s O
) O
and O
one O
ex O
##on O
- O
6 O
skip O
##ping O
( O
53 O
##5 O
- O
57 O
##3 O
##del O
) O
. O

two O
of O
the O
patients O
had O
only O
the O
i O
##6 O
##6 O
##m O
mutant O
m O
##rna O
, O
and O
one O
only O
the O
g O
##27 O
##od O
mutant O
m O
##rna O
. O

the O
fourth O
patient O
carried O
a O
compound O
he O
##tero O
##zy O
##go O
##us O
mutation O
of O
53 O
##5 O
- O
57 O
##3 O
##del O
and O
l O
##6 O
##18 O
##s O
. O

to O
determine O
the O
en O
##zy O
##matic O
activities O
produced O
by O
these O
mutations O
, O
we O
constructed O
m O
##uta O
##ted O
gal O
##c O
c O
##dn O
##as O
and O
expressed O
them O
in O
co O
##s O
- O
1 O
cells O
. O

three O
mutations O
, O
v O
##iz O
. O
, O
g O
##27 O
##0 O
##d O
, O
l O
##6 O
##18 O
##s O
, O
and O
ex O
##on O
- O
6 O
skip O
##ping O
( O
53 O
##5 O
- O
57 O
##3 O
##del O
) O
, O
produced O
diminished B-Disease
gal I-Disease
##c I-Disease
activity I-Disease
as O
expected O
. O

the O
i O
##6 O
##6 O
##m O
mutation O
in O
the O
wild O
- O
type O
gal O
##c O
c O
##dn O
##a O
( O
i O
##28 O
##9 O
) O
had O
normal O
activity O
, O
but O
when O
this O
mutation O
and O
the O
v O
##28 O
##9 O
p O
##oly O
##mor O
##phism O
were O
introduced O
into O
the O
same O
all O
##ele O
, O
it O
had O
decreased O
activity O
. O

thus O
, O
the O
combination O
of O
a O
unique O
mutation O
and O
p O
##oly O
##mor O
##phism O
causes O
conform O
##ational O
change O
in O
the O
gal O
##c O
enzyme O
, O
resulting O
in O
low O
en O
##zy O
##matic O
activity O
. O

a B-Disease
##o I-Disease
- I-Disease
g I-Disease
##ld I-Disease
mutations O
, O
including O
those O
found O
here O
, O
are O
located O
in O
the O
n O
- O
terminus O
( O
i O
##6 O
##6 O
##m O
, O
g O
##27 O
##0 O
##d O
, O
53 O
##5 O
- O
57 O
##3 O
##del O
) O
or O
c O
- O
terminus O
( O
l O
##6 O
##18 O
##s O
) O
of O
the O
gal O
##c O
enzyme O
, O
whereas O
the O
reported O
mutations O
in O
the O
infant O
##ile O
form O
( O
if B-Disease
- I-Disease
g I-Disease
##ld I-Disease
) O
are O
in O
the O
central O
domain O
. O

this O
difference O
in O
mutation O
sites O
may O
affect O
the O
clinical O
features O
of O
g B-Disease
##ld I-Disease
. O

